0001213900-23-065013.txt : 20230809 0001213900-23-065013.hdr.sgml : 20230809 20230809160548 ACCESSION NUMBER: 0001213900-23-065013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-05576 FILM NUMBER: 231155099 BUSINESS ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 347-321-7646 MAIL ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 10-Q 1 f10q0623_dominarihold.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one) 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number 000-05576

 

DOMINARI HOLDINGS INC.
(Exact name of registrant as specified in its charter)

 

Delaware   52-0849320
(State or other jurisdiction
of incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

725 5th Avenue, 22nd Floor, New York, NY 10022
(Address of Principal Executive Offices, including zip code)

 

(703) 992-9325
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒ No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer Accelerated Filer
Non-accelerated Filer Smaller Reporting Company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   DOMH   The Nasdaq Capital Market LLC

 

As of August 8, 2023, there were 5,345,312 shares of the Company’s common stock issued and outstanding.

 

 

 

 

 

  

DOMINARI HOLDINGS INC.

Form 10-Q

For the Quarter Ended June 30, 2023

Index 

 

    Page No. 
     
Part I. Financial Information  
     
Item 1. Financial Statements (Unaudited) 1
     
  Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 1
     
  Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 (Unaudited) 2
     
  Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three and six months ended June 30, 2023 and 2022 (Unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 (Unaudited) 5
     
  Notes to the Condensed Consolidated Financial Statements (Unaudited) 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
     
Item 4. Controls and Procedures 24
     
Part II. Other Information  
     
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 25
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
     
Item 3. Defaults Upon Senior Securities 25
     
Item 4. Mine Safety Disclosures 25
     
Item 5. Other Information 25
     
Item 6. Exhibits 25
     
Signatures 26

 

i

 

  

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

 

   June 30,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS        
Current assets        
Cash and cash equivalents  $3,598   $33,174 
Marketable securities   20,675    7,130 
Deposits with clearing broker   7,082    
-
 
Prepaid expenses and other assets   715    564 
Prepaid acquisition cost   
-
    301 
Short-term investments, at fair value   13    13 
Notes receivable, at fair value - current portion   6,339    7,474 
Investment in Fieldpoint Securities   
-
    2,000 
Total current assets   38,422    50,656 
           
Property and equipment, net   387    
-
 
Notes receivable, at fair value - non-current portion   1,622    1,100 
Employee forgivable loan receivable   98    
-
 
Investments   23,178    23,103 
Right-of-use assets   3,530    919 
Security deposit   458    458 
Total assets  $67,695   $76,236 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued expenses  $232   $447 
Accrued salaries and benefits   632    1,260 
Income taxes withheld   1,300    
-
 
Accrued Commissions   17    
-
 
Lease liability - current   353    82 
Other Current liability   124    
-
 
Total current liabilities   2,658    1,789 
           
Lease liability   3,259    680 
Total liabilities   5,917    2,469 
           
Stockholders’ equity          
Preferred stock, $.0001 par value, 50,000,000 Authorized   
 
    
 
 
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share   
-
    
-
 
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share   
-
    
-
 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively   
-
    
-
 
Additional paid-in capital   260,585    262,970 
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively   (501)   (3,322)
Accumulated deficit   (198,306)   (185,881)
Total stockholders’ equity   61,778    73,767 
Total liabilities and stockholders’ equity  $67,695   $76,236 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

1

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023   2022   2023   2022 
Revenues  $71   $
-  
   $71   $
-  
 
                     
Operating costs and expenses                    
General and administrative  $9,080   $2,262   $12,913   $4,049 
Research and development   2    36    3    2,052 
Total operating expenses   9,082    2,298    12,916    6,101 
Loss from operations   (9,011)   (2,298)   (12,845)   (6,101)
                     
Other income (expenses)                    
Other income   
-  
    
-  
    
-  
    64 
Interest income   160    220    297    399 
Gain (loss) on marketable securities   400    (2,239)   335    (2,736)
Unrealized loss on note receivable   (212)   
-  
    (212)   
-  
 
Change in fair value of investments   
-  
    (760)   
-  
    (238)
Total other income  (expenses)   348    (2,779)   420    (2,511)
Net loss  $(8,663)  $(5,077)  $(12,425)  $(8,612)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock   
-  
    (1,100)   
-  
    (4,109)
Net Loss Attributable to Common Shareholders  $(8,663)  $(6,177)  $(12,425)  $(12,721)
                     
Net loss per share, basic and diluted                    
Basic and Diluted
  $(1.79)  $(1.18)  $(2.45)  $(2.42)
                     
Weighted average number of shares outstanding, basic and diluted                    
Basic and Diluted
   4,827,239    5,251,023    5,065,055    5,251,766 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

2

 

  

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

 

For the Three Months Ended June 30, 2023 and 2022

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at March 31, 2023   4,659   $     -    4,815,597   $       -   $259,215    60,148   $(501)  $(189,643)  $69,071 
Stock-based compensation   
-
    
-
    529,715    
-
    1,370    
-
    
-
    
-
    1,370 
Net loss   -    
-
    -    
-
    -    -    
-
    (8,663)   (8,663)
Balance at June 30, 2023   4,659   $
-
    5,345,312   $
-
   $260,585    60,148   $(501)  $(198,306)  $61,778

 

  

Redeemable Convertible

Preferred Stock

        Preferred   Additional           Total 
   Series O   Series P     Common Stock    Stock   Paid-in   Treasury Stock   Accumulated    Stockholders’ 
   Shares   Amount   Shares   Amount     Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at March 31, 2022   11,000   $11,000   11,000 $  11,000      5,252,517   $           -    4,659   $       -    $262,624    -   $(264)  $(167,309)  $   95,051 
Redemption of Series O Redeemable Convertible Preferred Stock   (11,000)   (11,000)   -    -      -    -    -    -    -    -    -    -    - 
Redemption of Series P Redeemable Convertible Preferred Stock   -    -    (11,000)   (11,000 )   -    -    -    -    -    -    -    -    - 
Deemed dividends related to Series O and Series P  Redeemable Convertible Preferred Stock   -    -    -    -      -    -    -    -    (1,100)   -    -    -    (1,100)
Repurchase of treasury stock   -    -    -    -      -    -    -    -    -    242,902    (1,486)   
 
    (1,486)
Stock-based compensation   -    -    -    -      -    -    -    -    105    -    -    -    105 
Fractional shares adjusted for reverse split   -    -    -    -      (5,665)   -    -    -    (26)   -    -    -    (26)
Net loss   -    -    -    -      -    -    -    -    -    -    -    (5,077)   (5,077)
Balance at June 30, 2022   -   $-    -   $-      5,246,852   $-    4,659   $-   $261,603    242,902   $(1,750)  $(172,386)  $87,467 

 

3

 

 

For the Six Months Ended June 30, 2023 and 2022

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at December 31, 2022   4,659   $
        -
    5,485,096   $
         -
   $262,970    468,017   $(3,322)  $(185,881)  $73,767 
Stock-based compensation   -    
-
    529,715    
-
    1,375    -    
-
    
-
    1,375 
Cancellation of common stock   -    
-
    (25,000)   
-
    
-
    -    
-
    
-
    
-
 
Purchase of treasury stock   -    
-
    -    
-
    
-
    236,630    (939)   
-
    (939)
Retirement of treasury stock   -    
-
    (644,499)   
-
    (3,760)   (644,499)   3,760    
-
    
-
 
Net loss   -    
-
    -    
-
    
-
    -    
-
    (12,425)   (12,425)
Balance at June 30, 2023   4,659   $
-
    5,345,312   $
-
   $260,585    60,148   $(501)  $(198,306)  $61,778 

 

   

Redeemable Convertible

Preferred Stock

            Preferred     Additional                 Total  
    Series O     Series P       Common Stock     Stock     Paid-in      Treasury Stock      Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount       Shares     Amount     Shares     Amount     Capital     Shares     Amount     Deficit       Equity
Balance at December 31,  2021     -     $ -       -     $ -         5,275,329     $       -       4,659     $       -      $ 265,633       -      $ (264 )   $ (163,774 )    $ 101,595  
Issuance of Series O redeemable convertible preferred stock for cash     11,000       11,000                         -       -       -       -       -       -       -       -       -  
Issuance of Series P redeemable convertible preferred stock for cash            
 
      11,000       11,000         -       -       -       -       -       -       -       -       -  
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock     -       (1,504 )     -       (1,505 )       -       -       -       -       -       -       -       -       -  
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock     -       1,504       -       1,505         -       -       -       -       (4,109 )     -       -       -       (4,109 )
 Redemption of Series O Redeemable Convertible Preferred Stock     (11,000 )     (11,000 )     -       -         -       -       -       -       -       -       -       -       -  
 Redemption of Series P Redeemable Convertible Preferred Stock     -       -       (11,000 )     (11,000 )       -       -       -       -       -       -       -       -       -  
Repurchase of treasury stock     -       -       -       -         -       -       -       -       -       242,902       (1,486 )     -       (1,486 )
Stock-based compensation     -       -       -       -         -       -       -       -       105       -       -       -       105  
Cancellation of common stock related to investment in CBM     -       -       -       -         (22,812 )     -       -       -       -       -       -       -       -  
Fractional shares adjusted for reverse split     -       -       -       -         (5,665 )     -       -       -       (26 )     -       -       -       (26 )
Net loss     -       -       -       -         -       -       -       -       -       -       -       (8,612 )     (8,612 )
Balance at June 30, 2022     -     $ -       -     $ -         5,246,852     $ -       4,659     $ -     $ 261,603       242,902     $ (1,750 )   $ (172,386 )   $ 87,467  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

 

   Six Months Ended
June 30,
 
   2023   2022 
Cash flows from operating activities        
Net loss  $(12,425)  $(8,612)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of right-of-use assets   182    
-
 
Depreciation   32    
-
 
Change in fair value of short-term investment   
-
    1,646 
Change in fair value of long-term investment   -    (1,408)
Stock-based compensation   2,675    105 
Realized loss on marketable securities   487    568 
Unrealized (gain) loss on marketable securities   (514)   2,299 
Unrealized loss on note receivable   212    
-
 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   (229)   153 
Prepaid acquisition cost   301    
-
 
Deposits with clearing broker   (3,532)   
-
 
Accounts payable and accrued expenses   (428)   (239)
Accrued salaries and benefits   (628)   7 
Accrued commissions   (8)   
-
 
Lease liabilities   58    
-
 
Other current liabilities   3    
-
 
Notes receivable, at fair value – net interest accrued   (99)   (377)
Deposit   
-
    8 
Net cash used in operating activities   (13,913)   (5,850)
           
Cash flows from investing activities          
Purchase of marketable securities   (34,014)   (27,460)
Sale of marketable securities   20,494    28,272 
Proceeds from sale of digital currencies   
-
    93 
Purchase of fixed assets   (419)   
-
 
Acquisition of FPS, net of cash acquired and receivable owed from FPS   (1,112)   
-
 
Collection of principal on note receivable   502    
-
 
Funds to employee forgivable loan   (100)   
-
 
Purchase of short-term and long-term investments   (75)   (14,605)
Purchase of short-term and long-term promissory notes   
-
    (1,600)
Net cash used in investing activities   (14,724)   (15,300)
           
Cash flows from financing activities          
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost   
-
    17,891 
Payment for fractional shares   
-
    (26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock   
-
    (22,000)
Purchase of treasury stock   (939)   (1,486)
Net cash used in financing activities   (939)   (5,621)
           
Net decrease in cash and cash equivalents and restricted cash   (29,576)   (26,771)
Cash and cash equivalents, beginning of period   33,174    65,562 
Cash and cash equivalents, end of period  $3,598   $38,791 
           
Non-cash investing and financing activities          
Transfer from short-term investment to marketable securities  $
-
   $1,482 
Reclassify from convertible note receivable to notes receivable at fair value  $
-
   $2,147 
Promissory convertible note receivable conversion into common shares  $
-
   $1,508 
           
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:          
Net assets acquired, net of cash acquired and receivable owed from FPS  $3,112      
Less - Deposit previously transferred in October 2022 to FPS  $(2,000)     
Net cash paid  $1,112      

 

See accompanying notes to unaudited condensed consolidated financial statements.

5

 

 

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. 

 

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

 

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

6

 

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - Leases).

 

Revenue

 

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

7

 

 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

 

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

 

8

 

 

Note 4. FPS Acquisition

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. 

 

Consideration Transferred

 

The FPS Acquisition was accounted for as a business combination under ASC 805.

 

Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023.

 

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations.

 

Fair Value of Net Assets Acquired

 

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

 

   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 

 

9

 

 

Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.

 

Note 5. Investments in Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023   2022   2023   2022 
Realized loss  $(432)  $(344)  $(487)  $(568)
Unrealized gain (loss)   643    (1,967)   514    (2,299)
Dividend income   188    72    308    131 
Total  $400   $(2,239)  $335   $(2,736)

 

Note 6. Short-term investments

 

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   June 30,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   13    13 
Total   13    13 

 

There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.

 

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

 

   June 30,
2023
   December 31,
2022
 
Option term (in years)   1.3    1.8 
Volatility   76.9%   76.90%
Risk-free interest rate   4.47%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $0.96   $0.96 

  

10

 

 

Note 7. Long-Term Investments

 

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   Cost Basis   June 30,
2023
   December  31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in AerocarveUS Corporation   1,075    1,075    1,000 
Investment in Qxpress   1,000    1,000    1,000 
Investment in Masterclass   170    170    170 
Investment in Kraken   597    597    597 
Investment in Epic Games   3,500    3,500    3,500 
Investment in Tesspay   1,240    2,500    2,500 
Investment in SpaceX   3,500    3,674    3,674 
Investment in Databricks   1,200    1,200    1,200 
Investment in Discord   476    476    476 
Investment in Thrasio   300    300    300 
Investment in Automation Anywhere   476    476    476 
Investment in Anduril   476    476    476 
Total  $20,922   $23,178   $23,103 

 

Investment in AerocarveUS Corporation

 

On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.

 

Note 8. Notes Receivable

 

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

 

   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  01/29/2023   8%  $1,000   $199   $1,199 
Convergent convertible note - non-current  01/29/2023   8%  $500   $
-
   $500 
Raefan Industries LLC Investment  12/31/2023   8%  $4,518   $623   $5,141 
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $22   $1,122 
                        
Notes receivable, at fair value - current portion                    $6,339 
                        
Notes receivable, at fair value - non-current portion                    $1,622 

 

 

11

 

 

Convergent Therapeutics, Inc. Investment

 

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

 

The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023.

 

Raefan Industries LLC Investment

  

The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million.

  

American Innovative Robotics, LLC Investment

  

The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.

 

Kaya Now Inc. Investment

 

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023.

 

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

   

Note 9. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

12

 

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   Fair value measured as of June 30, 2023 
   Total at 
June 30,
   Quoted
prices in
active markets
   Significant other
observable inputs
  

Significant unobservable

inputs

 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $20,675   $20,675   $
       -
   $
-
 
Total marketable securities  $20,675   $20,675   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $6,339   $
-
   $
-
   $6,339 
Notes receivable at fair value, non-current portion  $1,622   $
-
   $
-
   $1,622 

 

   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
    -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

13

 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

  

Short-term investment at December 31, 2022  $13 
Short-term investment at June 30, 2023  $13 
     
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (500)
Note receivable, Convergent Therapeutics, non-current portion   (500)
Unrealized loss on note receivable   (212)
Accrued interest receivable   77 
Notes receivable at fair value, current portion at June 30, 2023  $6,339 

 

Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Note receivable, Convergent Therapeutics, non-current portion   500 
Accrued interest receivable   22 
Notes receivable at fair value, non-current portion at June 30, 2023  $1,622 

 

Note Receivable at fair value

   

As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.

 

Note 10. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

14

 

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

  

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

 

   June 30,
2023
 
Assets:     
Operating lease right-of-use-assets  $3,530 
      
Liabilities:     
Current     
Operating   353 
Long-term     
Operating   3,259 
   $3,612 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

  

June 30,

2023

 
Weighted-average remaining lease term – operating leases (in years)   7.0 
Weighted-average discount rate – operating leases   10.0%

 

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

 

   Three Months Ended   Six  Months Ended
   June 30,
2023
   June 30,
2023
 
Operating leases        
Operating lease cost  $179   $313 
Operating lease expense   179    313 
Short-term lease rent expense   33    63 
Net rent expense  $212   $376 

 

Supplemental cash flow information related to leases were as follows:

 

   Six Months
Ended
 
   June 30,
2023
 
Operating cash flows - operating leases  $72 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,796 

 

15

 

 

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2023  $327 
Year Ended December 31, 2024   750 
Year Ended December 31, 2025   688 
Year Ended December 31, 2026   688 
Year Ended December 31, 2027   688 
Year Ended December 31, 2028   770 
Thereafter   1,166 
Total   5,077 
Less present value discount   (1,465)
Operating lease liabilities  $3,612 

 

Note 11. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:

 

   As of June 30, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Options to purchase common stock   30,336    198,574 
Total   475,166    643,404 

 

Note 12. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

 

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.

 

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below.

  

16

 

 

Treasury Stock

 

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

 

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

 

   Warrants   Weighted
Average
Exercise Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2022   444,796   $29.25    
   -
    3.20 
Outstanding as of June 30, 2023   444,796   $29.25    
-
    2.71 

 

Restricted Stock Awards

 

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

 

   Number of Restricted
Stock Awards
   Weighted Average
Grant Day Fair Value
 
Nonvested at December 31, 2022   8,068   $5.64 
Granted   529,715   $2.58 
Vested   (537,783)   2.63 
Nonvested at June 30, 2023   
-
   $
-
 

 

As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

 

   Number of Shares   Weighted Average
Exercise Price
   Total Intrinsic Value   Weighted Average
Remaining Contractual
Life (in years)
 
Outstanding as of December 31, 2022   31,193   $302.97   $
     -
    7.9 
Employee options expired   (857)  $9,719.07           
Outstanding as of June 30, 2023   30,336   $36.97   $
-
    7.6 
Options vested and exercisable   26,578   $41.35   $
-
    7.5 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

 

17

 

 

Note 13. Revenue

 

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023         2022       2023       2022 
Underwriting  $43   $
-
   $43   $
-
 
Commissions   14    
-
    14    
-
 
Other   14    
-
   $14    
-
 
Total  $71   $
-
   $71   $
 -
 

 

Note 14. Commitments and Contingencies

 

Legal Proceedings

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

Note 15. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.

 

Note 16. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.

 

18

 

 

Note 17. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido Pharma reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Three Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $
-  
   $71 
Operating Costs               
General and administrative   6,957    2,123   $9,080 
Research and development        2    2 
Loss from operations  $(6,886)  $(2,125)  $(9,011)
                
Other (expenses) income               
Other income             
-  
 
Interest income   44    116    160 
Loss on marketable securities        400    400 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $304   $348 
Net loss  $(6,842)  $(1,821)  $(8,663)

 

   Six Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $-     $71 
Operating Costs               
General and administrative   8,056    4,857    12,913 
Research and development        3    3 
Loss from operations  $(7,985)  $(4,860)  $(12,845)
                
Other (expenses) income               
Other income        
-  
    
-  
 
Interest income   44    253    297 
Loss on marketable securities        335    335 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $376   $420 
Net loss  $(7,941)  $(4,484)  $(12,425)

 

19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

 

Overview

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (Dominari Securities), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.  

 

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass.  

  

Reverse Stock Split

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the unaudited condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements. We have identified the accounting policies that we believe require application of management’s most subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our actual results may differ substantially from these estimates under different assumptions or conditions. There have been no significant changes to our critical accounting policies and estimates since December 31, 2022. The following represent those critical accounting policies that we believe most significantly impact the judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements. 

 

20

 

 

Long-term investments

 

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

 

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

 

Refer to Note 3 of the Annual Report for a discussion of all accounting policies.

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.  

 

Results of Operations

 

Three Months Ended June 30, 2023, compared to the Three Months Ended June 30, 2022

 

During the three months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the three months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $9.0 million and $2.3 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

 

  i. An approximate $6.8 million increase in general and administrative expenses – driven by approximately $0.02 million and $0.8 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

 

  ii. An approximate $0.03 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

 

During the three months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.3 million and $(2.8) million, respectively. The activity for the three months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.4 million for the three months ended June 30, 2023. The decrease of approximately $2.6 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.6 million and increase in dividend income of approximately $0.1 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

 

  ii. Short-term and long-term investments –The changes over the three months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.8 million on the adjusted fair value of the investments during the three months ended June 30, 2023 and 2022, respectively.

 

21

 

 

Six Months Ended June 30, 2023, compared to the Six months ended June 30, 2022

 

During the six months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the six months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $12.8 million and $6.1 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

 

  i. An approximate $8.9 million increase in general and administrative expenses – driven by approximately $0.1 million and $0.9 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

 

  ii. An approximate $2.0 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

 

During the six months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.4 million and $(2.5) million, respectively. The activity for the six months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.3 million for the six months ended June 30, 2023. The decrease of approximately $3.1 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.8 million and increase in dividend income of approximately $0.2 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

 

  ii. Short-term and long-term investments –The changes over the six months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.2 million on the adjusted fair value of the investments during the six months ended June 30, 2023 and 2022, respectively.

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

  managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

  seeking additional funds raised through the sale of additional securities in the future; and

 

  seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $35.7 million as of June 30, 2023. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly-traded company or from continuing operations.

 

22

 

 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

Cash Flows from Operating Activities

 

For the six months ended June 30, 2023 and 2022, net cash used in operations was approximately $13.9 million and $5.9 million, respectively. The cash used in operating activities for the six months ended June 30, 2023, is primarily attributable to a net loss of approximately $11.7 million, approximately $0.5 million of realized gain on marketable securities and changes in operating assets and liabilities of $4.6 million, partially offset by $2.7 million stock-based compensation expense and approximately $0.5 million in unrealized losses on marketable securities. The cash used in operating activities for the three months ended June 30, 2022 primarily resulted from a net loss of $8.6 million and change in fair value of long-term investment of $1.4 million and is partially offset by change in fair value of short-term investment of $1.6 million and unrealized loss on marketable securities of $2.3 million. 

 

Cash Flows from Investing Activities

 

For the six months ended June 30, 2023 and 2022, net cash used in investing activities was approximately $14.7 million and $15.3 million, respectively. The cash used in investing activities for the six months ended June 30, 2023, primarily resulted from our purchase of marketable securities of approximately $34.0 million and the acquisition of FPS of approximately $1.1 million, partially offset by our sale of marketable securities of approximately $20.5 million. The Company also collected approximately $0.5 million in principal related to its short-term notes. The cash used in investing activities for the six months ended June 30, 2022 primarily resulted from our purchase of marketable securities of $27.5 million, purchase of promissory notes of $1.6 million and purchase of investments of $14.6 million, partially offset by our sale of marketable securities of $28.3 million since we invest excess cash into marketable securities until additional cash is needed.

 

Cash Flows from Financing Activities

 

For the six months ended June 30, 2023, cash used in financing activities was approximately $0.9 million, which reflects the cost for purchase of treasury stock of approximately $0.9 million. Cash used in financing activities for the six months ended June 30, 2022 was $5.6 million, which reflects the cost for redemption of Series O and Series P Redeemable Convertible Preferred Stock of $22.0 million and cost for purchase of treasury stock of $1.5 million, partially offset by net proceeds of $17.9 million from investors in exchange of issuance of issuance of Series O and Series P Redeemable Convertible Preferred Stock. 

 

23

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

During the quarter ended June 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, as of the end of the period covered by this report.

  

Changes in Internal Control Over Financial Reporting

 

We have not made any changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

 

Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

24

 

  

Part II. Other Information

 

Item 1. Legal Proceedings

 

In the past, in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. Other than ordinary routine litigation incidental to the business, we know of no material, active or pending legal proceedings against us.

 

Item 1A. Risk Factors

 

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q and in the other periodic and current reports and other documents we file with the Securities and Exchange Commission, including but not limited to our annual report on Form 10-K for the fiscal year ended December 31, 2022, before deciding to invest in our common stock. If any of the following risks materialize, our business, financial condition, results of operation and future prospects will likely be materially and adversely affected. In that event, the market price of our common stock could decline and you could lose all or part of your investment. This list is not exhaustive and the order of presentation does not reflect management’s determination of priority or likelihood. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

10.1   Employment Agreement, made and entered into as of April 3, 20234, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
10.2   Amendment to Employment Agreement, made and entered into as of April 19, 2023, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith

 

25

 

 

Signatures

 

Pursuant to the requirements of the Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DOMINARI HOLDINGS INC.
     
Date: August 9, 2023 By: /s/ Anthony Hayes
    Anthony Hayes
    Chief Executive Officer
    (Principal Executive Officer)

 

     
Date: August 9, 2023 By: /s/ George Way
    George Way
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

26

 

 

1.18 1.79 2.42 2.45 4827239 5065055 5251023 5251766 false --12-31 Q2 0000012239 0000012239 2023-01-01 2023-06-30 0000012239 2023-08-08 0000012239 2023-06-30 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-06-30 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2023-04-01 2023-06-30 0000012239 2022-04-01 2022-06-30 0000012239 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012239 us-gaap:RetainedEarningsMember 2023-03-31 0000012239 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012239 us-gaap:PreferredStockMember 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:CommonStockMember 2022-03-31 0000012239 us-gaap:PreferredStockMember 2022-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-03-31 0000012239 us-gaap:RetainedEarningsMember 2022-03-31 0000012239 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-06-30 0000012239 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-06-30 0000012239 domh:FPSPurchaseAgreementMember 2023-06-30 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 domh:VicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:VicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 2021-11-22 2021-11-22 0000012239 2023-03-01 2023-03-31 0000012239 2023-06-01 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-06-30 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-06-30 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-06-30 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2023-06-30 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-06-30 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-06-30 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-06-30 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-06-30 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-06-30 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-06-30 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-06-30 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-06-30 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-06-30 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-06-30 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-06-30 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 us-gaap:NotesPayableOtherPayablesMember domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowPromissoryNoteMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0000012239 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 domh:OperatingLeaseMember 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 us-gaap:WarrantMember 2022-01-01 2022-06-30 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 us-gaap:CommonStockMember 2023-06-01 2023-06-27 0000012239 2023-06-01 2023-06-27 0000012239 2022-01-01 2022-01-21 0000012239 2023-03-01 2023-03-06 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-04-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-04-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-04-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-01-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-01-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0623ex31-1_dominari.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

  1. I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

 

 2.

 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2023  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

 

EX-31.2 3 f10q0623ex31-2_dominari.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, George Way, certify that:

  1. I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

  4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2023  
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

EX-32.1 4 f10q0623ex32-1_dominari.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Haynes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

 
Date: August 9, 2023  
   
  /s/ Anthony Haynes
  Anthony Haynes
  Chief Executive Officer
  (Principal Executive Officer)
EX-32.2 5 f10q0623ex32-2_dominari.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

 

 
Date: August 9, 2023  
   
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

EX-101.SCH 6 domh-20230630.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - FPS Acquisition link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Investments in Marketable Securities link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Short-Term Investments link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Notes Receivable link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Net Loss per Share link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Regulatory link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Related Party Transaction link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - FPS Acquisition (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Investments in Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Short-Term Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Long-Term Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Notes Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - FPS Acquisition (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Long-Term Investments (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about The Company’s Operating Leases link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - Regulatory (Details) link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - Related Party Transaction (Details) link:presentationLink link:definitionLink link:calculationLink 062 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 domh-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 domh-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 domh-20230630_lab.xml XBRL LABEL FILE EX-101.PRE 10 domh-20230630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 08, 2023
Document Information Line Items    
Entity Registrant Name DOMINARI HOLDINGS INC.  
Trading Symbol DOMH  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   5,345,312
Amendment Flag false  
Entity Central Index Key 0000012239  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-05576  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-0849320  
Entity Address, Address Line One 725 5th Avenue  
Entity Address, Address Line Two 22nd Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
City Area Code (703)  
Local Phone Number 992-9325  
Entity Interactive Data Current Yes  
Title of 12(b) Security Common Stock, $0.0001 par value  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 3,598 $ 33,174
Marketable securities 20,675 7,130
Deposits with clearing broker 7,082
Prepaid expenses and other assets 715 564
Prepaid acquisition cost 301
Short-term investments, at fair value 13 13
Notes receivable, at fair value - current portion 6,339 7,474
Investment in Fieldpoint Securities 2,000
Total current assets 38,422 50,656
Property and equipment, net 387
Notes receivable, at fair value - non-current portion 1,622 1,100
Employee forgivable loan receivable 98
Investments 23,178 23,103
Right-of-use assets 3,530 919
Security deposit 458 458
Total assets 67,695 76,236
Current liabilities    
Accounts payable and accrued expenses 232 447
Accrued salaries and benefits 632 1,260
Income taxes withheld 1,300
Accrued Commissions 17
Lease liability - current 353 82
Other Current liability 124
Total current liabilities 2,658 1,789
Lease liability 3,259 680
Total liabilities 5,917 2,469
Stockholders’ equity    
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital 260,585 262,970
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively (501) (3,322)
Accumulated deficit (198,306) (185,881)
Total stockholders’ equity 61,778 73,767
Total liabilities and stockholders’ equity 67,695 76,236
Series D Preferred Stock    
Stockholders’ equity    
Preferred stock value
Series D-1 Preferred Stock    
Stockholders’ equity    
Preferred stock value
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized 50,000,000 50,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 5,345,312 5,485,096
Common stock, shares outstanding 5,285,164 5,017,079
Treasury stock, at cost 60,148 468,017
Series D Preferred Stock    
Preferred stock, authorized 5,000,000 5,000,000
Preferred stock, issued 3,825 3,825
Preferred stock, outstanding 3,825 3,825
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
Series D-1 Preferred Stock    
Preferred stock, authorized 5,000,000 5,000,000
Preferred stock, issued 834 834
Preferred stock, outstanding 834 834
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenues $ 71 $ 71
Operating costs and expenses        
General and administrative 9,080 2,262 12,913 4,049
Research and development 2 36 3 2,052
Total operating expenses 9,082 2,298 12,916 6,101
Loss from operations (9,011) (2,298) (12,845) (6,101)
Other income (expenses)        
Other income 64
Interest income 160 220 297 399
Gain (loss) on marketable securities 400 (2,239) 335 (2,736)
Unrealized loss on note receivable (212) (212)
Change in fair value of investments (760) (238)
Total other income (expenses) 348 (2,779) 420 (2,511)
Net loss (8,663) (5,077) (12,425) (8,612)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock (1,100) (4,109)
Net Loss Attributable to Common Shareholders $ (8,663) $ (6,177) $ (12,425) $ (12,721)
Net loss per share, basic and diluted        
Basic (in Dollars per share) $ (1.79) $ (1.18) $ (2.45) $ (2.42)
Weighted average number of shares outstanding, basic and diluted        
Basic (in Shares) 4,827,239 5,251,023 5,065,055 5,251,766
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Diluted $ (1.79) $ (1.18) $ (2.45) $ (2.42)
Diluted 4,827,239 5,251,023 5,065,055 5,251,766
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Redeemable Convertible Preferred Stock
Series O
Redeemable Convertible Preferred Stock
Series P
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Total
Balance at Dec. 31, 2021 $ 265,633 $ (264) $ (163,774) $ 101,595
Balance (in Shares) at Dec. 31, 2021 4,659 5,275,329        
Redemption of Series O Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares) (11,000)              
Redemption of Series P Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)   (11,000)            
Issuance of Series O redeemable convertible preferred stock for cash $ 11,000  
Issuance of Series O redeemable convertible preferred stock for cash (in Shares) 11,000              
Issuance of Series P redeemable convertible preferred stock for cash $ 11,000
Issuance of Series P redeemable convertible preferred stock for cash (in Shares)   11,000            
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock (1,504) $ (1,505)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock 1,504 1,505 (4,109) (4,109)
Repurchase of treasury stock $ (1,486) (1,486)
Repurchase of treasury stock (in Shares)           242,902    
Stock-based compensation 105 105
Cancellation of common stock related to investment in CBM
Cancellation of common stock related to investment in CBM (in Shares)       (22,812)        
Fractional shares adjusted for reverse split (26) (26)
Fractional shares adjusted for reverse split (in Shares)       (5,665)        
Net loss (8,612) (8,612)
Balance at Jun. 30, 2022 261,603 $ (1,750) (172,386) 87,467
Balance (in Shares) at Jun. 30, 2022     4,659 5,246,852   242,902    
Balance at Mar. 31, 2022 $ 11,000 $ 11,000 262,624 $ (264) (167,309) 95,051
Balance (in Shares) at Mar. 31, 2022 11,000 11,000 4,659 5,252,517        
Redemption of Series O Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares) (11,000)              
Redemption of Series P Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)   (11,000)            
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock (1,100) (1,100)
Repurchase of treasury stock $ (1,486) (1,486)
Repurchase of treasury stock (in Shares)           242,902    
Stock-based compensation 105 105
Fractional shares adjusted for reverse split (26) (26)
Fractional shares adjusted for reverse split (in Shares)       (5,665)        
Net loss (5,077) (5,077)
Balance at Jun. 30, 2022 261,603 $ (1,750) (172,386) 87,467
Balance (in Shares) at Jun. 30, 2022     4,659 5,246,852   242,902    
Balance at Dec. 31, 2022     262,970 $ (3,322) (185,881) 73,767
Balance (in Shares) at Dec. 31, 2022     4,659 5,485,096   468,017    
Stock-based compensation     1,375 1,375
Stock-based compensation (in Shares)       529,715        
Cancellation of common stock    
Cancellation of common stock (in Shares)       (25,000)        
Purchase of treasury stock (in Shares)     (939,000) (939,000)
Purchase of treasury stock (in Shares)           236,630    
Retirement of treasury stock     $ (3,760) $ 3,760
Retirement of treasury stock (in Shares)       (644,499)   (644,499)    
Net loss     (12,425) (12,425)
Balance at Jun. 30, 2023     260,585 $ (501) (198,306) 61,778
Balance (in Shares) at Jun. 30, 2023     4,659 5,345,312   60,148    
Balance at Mar. 31, 2023         259,215 $ (501) (189,643) 69,071
Balance (in Shares) at Mar. 31, 2023     4,659 4,815,597   60,148    
Stock-based compensation     1,370 1,370
Stock-based compensation (in Shares)     529,715      
Net loss       (8,663) (8,663)
Balance at Jun. 30, 2023     $ 260,585 $ (501) $ (198,306) $ 61,778
Balance (in Shares) at Jun. 30, 2023     4,659 5,345,312   60,148    
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net loss $ (12,425) $ (8,612)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of right-of-use assets 182
Depreciation 32
Change in fair value of short-term investment 1,646
Change in fair value of long-term investment   (1,408)
Stock-based compensation 2,675 105
Realized loss on marketable securities 487 568
Unrealized (gain) loss on marketable securities (514) 2,299
Unrealized loss on note receivable 212
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (229) 153
Prepaid acquisition cost 301
Deposits with clearing broker (3,532)
Accounts payable and accrued expenses (428) (239)
Accrued salaries and benefits (628) 7
Accrued commissions (8)
Lease liabilities 58
Other current liabilities 3
Notes receivable, at fair value – net interest accrued (99) (377)
Deposit 8
Net cash used in operating activities (13,913) (5,850)
Cash flows from investing activities    
Purchase of marketable securities (34,014) (27,460)
Sale of marketable securities 20,494 28,272
Proceeds from sale of digital currencies 93
Purchase of fixed assets (419)
Acquisition of FPS, net of cash acquired and receivable owed from FPS (1,112)
Collection of principal on note receivable 502
Funds to employee forgivable loan (100)
Purchase of short-term and long-term investments (75) (14,605)
Purchase of short-term and long-term promissory notes (1,600)
Net cash used in investing activities (14,724) (15,300)
Cash flows from financing activities    
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost 17,891
Payment for fractional shares (26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock (22,000)
Purchase of treasury stock (939) (1,486)
Net cash used in financing activities (939) (5,621)
Net decrease in cash and cash equivalents and restricted cash (29,576) (26,771)
Cash and cash equivalents, beginning of period 33,174 65,562
Cash and cash equivalents, end of period 3,598 38,791
Non-cash investing and financing activities    
Transfer from short-term investment to marketable securities 1,482
Reclassify from convertible note receivable to notes receivable at fair value 2,147
Promissory convertible note receivable conversion into common shares $ 1,508
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:    
Net assets acquired, net of cash acquired and receivable owed from FPS 3,112  
Less - Deposit previously transferred in October 2022 to FPS (2,000)  
Net cash paid $ 1,112  
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Organization and Description of Business and Recent Developments
6 Months Ended
Jun. 30, 2023
Organization and Description of Business and Recent Developments [Abstract]  
Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Liquidity and Capital Resources
6 Months Ended
Jun. 30, 2023
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - Leases).

 

Revenue

 

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

 

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
FPS Acquisition
6 Months Ended
Jun. 30, 2023
FPS Acquisition [Abstract]  
FPS Acquisition

Note 4. FPS Acquisition

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. 

 

Consideration Transferred

 

The FPS Acquisition was accounted for as a business combination under ASC 805.

 

Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023.

 

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations.

 

Fair Value of Net Assets Acquired

 

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

 

   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 

 

Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Investments in Marketable Securities
6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Investments in Marketable Securities

Note 5. Investments in Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023   2022   2023   2022 
Realized loss  $(432)  $(344)  $(487)  $(568)
Unrealized gain (loss)   643    (1,967)   514    (2,299)
Dividend income   188    72    308    131 
Total  $400   $(2,239)  $335   $(2,736)
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Short-Term Investments
6 Months Ended
Jun. 30, 2023
Short-Term Investments [Abstract]  
Short-term investments

Note 6. Short-term investments

 

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   June 30,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   13    13 
Total   13    13 

 

There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.

 

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

 

   June 30,
2023
   December 31,
2022
 
Option term (in years)   1.3    1.8 
Volatility   76.9%   76.90%
Risk-free interest rate   4.47%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $0.96   $0.96 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Long-Term Investments
6 Months Ended
Jun. 30, 2023
Long-Term Investments [Abstract]  
Long-Term Investments

Note 7. Long-Term Investments

 

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   Cost Basis   June 30,
2023
   December  31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in AerocarveUS Corporation   1,075    1,075    1,000 
Investment in Qxpress   1,000    1,000    1,000 
Investment in Masterclass   170    170    170 
Investment in Kraken   597    597    597 
Investment in Epic Games   3,500    3,500    3,500 
Investment in Tesspay   1,240    2,500    2,500 
Investment in SpaceX   3,500    3,674    3,674 
Investment in Databricks   1,200    1,200    1,200 
Investment in Discord   476    476    476 
Investment in Thrasio   300    300    300 
Investment in Automation Anywhere   476    476    476 
Investment in Anduril   476    476    476 
Total  $20,922   $23,178   $23,103 

 

Investment in AerocarveUS Corporation

 

On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Receivable
6 Months Ended
Jun. 30, 2023
Notes Receivable [Abstract]  
Notes Receivable

Note 8. Notes Receivable

 

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

 

   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  01/29/2023   8%  $1,000   $199   $1,199 
Convergent convertible note - non-current  01/29/2023   8%  $500   $
-
   $500 
Raefan Industries LLC Investment  12/31/2023   8%  $4,518   $623   $5,141 
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $22   $1,122 
                        
Notes receivable, at fair value - current portion                    $6,339 
                        
Notes receivable, at fair value - non-current portion                    $1,622 

 

Convergent Therapeutics, Inc. Investment

 

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

 

The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023.

 

Raefan Industries LLC Investment

  

The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million.

  

American Innovative Robotics, LLC Investment

  

The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.

 

Kaya Now Inc. Investment

 

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023.

 

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2023
Fair Value of Financial Assets and Liabilities [Abstract]  
Fair Value of Financial Assets and Liabilities

Note 9. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

   Fair value measured as of June 30, 2023 
   Total at 
June 30,
   Quoted
prices in
active markets
   Significant other
observable inputs
  

Significant unobservable

inputs

 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $20,675   $20,675   $
       -
   $
-
 
Total marketable securities  $20,675   $20,675   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $6,339   $
-
   $
-
   $6,339 
Notes receivable at fair value, non-current portion  $1,622   $
-
   $
-
   $1,622 

 

   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
    -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

  

Short-term investment at December 31, 2022  $13 
Short-term investment at June 30, 2023  $13 
     
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (500)
Note receivable, Convergent Therapeutics, non-current portion   (500)
Unrealized loss on note receivable   (212)
Accrued interest receivable   77 
Notes receivable at fair value, current portion at June 30, 2023  $6,339 

 

Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Note receivable, Convergent Therapeutics, non-current portion   500 
Accrued interest receivable   22 
Notes receivable at fair value, non-current portion at June 30, 2023  $1,622 

 

Note Receivable at fair value

   

As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases

Note 10. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

  

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

 

   June 30,
2023
 
Assets:     
Operating lease right-of-use-assets  $3,530 
      
Liabilities:     
Current     
Operating   353 
Long-term     
Operating   3,259 
   $3,612 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

  

June 30,

2023

 
Weighted-average remaining lease term – operating leases (in years)   7.0 
Weighted-average discount rate – operating leases   10.0%

 

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

 

   Three Months Ended   Six  Months Ended
   June 30,
2023
   June 30,
2023
 
Operating leases        
Operating lease cost  $179   $313 
Operating lease expense   179    313 
Short-term lease rent expense   33    63 
Net rent expense  $212   $376 

 

Supplemental cash flow information related to leases were as follows:

 

   Six Months
Ended
 
   June 30,
2023
 
Operating cash flows - operating leases  $72 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,796 

 

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2023  $327 
Year Ended December 31, 2024   750 
Year Ended December 31, 2025   688 
Year Ended December 31, 2026   688 
Year Ended December 31, 2027   688 
Year Ended December 31, 2028   770 
Thereafter   1,166 
Total   5,077 
Less present value discount   (1,465)
Operating lease liabilities  $3,612 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share
6 Months Ended
Jun. 30, 2023
Net Loss per Share [Abstract]  
Net Loss per Share

Note 11. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:

 

   As of June 30, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Options to purchase common stock   30,336    198,574 
Total   475,166    643,404 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock
6 Months Ended
Jun. 30, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Stockholders’ Equity and Convertible Preferred Stock

Note 12. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

 

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.

 

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below.

  

Treasury Stock

 

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

 

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

 

   Warrants   Weighted
Average
Exercise Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2022   444,796   $29.25    
   -
    3.20 
Outstanding as of June 30, 2023   444,796   $29.25    
-
    2.71 

 

Restricted Stock Awards

 

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

 

   Number of Restricted
Stock Awards
   Weighted Average
Grant Day Fair Value
 
Nonvested at December 31, 2022   8,068   $5.64 
Granted   529,715   $2.58 
Vested   (537,783)   2.63 
Nonvested at June 30, 2023   
-
   $
-
 

 

As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

 

   Number of Shares   Weighted Average
Exercise Price
   Total Intrinsic Value   Weighted Average
Remaining Contractual
Life (in years)
 
Outstanding as of December 31, 2022   31,193   $302.97   $
     -
    7.9 
Employee options expired   (857)  $9,719.07           
Outstanding as of June 30, 2023   30,336   $36.97   $
-
    7.6 
Options vested and exercisable   26,578   $41.35   $
-
    7.5 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
6 Months Ended
Jun. 30, 2023
Revenue [Abstract]  
Revenue

Note 13. Revenue

 

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023         2022       2023       2022 
Underwriting  $43   $
-
   $43   $
-
 
Commissions   14    
-
    14    
-
 
Other   14    
-
   $14    
-
 
Total  $71   $
-
   $71   $
 -
 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 14. Commitments and Contingencies

 

Legal Proceedings

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Regulatory
6 Months Ended
Jun. 30, 2023
Regulatory [Abstract]  
Regulatory

Note 15. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transaction
6 Months Ended
Jun. 30, 2023
Related Party Transaction [Abstract]  
Related Party Transaction

Note 16. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Reporting
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Reporting

Note 17. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido Pharma reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Three Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $
-  
   $71 
Operating Costs               
General and administrative   6,957    2,123   $9,080 
Research and development        2    2 
Loss from operations  $(6,886)  $(2,125)  $(9,011)
                
Other (expenses) income               
Other income             
-  
 
Interest income   44    116    160 
Loss on marketable securities        400    400 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $304   $348 
Net loss  $(6,842)  $(1,821)  $(8,663)

 

   Six Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $-     $71 
Operating Costs               
General and administrative   8,056    4,857    12,913 
Research and development        3    3 
Loss from operations  $(7,985)  $(4,860)  $(12,845)
                
Other (expenses) income               
Other income        
-  
    
-  
 
Interest income   44    253    297 
Loss on marketable securities        335    335 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $376   $420 
Net loss  $(7,941)  $(4,484)  $(12,425)
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

Use of Estimates

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Deposits with clearing broker

Deposits with clearing broker

Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.

Leases

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - Leases).

Revenue

Revenue

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.
Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
Recently adopted accounting standards

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

Effect of new accounting pronouncements not yet adopted

Effect of new accounting pronouncements not yet adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
FPS Acquisition (Tables)
6 Months Ended
Jun. 30, 2023
FPS Acquisition [Abstract]  
Schedule of Fair Values of the Assets Acquired And Liabilities The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:
   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Investments in Marketable Securities (Tables)
6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):
   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023   2022   2023   2022 
Realized loss  $(432)  $(344)  $(487)  $(568)
Unrealized gain (loss)   643    (1,967)   514    (2,299)
Dividend income   188    72    308    131 
Total  $400   $(2,239)  $335   $(2,736)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Short-Term Investments (Tables)
6 Months Ended
Jun. 30, 2023
Short-Term Investments [Abstract]  
Schedule of Short-Term Investments The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):
   June 30,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   13    13 
Total   13    13 
Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:
   June 30,
2023
   December 31,
2022
 
Option term (in years)   1.3    1.8 
Volatility   76.9%   76.90%
Risk-free interest rate   4.47%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $0.96   $0.96 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Long-Term Investments (Tables)
6 Months Ended
Jun. 30, 2023
Long-Term Investments [Abstract]  
Schedule of Long-Term Investments The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):
   Cost Basis   June 30,
2023
   December  31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in AerocarveUS Corporation   1,075    1,075    1,000 
Investment in Qxpress   1,000    1,000    1,000 
Investment in Masterclass   170    170    170 
Investment in Kraken   597    597    597 
Investment in Epic Games   3,500    3,500    3,500 
Investment in Tesspay   1,240    2,500    2,500 
Investment in SpaceX   3,500    3,674    3,674 
Investment in Databricks   1,200    1,200    1,200 
Investment in Discord   476    476    476 
Investment in Thrasio   300    300    300 
Investment in Automation Anywhere   476    476    476 
Investment in Anduril   476    476    476 
Total  $20,922   $23,178   $23,103 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Receivable (Tables)
6 Months Ended
Jun. 30, 2023
Notes Receivable [Abstract]  
Schedule of Notes Receivable The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):
   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  01/29/2023   8%  $1,000   $199   $1,199 
Convergent convertible note - non-current  01/29/2023   8%  $500   $
-
   $500 
Raefan Industries LLC Investment  12/31/2023   8%  $4,518   $623   $5,141 
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $22   $1,122 
                        
Notes receivable, at fair value - current portion                    $6,339 
                        
Notes receivable, at fair value - non-current portion                    $1,622 

 

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value of Financial Assets and Liabilities [Abstract]  
Schedule of Fair Value Assets and Liabilities The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):
   Fair value measured as of June 30, 2023 
   Total at 
June 30,
   Quoted
prices in
active markets
   Significant other
observable inputs
  

Significant unobservable

inputs

 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $20,675   $20,675   $
       -
   $
-
 
Total marketable securities  $20,675   $20,675   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $6,339   $
-
   $
-
   $6,339 
Notes receivable at fair value, non-current portion  $1,622   $
-
   $
-
   $1,622 
   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
    -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

Schedule of Fair Value on a Recurring Basis The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):
Short-term investment at December 31, 2022  $13 
Short-term investment at June 30, 2023  $13 
     
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (500)
Note receivable, Convergent Therapeutics, non-current portion   (500)
Unrealized loss on note receivable   (212)
Accrued interest receivable   77 
Notes receivable at fair value, current portion at June 30, 2023  $6,339 
Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Note receivable, Convergent Therapeutics, non-current portion   500 
Accrued interest receivable   22 
Notes receivable at fair value, non-current portion at June 30, 2023  $1,622 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Schedule of Lease Assets and Liabilities The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:
   June 30,
2023
 
Assets:     
Operating lease right-of-use-assets  $3,530 
      
Liabilities:     
Current     
Operating   353 
Long-term     
Operating   3,259 
   $3,612 
Schedule of Summarize Quantitative Information about The Company’s Operating Leases The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:
  

June 30,

2023

 
Weighted-average remaining lease term – operating leases (in years)   7.0 
Weighted-average discount rate – operating leases   10.0%
Schedule of Lease Expense to Current Period Operations During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.
   Three Months Ended   Six  Months Ended
   June 30,
2023
   June 30,
2023
 
Operating leases        
Operating lease cost  $179   $313 
Operating lease expense   179    313 
Short-term lease rent expense   33    63 
Net rent expense  $212   $376 
Schedule of Supplemental Cash Flow Information Related To Leases Supplemental cash flow information related to leases were as follows:
   Six Months
Ended
 
   June 30,
2023
 
Operating cash flows - operating leases  $72 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,796 

 

Schedule of Future Minimum Payments As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:
   Operating 
   Leases 
Remaining Period Ended December 31, 2023  $327 
Year Ended December 31, 2024   750 
Year Ended December 31, 2025   688 
Year Ended December 31, 2026   688 
Year Ended December 31, 2027   688 
Year Ended December 31, 2028   770 
Thereafter   1,166 
Total   5,077 
Less present value discount   (1,465)
Operating lease liabilities  $3,612 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share (Tables)
6 Months Ended
Jun. 30, 2023
Net Loss per Share [Abstract]  
Schedule of Computation of Diluted Loss Per Share Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:
   As of June 30, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Options to purchase common stock   30,336    198,574 
Total   475,166    643,404 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock (Tables)
6 Months Ended
Jun. 30, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Schedule of Warrant Activity A summary of warrant activity for the six months ended June 30, 2023, is presented below:
   Warrants   Weighted
Average
Exercise Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2022   444,796   $29.25    
   -
    3.20 
Outstanding as of June 30, 2023   444,796   $29.25    
-
    2.71 
Schedule of Restricted Stock Awards Activity A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:
   Number of Restricted
Stock Awards
   Weighted Average
Grant Day Fair Value
 
Nonvested at December 31, 2022   8,068   $5.64 
Granted   529,715   $2.58 
Vested   (537,783)   2.63 
Nonvested at June 30, 2023   
-
   $
-
 
Schedule of Stock Option Activity A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:
   Number of Shares   Weighted Average
Exercise Price
   Total Intrinsic Value   Weighted Average
Remaining Contractual
Life (in years)
 
Outstanding as of December 31, 2022   31,193   $302.97   $
     -
    7.9 
Employee options expired   (857)  $9,719.07           
Outstanding as of June 30, 2023   30,336   $36.97   $
-
    7.6 
Options vested and exercisable   26,578   $41.35   $
-
    7.5 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2023
Revenue [Abstract]  
Schedule of Total Revenues Disaggregated By Revenue The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):
   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2023         2022       2023       2022 
Underwriting  $43   $
-
   $43   $
-
 
Commissions   14    
-
    14    
-
 
Other   14    
-
   $14    
-
 
Total  $71   $
-
   $71   $
 -
 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.
   Three Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $
-  
   $71 
Operating Costs               
General and administrative   6,957    2,123   $9,080 
Research and development        2    2 
Loss from operations  $(6,886)  $(2,125)  $(9,011)
                
Other (expenses) income               
Other income             
-  
 
Interest income   44    116    160 
Loss on marketable securities        400    400 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $304   $348 
Net loss  $(6,842)  $(1,821)  $(8,663)
   Six Months Ended June 30, 2023 
   Dominari Securities   Legacy AIkido Pharma   Consolidated 
Revenue  $71   $-     $71 
Operating Costs               
General and administrative   8,056    4,857    12,913 
Research and development        3    3 
Loss from operations  $(7,985)  $(4,860)  $(12,845)
                
Other (expenses) income               
Other income        
-  
    
-  
 
Interest income   44    253    297 
Loss on marketable securities        335    335 
Unrealized loss on note receivable        (212)   (212)
Total other (expenses) income  $44   $376   $420 
Net loss  $(7,941)  $(4,484)  $(12,425)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Accounting Policies [Abstract]  
Money market funds $ 7.1
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
FPS Acquisition (Details) - USD ($)
6 Months Ended
Oct. 04, 2022
Jun. 30, 2023
Sep. 09, 2022
FPS Acquisition (Details) [Line Items]      
Cash   $ 3,400,000  
Transaction costs   900,000  
Net loss   7,700,000  
Revenue   70,000.00  
Professional service costs   $ 5,400,000  
FPS Purchase Agreement [Member]      
FPS Acquisition (Details) [Line Items]      
Membership interests rate 20.00% 80.00% 100.00%
Consideration amount $ 2,000,000    
Additional consideration   $ 1,600,000  
Percentage of acquired membership interest   100.00%  
Cash   $ 3,600,000  
Purchase price   1  
Net assets   3,400,000  
Receivable amount   200,000  
Transaction costs   $ 300,000  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities - Business Combination [Member]
$ in Thousands
Mar. 27, 2023
USD ($)
ASSETS  
Cash and cash equivalents $ 92
Deposits with Clearing Broker-Dealer 3,550
Other receivables 53
Prepaid and other current assets 89
Total assets acquired 3,784
Liabilities  
Accrued expenses 273
Accrued commissions 25
Wealth management liabilities 62
Total liabilities assumed 360
Total net assets of FPS Acquisition $ 3,424
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Investments in Marketable Securities (Details) - Schedule of Marketable Securities - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Schedule of marketable securities [Abstract]        
Realized loss $ (432) $ (344) $ (487) $ (568)
Unrealized gain (loss) 643 (1,967) 514 (2,299)
Dividend income 188 72 308 131
Total $ 400 $ (2,239) $ 335 $ (2,736)
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Short-Term Investments (Details) - Schedule of Short-Term Investments - Investment in Vicinity Motor Corp. [Member] - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Short-Term Investments [Line Items]    
Investment in Vicinity Motor Corp. $ 13 $ 13
Total $ 13 $ 13
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs - Vicinity Motor Corp [Member] - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Line Items]    
Option term (in years) 1 year 3 months 18 days 1 year 9 months 18 days
Volatility 76.90% 76.90%
Risk-free interest rate 4.47% 4.47%
Expected dividends 0.00% 0.00%
Stock price (in Dollars per share) $ 0.96 $ 0.96
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Long-Term Investments (Details) - USD ($)
$ in Thousands
1 Months Ended
Nov. 22, 2021
Jun. 30, 2023
Mar. 31, 2023
Long-Term Investments [Abstract]      
Purchase shares 250,000   64,377
Purchase amount $ 1,000 $ 80  
Additional purchased shares   150,000  
Investment   $ 1,080  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Long-Term Investments (Details) - Schedule of Long-Term Investments - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis $ 20,922  
Long-term investments, Total 23,178 $ 23,103
Investment In Kerna Health Inc [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 2,140  
Long-term investments, Total 4,940 4,940
Investment in Kaya Now [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,500  
Long-term investments, Total
Investment in Tevva Motors [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,972  
Long-term investments, Total 2,794 2,794
Investment in ASP Isotopes [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,300  
Long-term investments, Total
Investment in AerocarveUS Corporation [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,075  
Long-term investments, Total 1,075 1,000
Investment in Qxpress [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,000  
Long-term investments, Total 1,000 1,000
Investment in Masterclass [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 170  
Long-term investments, Total 170 170
Investment in Kraken [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 597  
Long-term investments, Total 597 597
Investment in Epic Games [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 3,500  
Long-term investments, Total 3,500 3,500
Investment in Tesspay [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,240  
Long-term investments, Total 2,500 2,500
Investment in SpaceX [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 3,500  
Long-term investments, Total 3,674 3,674
Investment in Databricks [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,200  
Long-term investments, Total 1,200 1,200
Investment in Discord [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476  
Long-term investments, Total 476 476
Investment in Thrasio [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 300  
Long-term investments, Total 300 300
Investment in Automation Anywhere [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476  
Long-term investments, Total 476 476
Investment in Anduril [Member]    
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476  
Long-term investments, Total $ 476 $ 476
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Receivable (Details) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Notes Receivable (Details) [Line Items]    
Principal amount $ 1,800,000  
Accrued interest 250,000  
Interest income 100,000  
Impairment loss $ 0  
Convergent Therapeutics, Inc. Investment [Member]    
Notes Receivable (Details) [Line Items]    
Convertible promissory note percentage 8.00%  
Promissory note maturity date Jan. 29, 2023  
Principal amount $ 1,800,000  
Convergent Therapeutics, Inc. Investment [Member] | Notes Payable [Member]    
Notes Receivable (Details) [Line Items]    
Principal amount 500,000  
Raefan Industries LLC Investment [Member]    
Notes Receivable (Details) [Line Items]    
Interest income receivable 600,000  
Unrealized loss 200,000  
American Innovative Robotics, LLC Investment [Member]    
Notes Receivable (Details) [Line Items]    
Interest income 44,000  
Impairment charges   $ 500,000
Kaya Now Promissory Note [Member]    
Notes Receivable (Details) [Line Items]    
Interest income $ 10,000  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Receivable (Details) - Schedule of Notes Receivable
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Convergent Convertible Note - Current [Member]  
Notes receivable, at fair value  
Maturity Date Jan. 29, 2023
Stated Interest Rate 8.00%
Principal Amount $ 1,000
Interest Receivable 199
Fair Value $ 1,199
Convergent Convertible Note - Non-Current [Member]  
Notes receivable, at fair value  
Maturity Date Jan. 29, 2023
Stated Interest Rate 8.00%
Principal Amount $ 500
Interest Receivable
Fair Value $ 500
Raefan Industries LLC Investment [Member]  
Notes receivable, at fair value  
Maturity Date Dec. 31, 2023
Stated Interest Rate 8.00%
Principal Amount $ 4,518
Interest Receivable 623
Fair Value $ 5,141
American Innovative Robotics Investment [Member]  
Notes receivable, at fair value  
Maturity Date Apr. 01, 2027
Stated Interest Rate 8.00%
Principal Amount $ 1,100
Interest Receivable 22
Fair Value 1,122
Notes Receivable, at Fair Value - Current Portion [Member]  
Notes receivable, at fair value  
Fair Value 6,339
Notes Receivable, at Fair Value - Non-Current Portion [Member]  
Notes receivable, at fair value  
Fair Value $ 1,622
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Marketable securities:    
Equities $ 20,675 $ 7,130
Total marketable securities 20,675 7,130
Short-term investment 13 13
Notes receivable at fair value, current portion 6,339 7,474
Notes receivable at fair value, non-current portion 1,622 1,100
Quoted prices in active markets (Level 1) [Member]    
Marketable securities:    
Equities 20,675 7,130
Total marketable securities 20,675 7,130
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant other observable inputs (Level 2) [Member]    
Marketable securities:    
Equities
Total marketable securities
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant unobservable inputs (Level 3) [Member]    
Marketable securities:    
Equities
Total marketable securities
Short-term investment 13 13
Notes receivable at fair value, current portion 6,339 7,474
Notes receivable at fair value, non-current portion $ 1,622 $ 1,100
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis - Fair Value, Inputs, Level 3 [Member] - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Short-term investment at December 31, 2022 $ 13
Short-term investment at June 30, 2023 13
Notes receivable at fair value, current portion at December 31, 2022 7,474
Notes receivable at fair value, non-current portion at December 31, 2022 1,100
Collection of principal outstanding (500)
Note receivable, Convergent Therapeutics, non-current portion (500)
Unrealized loss on note receivable (212)
Accrued interest receivable 77
Notes receivable at fair value, current portion at June 30, 2023 6,339
Note receivable, Convergent Therapeutics, non-current portion 500
Accrued interest receivable 22
Notes receivable at fair value, non-current portion at June 30, 2023 $ 1,622
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - USD ($)
6 Months Ended
Sep. 23, 2022
Jun. 30, 2023
Jan. 11, 2023
Leases [Abstract]      
Lease commencement date, description   The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date).  
Rent payment $ 49,368   $ 12,874
Increase rent amount $ 51,868 $ 13,502  
Lease cost   $ 400,000  
Lease term   5 years  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - Schedule of Lease Assets and Liabilities - Operating lease [Member]
$ in Thousands
Jun. 30, 2023
USD ($)
Assets:  
Operating lease right-of-use-assets $ 3,530
Liabilities:  
Current operating liabilities 353
Long -term operating liabilities 3,259
Total $ 3,612
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - Schedule of Summarize Quantitative Information about The Company’s Operating Leases
Jun. 30, 2023
Schedule of summarize quantitative information about the company’s operating leases [Abstract]  
Weighted-average remaining lease term – operating leases (in years) 7 years
Weighted-average discount rate – operating leases 10.00%
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - Schedule of Lease Expense to Current Period Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Operating leases    
Operating lease cost $ 179 $ 313
Operating lease expense 179 313
Short-term lease rent expense 33 63
Net rent expense $ 212 $ 376
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Schedule of supplemental cash flow information related to leases [Abstract]  
Operating cash flows - operating leases $ 72
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,796
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Details) - Schedule of Future Minimum Payments
$ in Thousands
Jun. 30, 2023
USD ($)
Schedule of future minimum payments [Member]  
Remaining Period Ended December 31, 2023 $ 327
Year Ended December 31, 2024 750
Year Ended December 31, 2025 688
Year Ended December 31, 2026 688
Year Ended December 31, 2027 688
Year Ended December 31, 2028 770
Thereafter 1,166
Total 5,077
Less present value discount (1,465)
Operating lease liabilities $ 3,612
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 475,166 643,404
Convertible preferred stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 34 34
Warrants to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 444,796 444,796
Options to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 30,336 198,574
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 06, 2023
Jun. 27, 2023
Jan. 21, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Mar. 20, 2023
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]                
Shares cancelled (in Shares) 644,499             25,000
Common stock retirement shares $ 644,499              
Granted shares   $ 503,876            
Total fair value   2,700,000            
Restricted Stock, Value, Shares Issued Net of Tax Withholdings   1,300,000            
Share Buyback Program amount     $ 3,000,000          
Share repurchased (in Shares)           236,630    
Amount of cost           $ 0.9    
Price per share (in Dollars per share)       $ 3.97   $ 3.97    
Retired shares of treasury stock (in Shares) 644,499              
Original cost $ 3,800,000              
Stock-based compensation expense       $ 1,370,000 $ 105,000 $ 1,375,000 $ 105,000  
Estimated future stock-based compensation expense           7,000    
Over-Allotment Option [Member]                
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]                
Stock-based compensation expense           8,000 0  
Common Stock [Member]                
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]                
Granted shares   $ 1,033,591            
Stock-based compensation expense        
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Class of Warrant or Right [Line Items]    
Outstanding beginning balance, Warrants   444,796
Outstanding beginning balance, Weighted Average Exercise Price   $ 29.25
Outstanding beginning balance, Total Intrinsic Value  
Outstanding beginning balance, Weighted Average Remaining Contractual Life   3 years 2 months 12 days
Outstanding ending balance, Warrants 444,796  
Outstanding ending balance, Weighted Average Exercise Price $ 29.25  
Outstanding ending balance, Total Intrinsic Value  
Outstanding ending balance, Weighted Average Remaining Contractual Life 2 years 8 months 15 days  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity
6 Months Ended
Jun. 30, 2023
$ / shares
shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]  
Number of Restricted Stock Awards, beginning balance | shares 8,068
Weighted Average Grant Day Fair Value, beginning balance | $ / shares $ 5.64
Number of Restricted Stock Awards, ending balance | shares
Weighted Average Grant Day Fair Value, ending balance | $ / shares
Number of Restricted Stock Awards, Granted | shares 529,715
Weighted Average Grant Day Fair Value, Granted | $ / shares $ 2.58
Number of Restricted Stock Awards, Vested | shares (537,783)
Weighted Average Grant Day Fair Value, Vested | $ / shares $ 2.63
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]  
Outstanding beginning balance, Number of Shares | shares 31,193
Outstanding beginning balance, Weighted Average Exercise Price | $ / shares $ 302.97
Outstanding ending balance, Intrinsic Value | $
Outstanding beginning balance, Weighted Average Remaining Contractual Life 7 years 10 months 24 days
Outstanding ending balance, Number of Shares | shares 30,336
Outstanding ending balance, Weighted Average Exercise Price | $ / shares $ 36.97
Outstanding ending balance, Intrinsic Value | $
Outstanding ending balance, Weighted Average Remaining Contractual Life 7 years 7 months 6 days
Number of Shares, Options vested and exercisable | shares 26,578
Weighted Average Exercise Price, Options vested and exercisable | $ / shares $ 41.35
Total Intrinsic Value, Options vested and exercisable | $
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable 7 years 6 months
Number of Shares, Employee options expired | shares (857)
Weighted Average Exercise Price, Employee options expired | $ / shares $ 9,719.07
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Schedule of total revenues disaggregated by revenue [Abstract]        
Underwriting $ 43 $ 43
Commissions 14 14
Other 14 14
Total $ 71 $ 71
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.2
Regulatory (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Regulatory (Details) [Line Items]  
Net capital amount $ 0.1
Excess amount 7.2
Dominari Securities [Member]  
Regulatory (Details) [Line Items]  
Net capital amount $ 7.3
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transaction (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Related Party Transaction [Abstract]    
Incurred fees $ 80 $ 600
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dominari Securities [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 71 $ 71
Operating Costs    
General and administrative 6,957 8,056
Loss from operations (6,886) (7,985)
Other (expenses) income    
Interest income 44 44
Total other (expenses) income 44 44
Net loss (6,842) (7,941)
Legacy AIkido Pharma [Member]    
Segment Reporting Information [Line Items]    
Revenue  
Operating Costs    
General and administrative 2,123 4,857
Research and development 2 3
Loss from operations (2,125) (4,860)
Other (expenses) income    
Other income  
Interest income 116 253
Loss on marketable securities 400 335
Unrealized loss on note receivable (212) (212)
Total other (expenses) income 304 376
Net loss (1,821) (4,484)
Consolidated [Member]    
Segment Reporting Information [Line Items]    
Revenue 71 71
Operating Costs    
General and administrative 9,080 12,913
Research and development 2 3
Loss from operations (9,011) (12,845)
Other (expenses) income    
Other income
Interest income 160 297
Loss on marketable securities 400 335
Unrealized loss on note receivable (212) (212)
Total other (expenses) income 348 420
Net loss $ (8,663) $ (12,425)
XML 74 f10q0623_dominarihold_htm.xml IDEA: XBRL DOCUMENT 0000012239 2023-01-01 2023-06-30 0000012239 2023-08-08 0000012239 2023-06-30 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-06-30 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2023-04-01 2023-06-30 0000012239 2022-04-01 2022-06-30 0000012239 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012239 us-gaap:RetainedEarningsMember 2023-03-31 0000012239 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012239 us-gaap:PreferredStockMember 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:CommonStockMember 2022-03-31 0000012239 us-gaap:PreferredStockMember 2022-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-03-31 0000012239 us-gaap:RetainedEarningsMember 2022-03-31 0000012239 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-06-30 0000012239 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-06-30 0000012239 domh:FPSPurchaseAgreementMember 2023-06-30 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 domh:VicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:VicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 2021-11-22 2021-11-22 0000012239 2023-03-01 2023-03-31 0000012239 2023-06-01 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-06-30 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-06-30 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-06-30 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2023-06-30 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-06-30 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-06-30 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-06-30 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-06-30 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-06-30 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-06-30 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-06-30 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-06-30 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-06-30 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-06-30 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-06-30 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 us-gaap:NotesPayableOtherPayablesMember domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowPromissoryNoteMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0000012239 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 domh:OperatingLeaseMember 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 us-gaap:WarrantMember 2022-01-01 2022-06-30 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 us-gaap:CommonStockMember 2023-06-01 2023-06-27 0000012239 2023-06-01 2023-06-27 0000012239 2022-01-01 2022-01-21 0000012239 2023-03-01 2023-03-06 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-04-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-04-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-04-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-01-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-01-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-06-30 shares iso4217:USD iso4217:USD shares pure 10-Q true 2023-06-30 2023 false 000-05576 DOMINARI HOLDINGS INC. DE 52-0849320 725 5th Avenue 22nd Floor New York NY 10022 (703) 992-9325 Yes Yes Non-accelerated Filer true false false Common Stock, $0.0001 par value DOMH NASDAQ 5345312 3598000 33174000 20675000 7130000 7082000 715000 564000 301000 13000 13000 6339000 7474000 2000000 38422000 50656000 387000 1622000 1100000 98000 23178000 23103000 3530000 919000 458000 458000 67695000 76236000 232000 447000 632000 1260000 1300000 17000 353000 82000 124000 2658000 1789000 3259000 680000 5917000 2469000 0.0001 0.0001 50000000 50000000 5000000 5000000 3825 3825 3825 3825 0.0001 0.0001 5000000 5000000 834 834 834 834 0.0001 0.0001 0.0001 0.0001 100000000 100000000 5345312 5485096 5285164 5017079 260585000 262970000 60148 468017 501000 3322000 -198306000 -185881000 61778000 73767000 67695000 76236000 71000 71000 9080000 2262000 12913000 4049000 2000 36000 3000 2052000 9082000 2298000 12916000 6101000 -9011000 -2298000 -12845000 -6101000 64000 160000 220000 297000 399000 400000 -2239000 335000 -2736000 -212000 -212000 760000 238000 348000 -2779000 420000 -2511000 -8663000 -5077000 -12425000 -8612000 1100000 4109000 -8663000 -6177000 -12425000 -12721000 -1.79 -1.18 -2.45 -2.42 4827239 5251023 5065055 5251766 4659 4815597 259215000 60148 -501000 -189643000 69071000 529715 1370000 1370000 -8663000 -8663000 4659 5345312 260585000 60148 -501000 -198306000 61778000 11000 11000000 11000 11000000 5252517 4659 262624000 -264000 -167309000 95051000 -11000 -11000000 -11000 -11000000 -1100000 -1100000 242902 1486000 1486000 105000 105000 -5665 -26000 -26000 -5077000 -5077000 5246852 4659 261603000 242902 -1750000 -172386000 87467000 4659 5485096 262970000 468017 -3322000 -185881000 73767000 529715 1375000 1375000 -25000 236630 939000 939000 -644499 -3760000 -644499 3760000 -12425000 -12425000 4659 5345312 260585000 60148 -501000 -198306000 61778000 5275329 4659 265633000 -264000 -163774000 101595000 11000 11000000 11000 11000000 -1504000 -1505000 1504000 1505000 -4109000 -4109000 -11000 -11000000 -11000 -11000000 242902 1486000 1486000 105000 105000 -22812 -5665 -26000 -26000 -8612000 -8612000 5246852 4659 261603000 242902 -1750000 -172386000 87467000 -12425000 -8612000 182000 32000 1646000 -1408000 2675000 105000 -487000 -568000 514000 -2299000 -212000 229000 -153000 -301000 -3532000 -428000 -239000 -628000 7000 -8000 58000 3000 99000 377000 -8000 -13913000 -5850000 34014000 27460000 20494000 28272000 93000 419000 1112000 502000 100000 75000 14605000 1600000 -14724000 -15300000 17891000 26000 -22000000 939000 1486000 -939000 -5621000 -29576000 -26771000 33174000 65562000 3598000 38791000 1482000 2147000 1508000 3112000 2000000 1112000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. Organization and Description of Business and Recent Developments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Organization and Description of Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. Liquidity and Capital Resources</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. Summary of Significant Accounting Policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis of Presentation and Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits with clearing broker</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Leases</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases under ASC 842, <i>Leases </i>(“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - <i>Leases</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenue</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenues under ASC 606 - <i>Revenue from Contracts with Customers </i>(“ASC 606”)<i>. </i>Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recently adopted accounting standards</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i> (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effect of new accounting pronouncements not yet adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the FASB issued ASU 2022-03, <i>Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</i>, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03<i>. </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023, the FASB issued ASU 2023-01, <i>Leases</i>, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effect of new accounting pronouncements to be adopted in future periods</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis of Presentation and Principles of Consolidation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits with clearing broker</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.</p> 7100000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Leases</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases under ASC 842, <i>Leases </i>(“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - <i>Leases</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenue</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenues under ASC 606 - <i>Revenue from Contracts with Customers </i>(“ASC 606”)<i>. </i>Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recently adopted accounting standards</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i> (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effect of new accounting pronouncements not yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the FASB issued ASU 2022-03, <i>Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</i>, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03<i>. </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023, the FASB issued ASU 2023-01, <i>Leases</i>, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effect of new accounting pronouncements to be adopted in future periods</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. FPS Acquisition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank &amp; Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Consideration Transferred</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FPS Acquisition was accounted for as a business combination under ASC 805.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair Value of Net Assets Acquired</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 27,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Deposits with Clearing Broker-Dealer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; font-weight: bold; text-align: left">Total assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,784</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accrued commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Wealth management liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total net assets of FPS Acquisition</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.</p> 1 2000000 0.20 1600000 0.80 1 3400000 1 3600000 3400000 200000 300000 The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 27,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Deposits with Clearing Broker-Dealer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; font-weight: bold; text-align: left">Total assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,784</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accrued commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Wealth management liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total net assets of FPS Acquisition</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 92000 3550000 53000 89000 3784000 273000 25000 62000 360000 3424000 7700000 70000.00 5400000 900000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. Investments in Marketable Securities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended <br/> June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended <br/> June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Realized loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(432</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(344</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(487</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(568</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,967</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,299</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">308</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">400</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,239</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">335</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,736</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended <br/> June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended <br/> June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Realized loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(432</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(344</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(487</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(568</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,967</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,299</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">308</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">400</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,239</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">335</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,736</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 432000 344000 487000 568000 643000 -1967000 514000 -2299000 188000 72000 308000 131000 400000 -2239000 335000 -2736000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6. Short-term investments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Investment in Vicinity Motor Corp.</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Option term (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td></tr> </table> The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Investment in Vicinity Motor Corp.</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 13000 13000 13000 13000 The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Option term (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td></tr> </table> P1Y3M18D P1Y9M18D 0.769 0.769 0.0447 0.0447 0 0 0.96 0.96 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. Long-Term Investments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December  31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in Kerna Health Inc</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kaya Now</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Tevva Motors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in ASP Isotopes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in AerocarveUS Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Qxpress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Masterclass</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kraken</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Epic Games</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Tesspay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in SpaceX</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Databricks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Discord</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Thrasio</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Automation Anywhere</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Investment in Anduril</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,922</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,178</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,103</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investment in AerocarveUS Corporation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.</p> The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December  31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in Kerna Health Inc</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kaya Now</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Tevva Motors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in ASP Isotopes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in AerocarveUS Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Qxpress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Masterclass</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kraken</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Epic Games</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Tesspay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in SpaceX</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Databricks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Discord</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Thrasio</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Automation Anywhere</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Investment in Anduril</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,922</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,178</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,103</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 2140000 4940000 4940000 1500000 1972000 2794000 2794000 1300000 1075000 1075000 1000000 1000000 1000000 1000000 170000 170000 170000 597000 597000 597000 3500000 3500000 3500000 1240000 2500000 2500000 3500000 3674000 3674000 1200000 1200000 1200000 476000 476000 476000 300000 300000 300000 476000 476000 476000 476000 476000 476000 20922000 23178000 23103000 250000 1000000 64377 150000 80000.00 1080000.00 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8. Notes Receivable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stated Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify">Notes receivable, at fair value</td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-indent: -0.125in; width: 36%; text-align: left">Convergent convertible note - current</td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 15%; text-align: center">01/29/2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,199</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Convergent convertible note - non-current</td><td> </td> <td style="white-space: nowrap; text-align: center">01/29/2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Raefan Industries LLC Investment</td><td> </td> <td style="white-space: nowrap; text-align: center">12/31/2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">American Innovative Robotics Investment</td><td> </td> <td style="white-space: nowrap; text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,122</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - current portion</td><td style="padding-bottom: 4pt"> </td> <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,339</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - non-current portion</td><td style="padding-bottom: 4pt"> </td> <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,622</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convergent Therapeutics, Inc. Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raefan Industries LLC Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>American Innovative Robotics, LLC Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Kaya Now Inc. Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.</p> The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stated Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify">Notes receivable, at fair value</td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-indent: -0.125in; width: 36%; text-align: left">Convergent convertible note - current</td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 15%; text-align: center">01/29/2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,199</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Convergent convertible note - non-current</td><td> </td> <td style="white-space: nowrap; text-align: center">01/29/2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Raefan Industries LLC Investment</td><td> </td> <td style="white-space: nowrap; text-align: center">12/31/2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">American Innovative Robotics Investment</td><td> </td> <td style="white-space: nowrap; text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,122</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - current portion</td><td style="padding-bottom: 4pt"> </td> <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,339</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - non-current portion</td><td style="padding-bottom: 4pt"> </td> <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,622</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 2023-01-29 0.08 1000000 199000 1199000 2023-01-29 0.08 500000 500000 2023-12-31 0.08 4518000 623000 5141000 2027-04-01 0.08 1100000 22000 1122000 6339000 1622000 0.08 1800000 2023-01-29 250000 1800000 500000 100000 600000 200000 44000 500000 0 10000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9. Fair Value of Financial Assets and Liabilities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Total at <br/> June 30,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Quoted<br/> prices in<br/> active markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Significant other<br/> observable inputs<br/> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Significant unobservable</p> <p style="margin-top: 0; margin-bottom: 0">inputs</p></td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in">Marketable securities:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; width: 52%; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">20,675</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">20,675</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">       -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,339</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,339</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,622</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured as of December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at <br/> December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/> prices in <br/> active<br/> markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other<br/> observable inputs</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant <br/> unobservable<br/> inputs</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-align: justify">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">    -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Level 3 Measurement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Short-term investment at December 31, 2022</td><td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Short-term investment at June 30, 2023</td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: left">Notes receivable at fair value, current portion at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,474</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Collection of principal outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Note receivable, Convergent Therapeutics, non-current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(212</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, current portion at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,339</td><td style="padding-bottom: 4pt; text-align: left"> </td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Notes receivable at fair value, non-current portion at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,100</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Note receivable, Convergent Therapeutics, non-current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, non-current portion at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,622</td><td style="padding-bottom: 4pt; text-align: left"> </td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note Receivable at fair value </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b>  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.</p> The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Total at <br/> June 30,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Quoted<br/> prices in<br/> active markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Significant other<br/> observable inputs<br/> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Significant unobservable</p> <p style="margin-top: 0; margin-bottom: 0">inputs</p></td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in">Marketable securities:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; width: 52%; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">20,675</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">20,675</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">       -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,339</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,339</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,622</td><td style="text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured as of December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at <br/> December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/> prices in <br/> active<br/> markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other<br/> observable inputs</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant <br/> unobservable<br/> inputs</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-align: justify">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">    -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 20675000 20675000 20675000 20675000 13000 13000 6339000 6339000 1622000 1622000 7130000 7130000 7130000 7130000 13000 13000 7474000 7474000 1100000 1100000 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Short-term investment at December 31, 2022</td><td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Short-term investment at June 30, 2023</td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: left">Notes receivable at fair value, current portion at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,474</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Collection of principal outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Note receivable, Convergent Therapeutics, non-current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(212</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, current portion at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,339</td><td style="padding-bottom: 4pt; text-align: left"> </td> </tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Notes receivable at fair value, non-current portion at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,100</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Note receivable, Convergent Therapeutics, non-current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, non-current portion at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,622</td><td style="padding-bottom: 4pt; text-align: left"> </td> </tr> </table> 13000 13000 7474000 -500000 -500000 -212000 77000 6339000 1100000 500000 22000 1622000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10. Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22<sup>nd </sup>Floor Premises”). The Company currently uses the 22<sup>nd</sup> Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22<sup>nd</sup> Floor Premises on the Commencement Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">Operating lease right-of-use-assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5pt">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,612</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,<br/> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Six  Months Ended</td><td style="text-align: center; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, <br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 4pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; padding-bottom: 4pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 4pt; text-align: right">179</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 4pt; width: 9%; text-align: right">313</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">212</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">376</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information related to leases were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six Months <br/> Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Operating cash flows - operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,796</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Remaining Period Ended December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">327</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">770</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,077</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,465</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,612</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). 12874 13502 49368 51868 The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">Operating lease right-of-use-assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5pt">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,612</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 3530000 353000 3259000 3612000 The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,<br/> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table> P7Y 0.10 During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Six  Months Ended</td><td style="text-align: center; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, <br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 4pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; padding-bottom: 4pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 4pt; text-align: right">179</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 4pt; width: 9%; text-align: right">313</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">212</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">376</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 400000 179 313 179 313 33 63 212 376 Supplemental cash flow information related to leases were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six Months <br/> Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Operating cash flows - operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,796</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 72000 2796000 As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Remaining Period Ended December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">327</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">770</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,077</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,465</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,612</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P5Y 327000 750000 688000 688000 688000 770000 1166000 5077000 -1465000 3612000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11. Net Loss per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">198,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">475,166</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">643,404</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">198,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">475,166</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">643,404</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 34 34 444796 444796 30336 198574 475166 643404 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 12. Stockholders’ Equity and Convertible Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treasury Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity for the six months ended June 30, 2023, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average<br/> Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br/> Intrinsic <br/> Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average<br/> Remaining <br/> Contractual<br/> Life <br/> (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">444,796</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">29.25</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">   -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">3.20</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Outstanding as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">444,796</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">29.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.71</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Awards</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Restricted<br/> Stock Awards</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Grant Day Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Nonvested at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.64</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529,715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(537,783</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Nonvested at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Remaining Contractual<br/> Life (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,193</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">302.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">     -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(857</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">9,719.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">30,336</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">36.97</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.6</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,578</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">41.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.</p> 644499 644499 25000 1033591 2700000 503876 1300000 3000000 236630 0.9 3.97 644499 3800000 A summary of warrant activity for the six months ended June 30, 2023, is presented below:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average<br/> Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br/> Intrinsic <br/> Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average<br/> Remaining <br/> Contractual<br/> Life <br/> (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">444,796</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">29.25</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">   -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">3.20</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Outstanding as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">444,796</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">29.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.71</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 444796 29.25 P3Y2M12D 444796 29.25 P2Y8M15D A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Restricted<br/> Stock Awards</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Grant Day Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Nonvested at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.64</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529,715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(537,783</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Nonvested at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 8068 5.64 529715 2.58 537783 2.63 A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted Average<br/> Remaining Contractual<br/> Life (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,193</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">302.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">     -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(857</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">9,719.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">30,336</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">36.97</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.6</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,578</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">41.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left"> </td></tr> </table> 31193 302.97 P7Y10M24D 857 9719.07 30336 36.97 P7Y7M6D 26578 41.35 P7Y6M 8000 0 7000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 13. Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Underwriting</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td colspan="2" style="text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td colspan="2" style="text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td colspan="2" style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td colspan="2" style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="2" style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"> -</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Underwriting</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td colspan="2" style="text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td colspan="2" style="text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td colspan="2" style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td colspan="2" style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="2" style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"> -</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 43000 43000 14000 14000 14000 14000 71000 71000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 14. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Proceedings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 15. Regulatory</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.</p> 7300000 7200000 100000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16. Related Party Transaction</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.</p> 80000.00 600000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Segment Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “<i>Summary of Significant Accounting Policies.</i>” While assets are primarily held within the Legacy AIkido Pharma reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Dominari Securities</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Legacy AIkido Pharma</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Revenue</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-  </div></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,957</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,123</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,886</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,125</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,011</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">116</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Unrealized loss on note receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">304</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">348</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,842</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,821</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,663</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Dominari Securities</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Legacy AIkido Pharma</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Revenue</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-  </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,056</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,857</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,913</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,985</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,860</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,845</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Unrealized loss on note receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">376</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">420</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,941</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,484</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,425</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Dominari Securities</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Legacy AIkido Pharma</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Revenue</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-  </div></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,957</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,123</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,886</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,125</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,011</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">116</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Unrealized loss on note receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">304</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">348</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,842</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,821</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,663</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Dominari Securities</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Legacy AIkido Pharma</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Revenue</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-  </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,056</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,857</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,913</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,985</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,860</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,845</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-  </div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Unrealized loss on note receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(212</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">376</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">420</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,941</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,484</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,425</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> 71000 71000 6957000 2123000 9080000 2000 2000 -6886000 -2125000 -9011000 44000 116000 160000 400000 400000 -212000 -212000 44000 304000 348000 -6842000 -1821000 -8663000 71000 71000 8056000 4857000 12913000 3000 3000 -7985000 -4860000 -12845000 44000 253000 297000 335000 335000 -212000 -212000 44000 376000 420000 -7941000 -4484000 -12425000 -1.18 -1.79 -2.42 -2.45 4827239 5065055 5251023 5251766 false --12-31 Q2 0000012239 EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +> "5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "W@ E7&/9TR>\ K @ $0 &1O8U!R;W!S+V-O&ULS9++ M:L,P$$5_I6AOCVS3EW"\:*T6?/B,_0S3"K!'BXX25&4%K)LF MAN/8MW !3##":--W ?5"G*M_8N<.L%-R3&9)#<-0#LV&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "W@ E77AXOUNP% #3'P & 'AL+W=OQ#]'D]5'#'Z()!,DX2( MCPL:\]5YRVNM/WB*9G-E/G#ZO069T0E5?RT>A'[GE"EAE% F(\Z0H-/SUL [ M&_J^*-YR38MH3 -E(HC^LZ1#&LT .J:O(#',OL? MK?)C.YT6"E*I>%(4ZQ8D$O^W,;9ZN6WT0 M&BF:6$]8'MBQ!YH+]DPN2$#/6_J*E%0L::O_VR_>D?N[C?8GA7UB[Y3L'2B] M7PR4)SJ+I!)$GX0Q2:@-&&BC!7,:TG9+ MVB[8RF=!PHC-T.0C>>6QC1*NUY0W-B:PJB'34DR&V;B\CHF5 JZ?DEC:.GL(EC7L,\^M%EEWIU[3 M8$(/S9%>$=_1G_3#NJK"4:[YYV'LG]HPX>*FG!LRX>W$65R)3W3!A* BXB$XK6Z)*BVN5N/@@*:LE=IX6YQDS;JYCESK#^W# M%PZK9=R'SWB5T'A;C.0[QJ);ZRGAN$=L9=R'WWB5X'BPHA37Z"0A<8PN4JF_ MEG8X.$>)U+JBP&5-\2K9\6 _*?"N$BIF9H;]IA/4W(C!@C#[7 0'UBZ=<%U3 MT$IXO)V,9S+7M_H@'AQ3C_>3O.@S7B4\'FPLY:7XF!*AJ(@_BF73R@AGU0[5 M?=@/KNP'P\I2W6OH6T4993?*]8Q;PFK[$:YK"EFI#]Y)?=QQD8D<1UQ;$4RVWYLXDM&K! MEO3+*ROR/K0'5]J#85@!'TRC(G_, /0Q'=G';/>F<^MBU\NY# M?7"E/GBGQSJ#,-3I\F#](G^J=<_L_0I''N,NZNIU:;"DS#XYP0%-F2L5PK"[ M@,S/*VYEAB,QUGI\'7-N57FXN"EOI45X)RTJ>8?FG;Y^G_F*65GAN#%=H1&ZIJ25+&%8<++!.A"4U(/! 5^.7?^K%6P?BN17BN3# M5G/+L]NP.6>0/6P).3W%;;VR=*V[!?NP([^R(W\G.QHQ;;CYSIUY?D#63XJL ML(T>#,%533DK2?)AC7F.E/8_/D4>_O+Z%4UHD H-;N6#DSX_X?W5/32/_="" M"+0DL7TEA1.;LF_LA\%JLX9%5^_!G+ 9K=T4VA(T'DPN!];M!;CP1PF=C6U3 MM!MD_K5(?GV]UWQ-R%2Q33J2YU#X_U(B_R'>3\ MC>*+;!/VE2O%D^SEG)*0"G. _G[*N5J_,3]0[N/W_P=02P,$% @ MX ) M5PN_F]AE!P -20 !@ !X;"]W;W)K_%EA?P MRUK(G"FXE8_S72--Y4&()WWS974]\30BGO%$:1<,_CWS&YYEVA/@^*MQ M.FG[U V/KP_>?ZK) YD'5O(;D?T_7:G-]22>H!5?LRI3?XB7GWE#*-#^$I&5 M]5_TTMAZ$Y14I1)YTQ@0Y&FQ_\^^-0-QU #[(PU(TX"2?&"I+8&;_JB'INZ-;!)"SV-]TK"KRFT4\L;4:Q@4O@*P54ILG3%%-Q\ M9ADK$H[NM>,2S="?][?H/^]^0.]06J"O&U&5K%B55W,%&+2G>=+T]WG?'QGI M[Y>J>(^H-T7$(]32_,;=_)8GT!S7S4F_^1R8M_1)2Y_4_N@8_4I*7BC$RA)X MVNCLV_OV]GJ3?2BW+.'7$]A%)9?/?++\_CL<>A]MY"[DK$>5ME2IR_ORAI4; M!).&$GW!_ZK29Y8!=ROKO:NP=J4CP?.2!HOX:OY\S,9B1''DMU8]F'X+TW?" M_(W))Z[80\91R9-*IBKE5HA[-\%1[\0+HV" T;2*,/7L$(,68N"$>,NWHDQA M6[RD:H.2C#.9%H_H08HG+FU0 Q.$%Y,!4F>?]K6!',LB;,F$3C)WDF]9ND+\ MVU;'@;)>(D)MN'1LBM RJL.1-VV"<&1M1"W6Z"2L+('5"S.@=2 1I;)!='HZ M:3CW-"*#!O6PG4;< @8L"T'.$$;DB:(;H$63(D-^<* %5*Z M&& WC2)_+)Q@KQ,XSXG_2SO$6KI^2GFVVHH4[NZ=X<7M]8P%U#CJ!RIO) 3A M(]W&3EI?A6)9._3C6[5QTUO L4^&T<=B%GAA$([ [/05.S4-MBQDG%+MZK"B M16>K9V**"F[=M8VW/MIHB/4-,NH*E;B34.S6T-?W0B&*V0G[H>FGMT]#",H$*XZ(63&;6FJD!.Z>WS UG29CMRAW MV]R^#4P-)I"L&/BM9MY(",6=R&*WRM;ET4RL9U7)79O5%$T:'*4K#4C3:H$7 M(Q [;<5N<6W"X0Z*H#J]L>(SU= /C#%T&_7A=9J)W:*YCW>.H3.5+XS"Q3 K ML9A%(:%C<:X32;PXJ9#(4O:09N.JXM3:<\N)2WGKETZ=LA*WLGY*$E'!?D-; MMJN#B([Q+$EDQ;M\TEI36221#H.?Q1OU&Y'E:ZB,@^UA;]&XH_NZ>WD"BDTWBELU?.8/@?=C@ MNR[QM5(QQ1(B^9"+:714%O9A=D)(W$+XW[IV&\:CG16DJ7:8^$.0%RY,22>: MQ"V:_13WEA/'JW^WGC(KT H[Z7#OUI6[UU?%? M%'NB4_3.>P^%,(;TH:F?I@BJFZFW_Z!RPZ06Z$IMA$S_YJN/*)A2'SZ8U+(= M3/TXF'J+\& *TJ)5!FJR7ZJ"M\?,M?$MU#;Y T3&P^GQ%,J=#^**/YF9I@1*V32'>6 F;>0JD24$\S-*M=F01C41">G0&[DY$ODJ(U)7< M'98@S*0^0)RBT)MB/ZXGT@]C/?GM^KO49)O)S2PX.DILF%NL*"4C60'MDA?J M3EX@ ZOR*JL?[JP@V4WL!1XU,Y(97L34"XB\04S#^I,M,ZF?B%O?>I=TD7= M)_NG9QYOR)#L.O7O'?4?*G99EN_.L@[K>X9/6>%N9^=.\Z6\]:EW29>/+[C" M_3>D$@[J%_+6I]YE)_YK3Q].7.%N/V>L\ LXVG.='[W3H5^H^8W)Q[0H4<;7 MX-E['X$$R/T[*OL;);;U:QX/0BF1UY<;SF#2M0'\OA9"'6[TFR/MFT++?P!0 M2P,$% @ MX )5^>5C&BI P W@\ !@ !X;"]W;W)KNGKPTLA(1 T&U>)#;,C'\S9/C;\R,7+W(/H-#7-,GDPMHKE3_8MHSV MD%)YQW/(])TM%RE5>BIVMLP%T+AT2A/;P3BP4\HR:SDOKZW%4YWL 'U=[X6>F8W46*60B89SY" [<+Z MA3RL2&@<2HM_&!SER1B95)XY?S&3W^*%A0T1)! I$X+JGP.L($E,),WQI0YJ M-6L:Q]/Q:_1?R^1U,L]4PHHG_[)8[1=6:*$8MK1(U&=^_ 1U0KZ)%_%$EM_H M6-D&VC@JI.)I[:P)4I95O_1K78@3!^)=<7!J!^=6![=V<,M$*[(RK2>JZ'(N M^!$)8ZVCF4%9F]);9\,R\Q@W2NB[3/NIY8IGL7XH$",]DCQA,55Z\D@3FD6 M-B:P1._65$"F]J!81!/Y'GU$/R(;R;V^+.>VTB FG!W5BSY6BSI7%OV]R.Z0 MBS\@!SMNC_MJV/T)(NU.2G>GZV[K])L:.$T-G#*>=R7>6O]S0 B=MBYW]/(! MY52@ TT*0.]8AIYXDE A40ZBROA]7\;5$K-R"=,[AR6^PQB3N7TXS6S4K).! MVV3@3LN %FK/!?L/XC[6*IA_ N'CZG-&>X-AA]=K>+U!WA5/4]W#WU%N[[9R MCYIU\/T&WY^ 7W7!2,G]BTH2W%_S6RP[U$%#'4RG9E(6_<3!Y;-W/=\ESAEO MCYT7^O@^Z*>=-;2SZ;1:AZ2B6&?(/7:8S/#LOA\Y;)## M0>2_M([*0GQKFE"AB$O51QI>$ 28>.$9YZ65%X2:M!_SOL&\'\3<@&"ZED^H M?6ML#' ?YV DL\5XD#F-8&'I/80$<0!K^=,/), _][W5WRA8)VF"6Z'#;_F. MK*/UO/O.'M(-AEWB$VDFTXBO-VL=Z13"#1W_''7$JLO9RB>9J)\C;5J'&X,= ML>K"MDI)AJ7R#_:E,)L./RH]XW;=#%KM),/B^=J_'\DM M'3P<;&H+OU6T;NJM[I)AX9W:PY=:>J6'QPV[Q*WFDF'1G=+#ETH:NN?2-6+4 MI6RUE@R+[>0.OE30'M1AHRYJJ[%D6&2_OW_#&_MWU*[*P#XY?)F3[Y]4[%@F M40);[8CO9KH HCI,5A/%\_(\]LR5/MV5P[T^@(,P!OK^EG/U.C%'O.9(O_P? M4$L#!!0 ( +> "5?X%&AF1@8 'L> 8 >&PO=V]R:W-H965T&ULK5EM;]LV$/XKA%<,*=#$(F7+=I882"RMZ["N0=)L'X9]8"S: M%B*)'DDYW7[]CK0B61+-)JV^6"^^>X[WPN-#\>*)BT>Y84RA+UF:R\O!1JGM M^7 HEQN647G&MRR'?U9<9%3!HU@/Y58P&ANE+!T2SPN&&4WRP?S"O+L1\PM> MJ#3)V8U LL@R*OZ]9BE_NAS@P?.+VV2]4?K%<'ZQI6MVQ]3]]D; T[!"B9., MY3+A.1)L=3FXPN<1\;6"D?@C84_RX!YI5QXX?]0/'^++@:='Q%*V5!J"PF7' M%BQ--1*,XY\2=%#9U(J']\_H/QOGP9D'*MF"IW\FL=I<#J8#%+,5+5)URY]^ M8:5#8XVWY*DTO^BIE/4&:%E(Q;-2&4:0)?G^2K^4@3A0 !R[ BD52%MA=$3! M+Q7\EUH8E0JCEUH8EPK&]>'>=Q.XD"HZOQ#\"0DM#6CZQD3?:$.\DEP7RIT2 M\&\">FJ^X'D,:6)G;S M";X8[@Z#Z@2W#QW9XOEU4]'WFVH$:%P%:.PLV;)CY6NTY!*:&+0EQ+YL=:>S M!FW<9\WV"1;V"1;U!-9(25"E)'#6['N60TY2DPH:PU*6Z!ZB:8(M(7NL\4%I MS;RIUZKCKA A 6D*A5TA3&;8;]5I5VKDC6:54,/C2>7QY"NS5#(JEAOC<@Q3 M-N5;W3]M_DZZKK2<[4KX0]CN[ZSR=^;T]SNYNJC9, ,4S-.#D.;]OK3S/ MZ[.3]HH6]HH6]876S,D!;\?.*CS,B3413O67+_*+OH#"OH"B$J@QJT=':IS4 M\23.>'[(%0.SRA52TNTY07M-L@@1TA(*;4*S26LR6X3\V9$E"==<'CN)Z?P] MA:W:20H]["V"C7I&Q2-3]"%E2+)E(1*5V#MW"=M<(3O.=X6@F_FSMOM=,=]O M]S(KUN1@S6L&H*;.V,V=[W/!:)K\![M<'04=A)PKA@1;LF2G(V%U?V09#6ZO M7&[3KYDK+S$7]6"N&<2:7F,G59PO-C1?,[WK7]%$H!U-"Z:_%"3Y#N:0^7!@ MC>(W$%![4QIWXS-IS\6P+W.1S1SQIT=*L6;$V$V)2^;TBM6U2U/]T;1=A%TA MF#B3SB2T4-YVHXJL6&-\C%'4S!B[J?'O3)G99W6R2U)/IT'@M]VTB(V]R:3M MID4,DQ'IM!NK57R$&^.:'&,W.PX9RZ#5Q,DNB5D>2^@SJ?G$ICBZ8P*Z+?ID M-@CEPPVZ93'HF):\X#"?A$KT_8U@*R:$^3C'EX_6R#F'\IKIU>7-IQBWVWW8 ME[W(9F^$O6.+7=0CV+4AJW]_IK^S)67VO:&&O:%%?:,T,U:R>N%G]ME1H!=YD3V M^\ K3 2 JQ5**JC5)%^_M'*=K/_5E=LG6M@K6M076C-Y];Z"N/<5=>6:IFKG M+\2RB9A"9VOO$!86P3'P#G,Y&I_9E*]K4Y*K\SY8.O]-3Y?8,O[$)]'^W/0&GY_+/N1BG622Y2R%9CR MSB8P6K$_Z=P_*+XU1WD/7"F>F=L-H[!Z:0'X?\5A)U,^: /5>?/\?U!+ P04 M " "W@ E7D3O2"\<" # " & 'AL+W=OEM)'6"V)($]6FP0/BP4M.&VM)'&RG'?^> M8R?-VI)5T]A+8I]\WW/; MB>5:.\,U6Z=*&^QH7-(UW("Z+9<"9W:KDK <"LEX002L)M:%.UJ$&F\ WQEL MY=Z8Z$SN.+_7D\MD8CDZ(,@@5EJ!XFL#,\@R+81A_&XTK=:E)NZ/=^J?3>Z8 MRQV5,./9#Y:H=&(-+9+ BE:9NN;;+]#D8P*,>2;-DVP;K&.1N)**YPT9(\A9 M4;_I0U.'/0+J=!.\AN =$X(G"'Y#\)_K(6@(P7,]A W!I&[7N9O"S:FBT5CP M+1$:C6IZ8*IOV%@O5NA]5TG.;@M:)0PQ[\G9D@J$I*!83#/YGIR3M\0F,D6S'-L*P]-.[+@) M95J'XCT1BD^N.*I)LL"0D@[^_#2_?X)O8UG:VGB[VDR]DX)?JZ)'?.<#\1S/ M[XAG]GRZUY7._WE?O-C[03'\=J/X1L]_0N^RB'D.CQN#_+RXDTK@0?_5M=2U M6- MIB^_D2QI#!,+;S<)8@-6].Z-VW<^==7Y-<7FKRFV>"6Q@Q4)VA4)3JE' MH>0?*ZP7A(6K1C?):U$&& M89MA^-(,:V*XYR\8>@///\[Q7USHA:XY40=9=N"Q-KU0DIA7A:H/76MMV^V%Z3)']JD[FKD=]CFVY[J;/LK7O?V*BC7#JSJ# M%;IR>@.,5M3]LIXH7IJ&<,<5MA1?F[]!#OR[\\IMDN*LJGV=,\/V1QM*X[[;9S756M^2Y*]K/[V_IW M#]G];7HLMLD^?LB4_+C;1=F7]_$V?;F;:;.OO_B0/&V*ZA?S^]M#]!1_C(L_ M#P]9^6Q^HJR37;S/DW2O9/'CW>PW[1?.G*I#W>+?2?R2GSU6JI?R*4T_5T_X M^FZF5B.*M_&JJ!!1^>,Y7L;;;44JQ_%7 YV=8E8=SQ]_I?OUBR]?S*6G:JC-E=P M2_:O/Z._FS?BK(/I7.B@-QWT:SL830>CTT&S+G0PFPYFMX-QH0-K.K!.!]V^ MT,%J.EC=".Q"![OI8'TZD&MH+IW^9DG^TKL'XNL_&M2]BONE^E^74HW7BOEHSS=)NNH*)]\+,H? MI::+7$D?E>4FVC_%N9+LE0_Q.BX/MT_;N.KP'&=%4CU^*"4:9UG=,UU]5J)] M\VB3;M=QEO_PG:-K]J^*]]=LEOYT7Y MFJJ1S5?-^-^_CE^_,/XKQ_,QSI+R!?R+"+!$!G@@ KCR !T2 ?#D@&6ZVY5I MXU)O7][[M_4ZJ=).M%4>HF1]4WX+8PD'QK): M'7?';:U -WY,5DE!0/C (-+>V.?E07$Z,O33D:'7'/,"YWVTC?:K6(F*GW^5ZWF&48M_/GF8$J1)'$:: MJJKB1[N4CFJ$WD <#\3Q09P Q E!'/YVCB!/=I(G^W;R/$^FE%19+PV14I6. M<.2Q[B)A'A+F(V$!$A8B81P$$]1LG=1LC5?SPQN2K33VE=E;A<9TT/"?"0L0,)")(R# M8(*:G9.:':F:>9X?ZTNJ\XE#UFIY=:;EPTG+>:WEQS135E&^H83L]*__B$F# M=&QC)PT38&3>!7%\$"< <4(0A[^=(RAU<5+JXILK=2C]+GH9DU*M=)QC58N$ M>4B8CX0%2%B(A'$03-"TIK8&@#I6U0^(_"L/.V+2VX &,KF+BN>A0#X*%*! M(0K$ 2!1KF=^E?;-Y3J4A.5#&#L);F@#.=V%!O6@-!]*"Z"T$$KC*)JH[M9S MTN2FTS+-"Z6\KDNHJ49MJKY],:(9@GA5QM2.?[+4**.%J:PK6Y37A +Y*%" M H4H$ > 1&&VMIO($ M&68>"N03X[XQ-;7CJ06H>"$*Q <'+DJK=;:T(6OK<,Q6FRBOLUWQ=0]!?E$> M(*]DB0*Y*)"' ODH4*!1/J'I6!U3'A6/-R!V,9XHLM:?TH8,JLLB&YP.(HV- M)93F0FD>E.9#:8'6MP%U4U^H>E>*4!L*11-EVQI1FMR)JL^1-]5NSG5Y9;,[ MQ/L\JA;^29FB7"84R$6!/!3(;T#"I*$[9PA0T4(4B \,6Q17:R-I^D^B9X"+3Z0" 7!?)0(!\% M"E"@$ 7B )"HXM8^TN3^T605#Y[VD=[0$DISH32OH0F3+EUWM,ZIU8=&#:"T M$$KC*)JHZ=9HTN1.DY]%JV93=EX+5(G6_SWFE9*K-(#PQ:WNK0U-^"R8977FDSXT: "EA5 :1]%$%;?>D"[WAOX9%\HVS]LQO'ZDY,^& S45"M':-?70/TC^/^G6*H=86' M3@H,5@0$JP*"E0'!ZH#ZUI-NE8=_KQ"(\IYLIG9+@2@GR]:-[O(D)QHZMFG9 M%_31NB+ZI&J@8:T@ZU*64)JK7U4:1+1BNFDYK'O- !U<0(0E%P&A43F*)JJL M-4ATN4%REH5^C[)3G1FMK/YZ/;6![+IFKGQ@8S((RMC0^_Z ;I7_S&X&(7P+ MHI:0EIW0)]0I_*6HD#]N@*3I7Q<8Z8H*(< !?)1 MH %"E$@#@")0FV=!GU"Q0JJ/%"_KLID*1_CZ&D2M&@%2O.AM !*"Z$TCJ*) MNFZ]!UWN/< +!>7QQEQ$]LM?R-(K5$ /!?)1H %"E$@#@")0FT-!5UN*'S3 MDD%Y[-%7L\0"-ZE<:-T*E.9#:0&4%D)I'$43;\;2^A:&W+?X?VY+E0]E1&Y& M@5P4R$.!?(-P1*J#MW-UCHH7HD!\<."B0%M+PI!;$F,WM\IQ8T2&LBE0( \% M\E&@H $-;6Y%Q>,&85->_*&TEPHS8/2?"@M, AC MA%K7AD;E*)HHV[-;J2B0;Q#V26\+%2I:B +Q@6&+@FNM'$-N MY2"W4,E#C3XI0RM.H#3/(&[N1FRA@@8-H+002N,HFJCBUE(RY):2; N5O.N8 ME(BRCU @#P7R4: !0J-?NW(#5/MCFG+!YN)@FJM'T-N_8S90B5'C1$8JH8$ M!?)0(-_HNUWD%JJFW= 6*@)';Z$B&DJV4!FMA6+(+92I6ZCDV-&G2&AUAM&O MIZ#NKMQO16^A@@XN(,+2EYK0@@H43519ZW\8X4&GU?=Y0Y8!)WVS+L[BH8*ER( O&A<8M":ZT!4VX- M7!+:T J$'#M:=%!; $KSS/[2.RO/7UIW"0(:-8#20BB-HVBB9%M;P)3; K*" M;E*JT&(**,V=0J/S(\HD0($"%"A$@3@ )$KV[,M9Y&:#]!X$0YEVPK*V1+Y( MF@NE>2:U[LYZ.[M\:-0 2@NA-(ZBB;)M+0M3;ED\3-XU( >/%BW4H)A"HW,N M".2C0(%)N"4+8]$[A$)41'Y%1%%\K=-@RIV&-XAOPM*X1'Q(F@NE>5":#Z4% M9M\PT W+,GI21$;E*)HHVM;-,(<*68HDJ[\8];KM?'+<:*E"*UBFT.@\B?(V M3,*S,&RKNY1(-.NW"E&CX@"0J+;6&S&'RDLNJVTP24+]$2C-A=(\D[A[E66: MYJ+[-970L,&U84-H6(ZBB9)LC113;J3(]@?(NXZ6'-0XF4*CDQW*.$&! A0H M-"GO13?USDH8'VXG?H=DZ[VPZ[R7CO]K4&*3H\:*#4ISI]!(L:% /NN;++JE M,J>[+L[ZW[5RP]2.]Q82M!MMX1AJ=], T=#2;-NY()36/F%R^^2*30.T:*!6 M"I3FLKX!0)AT1"MFF,SHW:L1.KB "&NIFNETA0']+@X43119:YVPJV_^='X_ M#EI84+L$2G.A- ]*\QE1]\ 6>M=\"1AQ0R@B+U'W@W(6EFET\U*_H;50[0NW M@MX."D431=:: M#4QN-HS9.R!'C186U%R80J-G22"0S_H&A6;T=C*APH4H$!\:MRBTL^]TE]L# M4_<.R+&C18?]7G>4.<"HNV$1VP:@PP]0PP^AP^(HFBC4UDI@TXL6Y%U'BQ%J M%DRAT6)$E2] 7U^ &E;(B.($Q[)ZT[JA9J*^VE5_-JF&@9[*05?\H31W"HW6 M&VK%G_67\NEU"<(9(.;_5,T#N2[1;RA;EV@7[-F;BQEHT4 7ZZ$TEUU5S$"T MNK N 5V$)\*2\W_H$CR*]BJR>;Z)X\*-BNC^]A ]Q>7%XE.RSY5M_%CBU7=V M^>*RY&ES>E*DA[N9-E,^I461[NJ'FSA:QUG5H/S[8YH67Y_,2_Y+FGVN8]S_ M#U!+ P04 " "W@ E7-!0JJ'@) W+P & 'AL+W=O_%AI7PRT+(-:W@HUR.U$8RFIM.ZV*$HV@\6E->#FZNS'=W M\N9*;*N"E^Q.(K5=KZE\^<@*\7P]B >[+[[QY:K27XQNKC9TR>Y9]7US)^'3 M:&\EYVM6*BY*)-GB>G ;?YBG1'KZ\%T@'*V MH-NB^B:>_\D:AU)M+Q.%,G_1<],V&J!LJRJQ;CH#@C4OZ__T1S,0K0Y@Q]T! M-QUPMT/BZ4":#F;D1C4RX]8G6M&;*RF>D=2MP9I^,&-C>H,WO-1AO*\D_,JA M7W4S%V4.06$Y@BTFW.8+;QSZR,.&OSWMGR/2/0.X0@3!Y[Y\=UQ [9CS(Q]HAOE/4 +LP M+J18(UB%DE:\7-;3F%><.4>MMIJXK>H5_D%M:,:N!["$%9-/;'#SRT_Q./K5 MY?*%C!T,0+(?@"1D_>8+)*1"**>3=<^QZ:FSSM/-,,8)3J]&3VWXCF;3<8SW MK0YPI7M<:3 PM_G_8(W5$[T2D),WX6,'8S3>#].XV#\;M="5OPO:E(O9 2IL^-0+(8P)(@JQ2IG:&NC:2MF M\11WXAI\L=LM%/!HLO=H$O3H$P-[&3<>N:!/>M!)%WGP!:APO*)7JBQ9;IF*@5Q&A8,;F&WYY8/:U=K@7-'X6[]G_:C^XX&;L7Y&SO MW.PLYPI1+H_Q+6C]U!4WZSDXC)-HZO8PCBSE1D$?[RN1/0ZU^,A1)M:@R)1W M&C:FVACP>-+-C8Y6<91Z<+:D01S$^8W1@O\%($TBA(4/0N^15?0!\J-BV59Z M>:LQW,:33"==T/U&Z=@WN-B"QD'0WTNY@_UF"3+V[1GH<3_N:9QTX?=;83R; M>?!;I1 '>;B-?P>\%!73U,3XDT;OA$SZ8.)NO@J_^?2$%5OVCY.P_C&K6G6X MT] & L6("DX?>.'GT3BH+DY=UI>R=C@85G+$0::^N9-L0WF.V ^]\ED] J): M,1E@TL;FP9R$Z=:-<+]5G!+/E+3<'X?)?P>89G]NN>)& V1".?-OW*=\$L5= MF!?F_-B2?OPJZPOP0,$NJUJAK&!4ZJGX(,4CDTY_^CI@2-*>% B_]@R/K!B( MPVK@-LO$5LO7#7TQN4W/)IIE!%]WAB>6XG&8XK\ GZL6H;]#M&K+W5]^FN(X_M7L.WD)HA?T[FY) M.YWMD_]PUJ4&5R,R\:T.R^PXO+%O$JH3UADTZ]QG-(;:T#TR$5L2QF$2_G+, MGM[IE8.(8S*+>]/+T2Z=II$'N"5C/#ZIE%1OAX[ ?0;G^B74I:P=#H*E<1RF M\;NMS%8ZH\'.\&A9CUU4GD0]8>]JAR?)V!H = MS:9XXBF-84O2.$S2=U)DC.7-1%,-^IPO>46+)A-G/NAG;,3=B[]/Z3./HB66 MTTF8T]OS9\%_0 ;P*V_B(/8D[J;7\ M/9Q-BJ9V$J?VVIEX7PX,X[BWJPS#.\-SJPA(6!',1;$[#0)G M-Z#D,[Z!F7GP* M09W5(N(@^3B*NDY=N Y K%H@8;707G>MMB!4:)+SK[RFD M8Y4&Z9< 8.PGN$M;SG8I\2*WZH!,3I)("UY22 VO S]C$Q\X;KN0M<-!L&*# MA,7&(7G#;-S"&)AI>\_,CONKF;3-ASOTC>6,K4UVF0N(M*RX?KZ3;,&D-$?" M(GO<4TO.E:D[U,6K!;31X^NK"H6QGC+9'6<.D^DL]DP9*W7(*U*'ONB$HW,L M#!@UI ),HE94>N;*I?0-<10VL.<0);$")PD+'!W-]69'C7\GXLX3V[\O=IHS M78>VPCCRI8#$BJ(D+(K::;J2C*HMY&+E]<>A=&:D*_%)DZHN5E3%)6,;T M$NVQ^2IQG%,X8+M.,\;8LV02*U"25ZH8 #MGF325)4!=BTV88.:!@>A\@AU# MV53X=0U#\DS?+=&_.]UQB!<\2R?CKD.N=N/)Q.=1ZXY"6)W,?1Z\0P]LRA]&4'26;?\ MYVHUG?CR;V+%1A*N:GP1Y=" ;HD,0'ST2KAH<>-2U@['PLJ7)%S<^$/24D$* M;K;=KE-]O2\XNHH0?MTIV;I?&('\YYNU5JDD8:7RC64%;+_YXJ7V.&N146>XG=MJ'WW*DY]]R!2*U+2*+CHOY;H=PH\C?"DOJCW#E4K+4;6&UJ^ MM H71>$Y+&X*'O"K$:2%:!A45]A1XKZ2=89V"=S)NI"UPQ&T,B<-RQS-P;N1 M:4;K0L6?M"]V2+_V$X9WKOM6.:5AY?0;4PH-47,& =MN]L3%5A4OH/GJ'"KK M^? UJ\0#9%1]G5/G$)_3#JETH$8;K\\H"KWNM15>Z>O"RP17'\H[W2#]Y>J( MW47O@XY:5Y#73"[-S6R%S!ZQOK:[_W9_^_O6W'GN?/\Q_C"O[W!;,_657Y[8* MN39T[X2OBD*Z]17E=G71'76W%P]ZG@6^&%R>EW).4PJ_E?<.IT&C)=$%&:^M M$8[2B^YD]/KJF/DCP^^:5K[U+3B2F;4+/MPE%]TA.T0YJ< :)/XMZ9KRG!7! MC<\;G=W&) NVO[?:W\38$KJV^1\Z"=E%]U57))3**@\/=O6.-O&\9'W* MYC[^%:N:]_2D*U3E@RTVPO"@T*;^+Q\W.+0$7@V_(C#>"(RCW[6AZ.6-#/+R MW-F5<,P-;?P10XW2<$X;3LHT.% UY,+EKVXNC?Y7UA"91-R05TZ7\6Q3<55Y M2'@?:0^DR 2P+)',$JD)_GP0X 7K&JB-Q:O:XO@K%D_$!VM"YL6M22C9EQ_ M^R:$\3:$J_&3"G^N3%\<#7MB/!P?/:'OJ('D*.H[^DZ0B+\G,Q\?.U+J>BBBR;SY);4O7S^;'0R/'LBM.,FM..GM'^7;#]I\7 \'VT@ M,>J+;W6G\S6DOSF>&XO>D4Z+=S9/M)E[<6=47_P0,A+/G[T:CX=GU[8HI5G' MT^CLQUZ')QZY?"TF=PN=6'&?28R!7I3LB97T(K45U[#01HQ^.CD5N)J6&3G] MR$S6E=;)0$E?3+51A/HOR@LYER5$U (6DF8,95H15YO PSKQ.-QZ&WR]B;AJ].V29= M6WJGH3>9$Q$N]D";&!2CE.DT(/%MQUA@='KF1>DTOTB;5#!7:C%[A5Q)>.]L M\45:@HUJ4E:O,@:SQ2)Q'L?=OL=I.)VC]3(8(X2K3QE8NE M7$:0,$E0(FB9@"VF1572(7W.Q]9L$["N&(4ZV&05F29L24FTSK;25.1FOKU2[TCO";S*8@WSL37 4L\* M^- P17YX* O*:YF(F"K#/5@Q\B M%:/X1JM./= A*KPBF1[O"WA^%M94,-P+]H%H@,O[9 WFYE%C $#OF24B@':-)HNEB&=9( M_B7-0G[I>:WG@^1N5H 7)7UH(1FT5E&\GO.X<'/]5";46VESV^STDWJ5W;'7 M/P@^2#='RR&)*42'_=.77>'J);L^!%O&Q79F ];D^)FA_,@Q ^BI125O#FR@ M^:5S^1]02P,$% @ MX )5[&\:/I7 P 5 < !@ !X;"]W;W)K-'#)^[*T=6/J)(U:+QRAIP M6*VRBY/SS8+]D\,7A7M_L 96LK7VAHVW MF8TI.?!P?8_^=]).6K;"XZ757Y4,S2H[RT!B):(.UW;_!@<]SQFOM-JG7]CW MOHMY!F7TP;9#,#%HE>G_Q>U0AX. L]DO HHAH$B\^T2)Y2L1Q'KI[!X<>Q,: M+Y+4%$WDE.&F? R.3A7%A?4_ZF=44H4[$$;"I>A4$!JNT=OH2O3+/% 2=LW+ M 7#3 Q:_ #R%]]:$QL-K(U'^/SXG/-1 M\3SAS?],,7R[V/K@Z&OY_I#X'GOQ,#;?H'/?B1)7&5T1CVZ'V?KQHY/3V/1/.4!'R^A"!F7U8"LZ=E3' MSIH4\\18\ZQ21IB238=:!)1_T6*'1&D*7QNE$<)#="=,M^TTTD0)H(*';?14 M#\J3&&-]1[GIQ 0T,JGK,V%R3M-#!<6Z&V=CW= M-*)F'E0#QZ"E\ T5 QI6 M7CG;'C)Y_.BL.'GQTD\ZX0,@%9S*;:L*'4'X*6QHM$B()!4Z9W_0T"(S(5:: M/Q..<(D\U8AP)_<*&T'L)!V3ACZ TZ<%Q^R$YIBT26/W!H/84HT\$NM!#RF- M=,HR:=AS]ZSQ0 ,?1 "-S)>%&+REQ1[U#J'M[_@H4G)RZA>OE?>P*()_= ; M=\^&H>YX$5A0ZF[YXGH'K9WAO!-NEN;FU@:9P6C;T[*%C M!SJO+%V?P> $XT.Z_A=02P,$% @ MX )5R> 0[ON"0 IQD !D !X M;"]W;W)K&ULQ5G?<]NX$7[G7X%1.IF[&5F69 NOOWU M[8(Z7UMWYU=*!?&]*HV_&*Q"J-\<'OI\I2KI1[96!BL+ZRH9<.F6A[YV2A8L M5)6'D_'X]+"2V@PNS_G>K;L\MTTHM5&W3OBFJJ3;7*G2KB\&1X/VQF>]7 6Z M<7AY7LNEFJGPI;YUN#KLM!2Z4L9K:X13BXO!].C-U0D]SP_\IM7:]WX+LF1N M[1U=?"@N!F,"I$J5!](@\76OKE59DB+ ^)9T#KHM2;#_N]7^GFV'+7/IU;4M M_ZF+L+H8G U$H1:R*<-GN_Z+2O:\(GVY+3U_BG5\]N1X(/+&!ULE82"HM(G? M\GOR0T_@;/R$P"0)3!AWW(A1OI-!7IX[NQ:.GH8V^L&FLC3 :4-!F06'50VY M<#F+P1!V(69Z:?1"Y]($,'#^C[[@S_ICU'3^A M;X^5XE_3N0\.R?+O?09'?2?[]5$!O?&US-7% !7BE;M7@\N7+XY.QV^?07O2 MH3UY3OO_&*KG=?_=!B6.1^+W[R%^72FGQ$K>*S%7R@ACD9=!.2U+D:^D6>(9 M;418*7%MJUJ:S.%M!T'HEX,=[;1M?;D2A?5[B M7M&J119,Q-28!CM^5K5U05C<=UB4)LF34.-):$X$-!)7TFM/]MU2A$R0D1Q, M@1O:Y+HN%2]?6^.!IXCK,):1LAV$M3&R*72 WMPBNXV/OY*(*K*%-A+J ,UC M#P4>"[[G+=A52Q=M@1RQJPX;%']8B2^CV4@LE5%.EK ;^ZJ:=NJ[:HOU)W+K M9/R6I?X\G=[R]=';GX=D5;9'/_G.-21+9CNU;$JVDNVFQ=G-]4A\B$ZVM3;D M 2Q5TH"GR9(A+<&[>XW$=@'=0 "\D,57\A'XA10+J=UVIQ8MX@@*[L!K0TE8B1J?MO"BCG%6Q8BCV(4K MF\L2X)6(S4\&\0[;57/DS_$14\QD*-;2@^,=&D<1L[*-NHQIM]<2%Z HXJMP\&P._LDU).2^H4Z_$K7% 6) M7/YJ'55$BDG%N_,Z)Y#RP.P$QA@XP9#'Q;WEU$5+SN]&SS!"MI\1]@3%& M(]9WE\G)>/:]QNWURA(?D"4%IJBYUX66#@8/Q53?Z<**CW*.BW<6@P(6LO?M MCDP%W7TQHW)C5R&CD)=]/F;KDUDBE4@,/[JB\3*/3+%E,E5J4ALZ+MO2Y@C1 MC[5)$7]8F* _KI"VRG6Y 5L5@$&#&CFAK6S$&IFLOM<8Y."(@JJNFR!C$I%6FHYUV6L [KN<0P]224!VVG[ MIX0")Q]754K$/Y3:,>]IW M;65QO1[0Y$Z@*]J*DY/Y4]S+LHDM'J"TN5==\WFT&ND/K4KI>SDO56=?]U0& M%K)K;BI.E>P9Q'@?.>++?\.YFMJ7E+[C$U:+C9P(LH M+T/#%V*DV0?#+#HA.I7&H<;H;_#Z+BHV),T;0D$M/B4]FP0B-!5B9/:DL\Q*$0>Z8.WL'';NK>P@R >P$LR289AFXGLJOKIW] MS@C@FS^]'AWAJ%:6E#*@>*1[*$IDNL*1R35'9%&XB-"EJBO"W;;99B3\5W&9X )6J:SZ^SL M!)-/DDQ?GU.Y]A6A$BP*\3]<%+S<5W(Z/A4'G1S'ZIK:,<*9O'W-IULT7<%E MGBTL54^<;NV]+H@0%)Q0,L/&]P]^I.I@\?;Y[O9YN_V;[.6+ M7TY?__)6?"'T:PH\ DW'-YVK+9$TO54.7EWBJ,=,+IE0>Q)B;M.(1;P?8HD5 M:@X:E[4.LLQB*H!GMB6*H?Z>6#>)=.KY(6R+*JB;.08@V(L"@ A6HM<.V GM MS8QV>P07G2 XC>&4]XJ*V(RT+<$;[?A@GY59YU3JWUT.%-0W)'A!\PPA4(^* M(^5DH0ZH2PPI0\DC>:EY>I]3@J=;<5!CW',0T4*';>_IX6E-C$T*'[P?F--Z MZF3>6S0A*DJ.<%\TVYE>"'I'P72D*E-*1=)NFQ-S7F=@&EJ56;8-G Z2- ZO MM5?4&M- S!R4G./H!ATPQ=*!,^D-DHX)F,;FEG=9J #_4)3B!$2'=%2HJK+T M[(\&EOZ80B'WV,#V2KRC?47:CKN@@7VE/+_FB#%C-M!T--$PHA[NS)Q%7 MVH6@5SPZ$O18.,,L?A^D< ZWQ0=B*9J<>VVWZY8E'N8/YVZ+@F*X8U'VHX3O M;]+C(M*R/=S74G-^8 ((9%H!RJL:3K= M HEE+#>D/7N\%TWI.2[H54-A'[YIX../I*T_&/$/-'8ZI*&Y',4)Z?UT=H5T M\@VDIK,OO'(P/AMF5XU'^B+C8<&T1G;M]'7$3F7L[/HA9,_]*>!"K%C)-,S.)V0F'(Q!R M2FI^X?))NGS%K?M)",<'XZ-AEMKR[S4VV(RFQ60JLG7GK.0?M/5[K=:4!/3& M@DO6M?D1H61/;Q2'MY8(V^$04PN]*U2:M=&9#Q,3V@]/T3;>Z4YW\!0?L>3N ML13@NNG1_\$CR6C?6]C#WLMS9-"2_R+@X=6$^!Z]N]O]"S&-+]^WC\>_,!"^ M);6T4BT@.AZ]?C40+OXM$"^"K?E5/*8#I"O_7"F4J:,'L$YOAMH+VJ#[;^;R MOU!+ P04 " "W@ E7YM!JMXT( #Q%@ &0 'AL+W=OO(#R9H@.XOLA.G#87P$D;; >]!'$Z\[#8 M!UJB;2*2J))4W.ROW^^0DBS92C;SDE@2>:[?^"QVY0FPW T.AFF7&:]RW/W[E9? MGJO")C(3MYJ9(DVY?KH2B=I>],:]ZL6=7&\LO1A>GN=\+1;"_LAO-9Z&M918 MIB(S4F5,B]5%;S[^<#6E]6[!7U)L3>,W(T^62CW0P^?XHCI!+C_K*M7QO.>BPJC%5IN1D6I#+S__FO,@Z-#:>C9S:$Y8;0V>T5 M.2L__2RDD12E\Z&% M4/HTC$H!5UY ^(R $_95979CV*EG3;EE4(1],SB-QT4,)&*$?1>_R MS6_CD]'9"Y9.:TNG+TE_32Y>%O!-6<&F [;O\O>,+41N1;H4FKUWD0W[[*," MGKB6[ ;_LDCRA(G,"BWB0&96,B,K+RMI,TK:>[C^.P/ MU('=!#=2)'&NH)W=:OD(J>R*9P_L#4_S,W:O42#L;2EO@=(6NMH/J]BURC*J M_JBP*-WLH<_ 8HQ,J+U0*R:M8=N-2I(GIK89S#;%TLA8@J/Z;&= 4!FP$%&A M$5AA^NS+E^M]18E,)3F?2+Z4B;1/+%)ISK.GVE XOK/2;KAE$@%D2ZT>A'X7 M"PXW$,2U-"X;+A+LYO.WNSF%-^ 9LO&(&%.X&(\?I>E83UXN/ET?1+R!B\J( M :7!%!S2D'9:#SFIH=C00W>>^D$'?JJPQFRE5>IM<%EAX]'H]TI@!ZP,?CE% M^^9^W:W]7*VM[0[*2(YG9Z89@'8D"9(= 5L6!N5CC$#VL0O[,X#8(W@KDX2A M\6G*-]!=N]K,/2]1$^RCAOP\#,Z W3\;3)9K]2ACF$( /=Q;.\D;50TM#?^# MKDA15.U6L2A1<'9M^B[^*ZE1-MB^W4@4IXK@D_;E^CVRBDABZDFBE8[/&?0B MR==>6*/0K)?4B0@NXPI5)12.PL$(K2Q)R D8&"FT^)AB32\H )R!H#.SHBP] M-;="4(<.>!*.?@\:<.V*!6@1V5);F.[6[;G3=QM7,B$(D$U69@6M;:"5YWDB M(V^G%C\+B*45>(WT\23PMB.WV=HQ"P'#[>P[@5HE?:9VR"L1!FFF6>.29I5( MZ1CNB>:'NR(1**3QK)66W=OYSKQ=B1#H.I>P+=&V,YU*YJE4LN/LL@5[W!H! M#^(*2"T#%O[3'BQ:L'(2@ZH+#+J2V $4$!V/8P=V+'"F_I(IE>31>'!20^CU M^ F>Q0^MT8*&6/+N=,=5SZ/INJ7VOE1(#E=UWFS!+MC(:I%1;W!&.LXOH1"@ M1RQAD%M;H)-J-E]^3!^,([8%+&9?A(4D MD$&3E)]SU).CXQU=6AYQL]F+.H0T\@-./)H,IE6&^B718-ZF81Q2' MQJ1FJ MIG"EDN'\P4'&UM2Z^BQ/"@K2T7C7KW,M(S%@78Y4#U-\V$7W&,:EIETLSUF-JM>.AZRR M'J"MZ#)$]Z1%H9215O'XJFV'C7'PGR_^ *F#YRL)+8W0=REJI!& P&&'XD4< MA<=(8"1:@EQB1&J_Y3N0MZ6-!F$ES1D8-$1@!J)S2FDC 65^J.("5[E"2Q6[J<8S MRDX7]+ANXW%?&EB_/<3AI"X?\HET M_JB<_2.8+Q:?[A?!-;&8@Q_]0 ,#,R2N=1VQ]V'P4>0@S;(XP: "IL.5*S_L M?_3#_J1_?#P*OKM:WI&+8<<3G-]\U>^*W8$CJ]GO]'UP[_AVW^M)?W8Z#;[L M_ 8.(EV('8/ PG VJ5\#YZDTQDUVX7'P-VR#R2G/^-K/^\T8GH2EVJ[ 3DY& MY=\SW:0_#:==YQ1$(5?:NFY"(M!X#GD^.)H-9G5%5(=DN\%0\2[UUSO^ M>/]GD8GZMAKG.YF\DZ[?U?>[<7V/NEOO+8)#%6B(*B5AA MZV@P.^XQ[2]8_8-5N;O47"IK5>I^;@1'-Z$%^+Y2RE8/I*"^Y;[\'U!+ P04 M " "W@ E7#2KGWSD# N!P &0 'AL+W=O;$HB#\^A)&JV-?;.58@$#[72;AY51)O3.'9%A;5P M1V:#FE=6QM:">&C7L=M8%&4(JE6<)LDDKH74T6(6YJ[L8F8:4E+CE077U+6P M/\Y1F>T\&D6/$]=R79&?B!>SC5CC#=*GS97E4=RAE+)&[:318'$UC\Y&I^>Y M]P\.GR5NW9X-7LG2F#L_N"SG4>()H<*"/(+@WSV^0:4\$-/XOL.,NI0^<-]^ M1'\7M+.6I7#XQJ@OLJ1J'DTC*'$E&D779OL>=WK&'J\PRH4O;%O?,6F MW@7SN):Z_8N'71WV J;);P+274 :>+>) LL+06(QLV8+UGLSFC>"U!#-Y*3V MFW)#EEH$/AA-E8.WNL3RO_$Q,^QHIH\TS].#@/\T^@BR9 AIDF8'\+).=A;PLO^7 M/80+7!((7<+;[XVD'WO*X>O9TI'EH_/MN2*T.?+G<_CK=.HVHL!YQ/?%H;W' M:/'JQ6B2O#Z@(.\4Y(?0_WKC#J-^-(0P/H(_08?;"OE>"B5_8@EK;@!@+"CC MN*2-?KK0:Q=\F4MY+TMD0^K"U!Y#"6)/,GRRNT3N5R+N/4")X++W@JC19-*3WKPC ![5K+&27+(,81_]H"<@9NHE;X-N1+P&2$ZZV, MXH[HH/_25Y@JTSAFX :GO=L@<_\&P0WKW9_H!9E>(G16[_JQY%X$O(1^GJ4P M\$:6YZV13X];8SR9PJ#WZ;-UH M.H7CE L_A5$VZMT:$HKA\R3Q23@J.PGYLFS<3AQG$Q@\=_SCO1Y6HUV'3NVX MIHVFMIUUL]UC<-;VP%_N[4O"IW7M-U3ABD.3H^-Q!+;MSNV S"9TQ*4A[J_! MK/A!0^L=>'UE^!KL!CY!]T0N_@502P,$% @ MX )5V9O%H,[ P /0< M !D !X;"]W;W)K&ULE57;;MLX$'W75PS4"UJ@ ME639==+4-I"D+=I%VPV2-'U8[ ,MC2TB%*F2(SOY^QU2BN("CH$%#/,VY_"< M(3F:;8V]=14BP5VMM)O'%5%SDJ:NJ+ 6+C$-:EY9&5L+XJ%=IZZQ*,H JE6: M9]DTK874\6(6YB[L8F9:4E+CA077UK6P]V>HS'8>C^*'B4NYKLA/I(M9(]9X MA?2SN; \2@>64M:HG30:+*[F\>GHY&SBXT/ C<2MV^F#=[(TYM8/OI;S./." M4&%!GD%PL\%S5,H3L8S?/6<\;.F!N_T']L_!.WM9"H?G1OV2)57S^#B&$E>B M571IME^P]_/.\Q5&N? /VRYV/(FA:!V9N@>S@EKJKA5W?1YV ,?9$X"\!^1! M=[=14/E1D%C,K-F"]=',YCO!:D"S.*G]H5R1Y57).%I<5<;2VVNT-7S5&W3$ M"25D/Z5_+R>N$07.8WX0#NT& MX\7+9Z-I]N& X,D@>'*(O1=,7K \?#('>?:K_&$(89K _DW@ND)8&<4O5NHU MD%@JA #VB\2+YZ9NA+Y_^>PX'QU]<)';SR,)PE&] Z!(^8H'U$BV, M1V$ZAU?/&HW=;FQ32 L;H5KT4OW,HY=HUPL7P&Y9WD'=W77T=_U/ M>\D3N3,;6:*#WZW0)$GX4L0*NJ+*U2FRN!:V](AON$$%XUUA-0K76NQ--ZW/ M+'DQ'+&[5@I"]U3B_FY"&0QG](K-WZ.P[C6,$LY0&ULE59M;]LV$/[N7W%0@R(!'%F6;"NO!IRT7=,M;=8DVX!A M'VCI;!&12(VD[/C?[TC9LN,X1O9!%"D]]]P+[XZ\F$OUI#-$ \]%+O2EEQE3 MGG4Z.LFP8-J7)0KZ,Y&J8(:6:MK1I4*6.J$B[X1!,.@4C MO>.&^W:GAA:Q, MS@7>*=!543"UN,) /SC.]<8E;OD3F MVHTPK[%1Y$%2:2.+I3!94'!1O]GS,@X; B?!&P+A4B!T=M>*G)6?F&'#"R7G MH"R:V.S$N>JDR3@N[*;<&T5_.18OI2OD,F-7:%*[NNPKV$WRKA0Q2T(0S": ]?U/@9 M.;[H__@)?X_&VBC*C']VN5PS]G8SVFHYTR5+\-*C(3<8,#6OV$E6"5'Y.IB2CA.'$?'/W Q(F M4IX2O_:=01.94Z?@8@J&C7,$%]R:M.'[^.$D[,;GNK5;/>F0$Z 4PB:%VD!J MX!,F6(Q10=1UGT,X/+">FDQ6F@#ZZ*QU+;6!*Z:Y7C-LRK76$;2BOZ(2#+XB MRTU&P4W@ ,)VMQ?0N]<^7;^WQ=B"P7?*B6Z['P1P#,=;@ >+!ZMFW+%.60!+L7RV=[/RIJ[O46C,1BGE'A[>$;B;12/'^!>)"&BH@2 M+FB?4B[3)&IWXY/E)(C@?0GP0U FSNH$#T-7&%0>F^6+KBVD+6H/D@H)V%0A M.MI#"[/E& ;GF_RC%<+]ZYX?T;E&!?*&"6TX?,VQDO3AD0X590UJ[53QTE9G M6PID:%FI)*,3&\)^X+)69XPRV?8&ZF$%>4[':_)DUYN\=-.!@ZX?T'&;YV2< M_T(K,8HI\7/J,X*RU"I:VOXH*EW1AMRR)*,^K-NV'_A+-X#4?:OR!?3KSN/3 M3T*2A59_W:(VW9A3$^-:5Z2*B19+4VX#1>R#7CN*XY4OU&>%)'>T<82N8[TF M6T4B=9NWYNKN#PQ%HL7*4LEG7K@# X"/SAI N/Z-7]7CATR_\EG=BMWQ>C( MN3MCN7/7P NE+;L9C=)=S=W?=>!V-BY%!:JIN_II IK ME(P73&@N!5%L6,=7L3N9_\\S,KCO##LG8A%:Y>9"+ M/]E*SZG%2V6NW3]9^+D))J>5-K)8&8-!P86_TL=5'%H&P^@)@V1ED#C>WI%C M^9X:.KI2^.D.FN0X\(NRC>C,,IA9T9?I6&:/+"4\3D=Y^PJ-$"U M8V&Z0KCU",D3"&?DBQ1FILD?(F/9IGT(-C6E9$WI-CD(^*D2/=*/NB2)DOX! MO'XML>_P^D=*)/_[,M[Q47*2YJ3FT)6PK2&&V\?*%?D)\TK%GS=8M(EU)")'9^[ M\3LIYDQ-H82D[M9PBV %D+<'T& M2DCQ]DFX4P?VUM\%#Q2=04!9AAI6'/P_?[[#XQPR"VL?)V$_;ML/NJ?Q$-9!C:7BJVV#1((PFL8Z[9_#?"BER4-&2599^%_S37EO$]]TD),.7&^M0 M*EEPK:5:NO0DK^W$)+IL^;AK3;?$W8SX\@V!7854'"^?8;2+V4 (5REEG;_4 MY6^ LJ EN#UR;!,L7Y*3N#=$M\YS&XBR4KJB<&8DH8X3N:]4.L->0FZFBC&G MOK!U WXP^$1%A0V2).>^RGKD1XG7Q:JRNFT!S)5.%G#AT!$LU]DJD%.LI$N' M;;?RK$) %MS,VL7>LTQJ@#F&6!#L=OOR,J%7L4F\!&Q MXR?):51W!N)^::KL$O!5N7<)@X<);U7'(T M<1_3G(J463=>S;[E=WE+%FA;!Q9G3U/KM3/1IKU4V-A:WIO 6IE1[[1!$XTZ MW*2R8'N2(^K%M844!Q3X9,&7EU\:_K@.$K-;[3;K9UO.7EFPV&+\ZOJ_KU$O8MW7XK,!ZXULRY_^!2BZU7F.Z\I:38,=[LO;>(X>Z8_]=UO@L6OT%UW:%K#8:7[O4=IV7W:[=*50IK_1 \#.(0A&*A=CCG&N'.2:D_/)&U>V(! "C>]6)SA#NJ$5H2&) M*7.%;"WJ%CRN-+XQ[,J4Z)6VM2.XB%=>96 @L*C?GN^%12!HKE[B-JU:'K%-IVMV<7 MBESR'IF<^[Y?P];)HK -RIZ?-)8:;=H?,NJW]1'MQI],FNG^?/<%R\.%)CF; MP#3JO3OM$.7/3/[!R-*=4U!B./6XVQF.F4S9"1B?2*A&ULM5A;;]LV%'[7KR#NRT+9LU[N7'4R'-HT M%R6W UT)A3=S;4KN,#2+H:V,X)E?5!;#R6AT-"RY5+WS4S_WP9R?ZMH54HD/ MAMFZ++FY>2X*O3SKC7NKB8]RD3N:&)Z?5GPA+H7[7'TP& U;E$R60EFI%3-B M?M:[&)\\/R!Y+_!%BJ6-GAEY,M/Z*PW>9&>]$1DD"I$Z0N#XN1(O1%$0$,SX MUF#V6I6T,'Y>H;_VOL.7&;?BA2Y^DYG+SWI/>BP3_B0:?PX)+]6% M]?_9,L@>0CBMK=-ELQ@6E%*%7W[=Q"%:\&2T8\&D63#Q=@=%WLJ7W/'S4Z.7 MS) TT.C!N^I7PSBI*"F7SN"MQ#IW_II+P[[PHA9,S]EKJ;A*)2_8A;7"6<95 MQMY*/I.%=%+8TZEHY3!O\YP%_L@/_B+W3RN66O5*9R#;7#V%K:_!D9?#S MR9V /]=JP*:C/IN,)M,[\*9M *8>;_I# L!^OYA99U!+?W3%(J@ZZ%9%^^O$ M5CP59SUL("O,E>B=/WHP/AH]N\.1@]:1@[O0?T F[\9_KYU@3P?L^WJ2.&!K M :D0N1H;VMD^!FE19U(M6,IM[JVCAT1\J^45+X(03U-=XXE5_(;/"N'%,&EJ MD;$B4L*-P')C).:Y8ZFVKL^6N4QS[!4%9RT5B9-]]P9><"+UL--VP/DN):.N8A]^&$UX01S*I@%P!*A(WQ[(HKAY#I MVB)XYJMP"6DBZ5;5&AM14) JEGM&]\,4A5U4TD08R;HA3S6FT++W.RR*NEVELG M:5,U$ C*",$*5$QA":^!\-DH^4TR\YI\R!M'(KP3]I86LC%[S+[5V#I9B+SU M$?-'41,9Z\,K,P1!INL"B:),]1'0)EMHM-;"]X*;9$=I;2DD[-@9VCU1J(*J M*53=%HHCFNR1:G'-RZH0_;"+YSCB4449]AF"VZQN*QOFU65%M6'WV2_;>82" M5K8I&A0%AVD.S87(DKG1):0S@8Z$PL6LK@V"X+=Z(3H3OH'JUBE^].#)9'S\ M;%7BL7$#]KD#R! S ADIWJ!NP MRQKTG GB6+"C"UV>U[\)TQ'EL%OGNH QWBZ?*7^H*F>[\KQK<[2UW9CFSX_( M8NYCC*9#M$U'WX.\! V7,[#L=.RG)VSO86!5$"<$[/Y)\GK+\ZP+,/FD'6U\ MQWX->_LR\E[#&;,QTU'F"<&PO89R]E=/D_9INI^$\SEYY^O=K[4B!0U2&$Z2 M5PB\#\A#F-0_.CZ,'Q[37V-EV;7^CE67ZX-4*AR^SB?R(1M/5R)^D%![89O# M+9SU<1Y ,+7QA5\!CDKE(3OJ3Z=/(Q __BZ.TNKQ-M:X?X0,1@;1^([\;67_ MW^4P"07S8_)UW!]/1]'O/\E6]YK_+U?'_8/C@PC$C^^=J_%HM)$K&J].K7<1 MHW61A&?J4W1%HZ'KLJOF:+.%ZSH\5DJWVKOOT0H=A^0XG"/3<$*! M.[<)I#LA@-IF'Y^8G?(;?'._).[0&C*)C^+5=S9"%765("<)PNU8WI]W=B62"OH_Q@EANM-U,-8]+=XJ)4^=WMJ/.[#P M;=AQBG9O,4JC32*KEF#<=A"-3BG5'^?-C),>IV6C+_K9+0N_!)4H8;%6J"L\V@#KKN M$8;1[5!)!41W8);Y3^MP4=3.MM=L%^%V:2T>[NAP&"W03*+YFV/I:'!\V&,F MW'N%@=.5OVN::>=TZ1]SP9$D$L#[N89WS8 4M)>/YW\#4$L#!!0 ( +> M"5<9B-UW @8 # / 9 >&PO=V]R:W-H965TSI9#?U8)2#<]%SM5Y9Z%U>3(8J&1!"Z+ZHJ0< MOV1"%D3CJYP/5"DI2:U2D0]"WQ\/"L)XY^+,KMW)BS-1Z9QQ>B=!545!Y,LE MS<7RO!-TFH5[-E]HLS"X."O)G#Y0_:6\D_@V:*VDK*!<,<%!TNR\,PU.+H=& MW@K\P>A2K3V#03(3XKMY^2T][_@F()K31!L+!'^>Z!7-]#Y']%>8/#G=*:TQ+W_:Q=&9V*X MVX2IAQ-5DH2>=Y#PBLHGVKEX_RX8^Z=[ ARV 0[W6=^3^;UZNZ/Z)#2%P.]# M#?LSAVN:T&)&)00VI_A?+RA)154<*C6*([%"^H3!C)X?;VJ@L$/F%M M?L/:A)P53*/3G)$9RYE^@<39[L,7I)'TUB+<=+<9O,00%1HNA;2E+3+[62]Q M_:6G:")X"EDNA 2B(0Y'<,,R#'/Z1'F%MIJ 5D\;@,,04-_]82(?:*E=)L/( MIC+LPK7 6B22H6%.N 5;9]0S&84=&:V-;VO^'XGU-A.[(][7^=V!:$>:R;]+ MJ[>>UCM)"X;D;!#V=_E,*FGC %"B*$. P/H(72J0RM,1-2QB? ^(V0:0$ M"TPO$'>X#'MXU5L6?<,<)3SV+&9X=X+5%OQV0,6$]J M07*,AR?29M"X' 7=R7@"N!DN*+<93<5J/):W,^>M,L?AALYDA7.!/0"(>'Z>C<< M'7O&R#@(+<1,Y C.?*O!NNF(_4T!=Y-KIHG=/\;= (;)\\@,IZM=66AJH8&@ MNE!9NAE9DHJR*>/IPQ5,AN$J"38GWE<[P]"T1Y#".))ASLU)YSC-Y8/($2JH8-X# ]56>;V.#*=EJB%Z>;+=6ZA;DZT M[2]>O1UX])C"JIF*=%]A]W: ;&][]6F$U)2MF&IEF!Q(,/5D0 M/G=-ZY6)C;I&;-WX> S3[?KN0E;I"B/'GL:*JC#=LK#G66IY94<-3I\U9*:\ M7!,T?0/7L:EEF&4@KX"W(#TW97GW;7G<.=8X2 M5VM%?1ATA^,1'&W1>'/'7.O;-3\/UFXQ..C,[5W-G,5HW5UHVM7V.CAUMZ"5 MN+M+?B1RSKC" #)4]?OQJ./:>?.B16GO1#.A\89E'Q=XI:72".#W3.! 7;\8 M!^TE^>(?4$L#!!0 ( +> "5=\OI>:@P, 8( 9 >&PO=V]R:W-H M965T99M*4Z:V0;B=,,VK&W0 M;.O#L =*.EM$*%(E*2OY[W='V:J=N48!P^*/^[[[[L@[+CICGUR%Z.&Y5MHM MX\K[YC9)7%%A+=S8-*AI9V-L+3Q-[39QC451!E"MDMED,D]J(76\6H2U![M: MF-8KJ?'!@FOK6MB7-2K3+>-I?%CX)+>5YX5DM6C$%A_1_]4\6)HE TLI:]1. M&@T6-\OX;GJ[SM@^&/PML7-'8^!(>/);N8PG+ @5%IX9!'UV>(]*,1') M^++GC >7##P>']A_";%3++EP>&_49UGZ:AG?Q%#B1K3*?S+=K[B/YXKY"J-< M^(>NMTTG,12M\Z;>@TE!+77_%<_[/!P!;KX%F.T!LZ"[=Q14OA->K!;6= MFMAX$$(-:!(G-1_*H[>T*PGG5Q_HW/\PSD&#%AXK87&1>.+EW:38XA/2,XB:'42M9Q<)?V_U&-+)"&:367J!+QV"3 -?^MU! MPC]WN?.6[L2_Y^+MZ;+S=%PGMZX1!2YC*@2'=H?QZHJ::H>N8?$$TO&\:3V64?X" MI=S)4NHM^ I!$V> "Z5,(7*%X,T)O#*J1.N D SH0KU@^:/8H:7R!]W6.;DF MI\&[^Y][8T_G^*65.Z%0>Q=1NW%>:)8SAG=2L<:OX1Q@(:JC*,#)6BIA66I^ M+@/X7&#C2:_P(#TW(>XF+@304#JUET)1(L@?M9@HV!6F5268HF@MR,U^JE?I7@,CX.3 M8S/72Z\'7@4H=8MJTOJ59@ ;/VE#@NE!M&?P%HSY[036?4?DZVSTCO1=L M'3GY#'7?'I#; U!QXU#<(Z!#X]$,&"0@"=>XVN@LWX& =L74PC.[[!$B^ M8W2[-V@M'V5(5YK1+_HLK!7:AYPVK2TJ:MNG: "5=CW=:8M08 ! 1 9 M>&PO=V]R:W-H965T,A.JBDO\LE*Z9!8?]7I@*LU9YH3*8A!' MT610,B%[E^?NW;6^/%>U+83DUQI,799,;Z]XH387O6&O??%9K'-++P:7YQ5; M\QMNOU;7&I\&.RV9*+DT0DG0?'716PQ?78UHO]OP3?"-.5@#>;)4ZI8>WF47 MO8@ \8*GEC0P_'?'7_.B($4(XY]&9V]GD@0/UZWVWYSOZ,N2&?Y:%=]%9O.+ MWJP'&5^QNK"?U>8/WO@S)GVI*HS["QN_=S+J05H;J\I&&!&40OK_[+[AX4!@ M%CTA$#<"LJDT9P0E)0;JS&KP+E[.6-5>EM MKHJ,:_/+BUD\G)[!VW]J8;? 9 :OE;SCVHIEP>$:^>):\PR5OR$K0E\4-+F!M[*C&(>P<^;L%?Q<\J?%_+$)*H#W$4)\_H2W9D M)$Y?\K^3 7\MEL9JS+&_NWCQ9D?=9JGN7IF*I?RBAX5EN+[COT_X_1_AY6Q^5Y3",0_AYH\$QDZ]566*Y^H=/$CXPG>8P\4'N@\TY M;:F8W$+*9(KUC**3T:@_FL\#DS-D$-0*4J_&.#7, ,,68K!4Z9OF5FB.K<4] M-;*PE[78WDRMMUXZW*.(H^=AQ.-^%$5/H5 ;B7N62 $L%=,9E+Q<-KJKFIM:H;@K((;I>#/NJ'0 "^K0FT)><#6FGL?B-$#/+O-J"UN67^'$"4U M0+@NF'R(G]_SM+8(C<'OFNPN6M6T3ZMZG<,F%^B_1P,;Y'--.WD6#/M1DO3' M\^$A?QU@#ID(X6N%:V'(S91[-(WXAFL.J[HHMJ=WW#A4Z)Y4$@?0B@O+*%$W MPN:(UBK+"E@QH8,[5M2<;+.JTNI>8+_FQ19.XG"*;;,H< *$<'U +)GL\';/ M"MG(>9'!.$KZL^FD=:S!V?A/J@RSPJRVP5&L++L'M2S$FKGY\QC;,$Q:;,Y) MS5.E,_+8@)!(&"<=Q$D+A19".ABU9'4F"$&JL)U*XU=&%2)C%)@E*XA<<+,! M*Y)S^(R$:I':7:UI512G2.R&LG%)$SJ$+VWR[RKP/9,U#FR(ARY#XWYG@%U* M!^AEAK656J6QYFJ;*RW^=:GE>(-EO5TR5(M$((,EO"15I"..SF[=NI!5)!I8J6I?^G7E4P$38!>)##EAVH3PIM9" MKGW,Q3V4?G9QFEV^8I/.;J Y DUS/"ED09Q,^I,D:G.&8:UBD(SM2(8HG.\@ M* TG23B?0L5UPUM;AWARNN6^" Q6K196D.(T=2[5"$X[-,[_X,A_#.X#H)1N MYJC;06U:KQW2DB.O6?B#3NP[:E\(6F* D;H^G0^@1.(YV$\AE-(PCCJ$'T J$,,6];P<:DN MJ$:/2-#[3:Y+Y-VPY2 M9OUH,D/?QN%D%/S>M,QQ/.]/AV-R.1S/@F]>_N4XF?:GLP1^Q=>3Y*'FAYR= MHN@I+!ZSZ9(2JP7]D0JK@5)\+:DI!(Z@4SK 4Y\L\5)C?%_F][3F2&;!FH;^ M!*]AVQ(K$CR*A:KVMPS*QWTI'C7*H#D,^/T5-NF.W.T*TP^B=.-+[CA"32J_ MD^@17J52^.8FY:- _DR*XV(X3Y#\)(JI/5$4IN$\>.M.)=A#5<,,(KQ/ $*^#R,IC\L!UPD"55#,ME;F 0MY0=' CRUZ%08UPKC27\\I3P;X4P= M-U)C'ZZNF#-C5"I+JR-1;)CRHB7O[#NWNZN^PM_R]UO][\5X"3" 6*@X"L4C<+IN ?:W[_] M@U65N_,NE<4;M%OFG&%%T@;\OE)X4VD>R,#N1Y#+_P!02P,$% @ MX ) M5YB0S$&. @ PP4 !D !X;"]W;W)K&UL?51M M;],P$/[>7W$*$P()FC3I7BAMI76 &DP[04^(#ZXR36QEMC!OJS;O^?LI*%( M7;XX=^=['C\7^VZ^U>;>%H@$CU6I["(HB.I9&-JTP$K8L:Y1\#:Z2M=;W MSOF2+8+("<(24W(,@C\/>(%EZ8A8QI^.,^B/=,!]>\?^R=?.M:R%Q0M=_I09 M%8O@+( ,-Z(IZ5IO/V-7S['C2W5I_0K;-G?R+H"TL:2K#LP**JG:KWCL_L,> MX"QZ!A!W@-CK;@_R*C\($LNYT5LP+IO9G.%+]6@6)Y6[E!LRO"L91\MK?$#5 MX#PD)G.A,.V JQ88/P,\@4NMJ+#P4668_8\/642O)-XI6<6#A%\;-88D>@-Q M%"<#?$E?6>+YDN'*X-?YVI+AV_]]J,B68WJ8PW7$S-8BQ47 3]ZB>V-TH:M*6CXU5HF\6/&71N 3>WVB^X,YQ!_1S>_D74$L#!!0 ( +> "5?;R [DTP( %8& M 9 >&PO=V]R:W-H965TX^4 MR$RWQMZ[$I'@L5+:S:*2J+Z,8Y>56 DW-#5J/MD86PEBTQ:QJRV*/ 15*DZ3 MY"RNA-31?!KV5G8^-0TIJ7%EP355)>QN@MJXE45)?B.>3VM1X!W2 MUWIEV8I[E%Q6J)TT&BQN9M'UZ'(Q\?[!X9O$K=M;@\]D;8_QT?L[1>7_JD;Y$>!/S8Z"&, MDP&D23H^@#?N\QT'O/'_Y L_KM>.++^4GR^EWB)/7D;VW7/I:I'A+.+V<&@? M,)J?'(_.DJL#NB>][LDA]'^_I\-PGPTAC"9#.%R/3U@(!2MK,L2SMQ;X0MF(IO8<.AR?#\ M-&JK^V1P;&GU%G>(+^KV3^!U!+ P04 " "W M@ E71K#3S'4# "T!P &0 'AL+W=OO.%"+8@-*.E8XD*1*DG5\;_? M(24KRN Z+Q)OW\?O7+G8*_UH*D0+3[609AE4UC8W463R"FMF0M6@I)V=TC6S M--5E9!J-K/"@6D1I'%]&->,R6"W\VKU>+51K!9=XK\&T=;6,3#Z_< -"N&(2,;WGC,8KG3 \?C(_MG;3K9DS.!& MB;]X8:ME)S0V\J1Y-XKAT07FPFG8YX>QJ MBV4KF%7ZL(@L\;G5*.^QMQTV_0GV$KXJ:2L#GV2!Q4M\1#H&,>E1S&UZEO#W M5H8PBZ>0QNGL#-]L,&[F^6:O&@=_KS-C->7 /Z?L[&@N3M.XNK@Q#Y-Q=\HB)/,01I9^5)0F3'-XP+S5W'(T M4[ 5PD;5#9.'=V^NT^3J@X%,JT?4[PMD O7$M)GA!:?"G (W5&\E-Q8U%I20 MMO($#Y\VP PP"5Q:K8HVY[)\24.;A8,SJ+'.:*YV\/G+W78=PA^O28!G"1.B MH-F_5+I@E;_XF^2N!<$=-:H-:[AE K:M0/C%?Y-Y/GN?_ K[BN<5J?_><@J5 ME^U:DT7)9(Y.#GF'UVT-DHCRGLBI'F&8]4#-J'%,",+*DOS!R-><,CVS6$@T MQBD;D4PA4^0H*>GTI#T%"_<[ES;D/XG3NT5 MQ0'>7H4S$B<$->QI'\N]2[G_GTJ/IR9<>N<:KZ&WHS@99-I_&X?)$1F>JMUH MU$EKU*5_+PSDJI6V:ZK#ZO DK;M._'R\>\^^,EUR:4#@CJ!Q>#4/0'=O1#>Q MJO%]F=*&NKP?5O2LHG8':'^GJ+K[B;M@>*A7_P%02P,$% @ MX )5W(B MO!DB P RP8 !D !X;"]W;W)K&ULE57;;MLP M#'WO5Q#N4&Q $#M.F@;-!6BR#>O6#D';K0_#'A2+<83*DB?)N?S]*#GU,J - MT)=8I,BC0TH\&6VT>;(K1 ?;0BH[CE;.E9=Q;+,5%LRV=8F*=I;:%,R1:?+8 ME@89#TF%C-,DZ<<%$RJ:C()O;B8C73DI%,X-V*HHF-E-4>K-..I$SXX[D:^< M=\234,FB-]XN'Z&?USJ)UJ63"+,RT?!7>K M<32(@..25=+=ZZAI#96^ M6'6ZWP[EW#/UM]W,ZTP*T0 M9KHHF=H!JIS&DP>?+T]D:$$O"6:-!D_N,:N,< )M"VYN9O#^['20ILFPW@Y& M9_@!G ;?8H>YR)B4.WK$BF"!*0Z+2DA^>*;/ZEP,+0BU1NM(!!R41M/!%FT; MONTDPJ/6L@53S0R'6RP6:%HGP@*35@.#(G@\30^["%%D<&%(#K0Y** -#P?% M"D75&*IVB765K*2#MX+F'XGTNZ2=#&@.I0R20MS)TV\**\4J+NB63S)-XT@['&AEM10\7+YU]/&-#562R'L<"FB_ M]&CC X$IT.1!1BT!5LK56M-X&Z6^J@7J7W@M\[?,Y$)9D+BDU*1]<1Z!J:6S M-IPN@UPMM"/Q"\L5_=N@\0&TO]3TCO>&/Z#Y_YK\!5!+ P04 " "W@ E7 MIUOC/5P% #M# &0 'AL+W=O@#+8TM(I2H)2D[Z==WAI(5 MI^ND^U*@#Y8IDC-SYISA11=;;>YLANC@/E>%O>QDSI5G_;Y-,LR%[>D2"QI9 M:9,+1Z]FW;>E09%ZHUSUXS <]W,AB\[LPO?=F-F%KIR2!=X8L%6>"_-PA4IO M+SM19]=Q*]>9XX[^[*(4:UR@^UK>&'KKMUY2F6-AI2[ X.JR,X_.KH8\WT_X M3>+6[K6!,UEJ?<HU+LB&!\:WQVVI!LN-_>>7_G MFL")PL6 M9>$,C4JR<[,%KHEB![=8:N-DL;[H.W++@_VD<7%5NXB?<3&&C[IPF86?BA33 MI_9]@M-BBG>8KN(7'?Y:%3T8A%V(PWCP@K]!F^/ ^QO\:([PQWQIG:&*^/-0 MNK6WX6%OO$K.;"D2O.S0,K!H-MB9O7D5C7_)$*YU7HKB 6A=&^'0@BS ;36M,)XEE@J#967)I[5@:P_V#(ZB8WBK MJ0"%D>0XJ8QTDHQ%D<)1? P?<"V2!YB_OY.IAIM,T(KI^7B'K!YCP3]C\1C3 M2E$#]PCWS:MI'$W.+2R-OD-SDJ)0:%KK+FPSF60@+21DH"VFH%=0446:+0>E MY!DJB5Y8X3<$H8#%DPG66X-'5D-^DDQ0)_,B9EDDJDHIL;GT^7\0RQ92+@K: MW2QP,K+8H'6>4LBT2@F699P\INJ@-";=0P]NC-0&G/9C[VX6,$^^5=)*AMX% M][V0*0B2 PC9FB#6G9SV#B/S8F1#S/-R)9G$U9YYBHGD'?@D%\0['+$0<7A^ M_?GM1]^,SH^#C",G"3-"@)EG@^M*":,>J+7AG912=VB8]!550Y%(:IFV+NEP M 11$5LLL.ZFLITTPO_7QP_LX16 H.XA>R!U(&["=4$HGQ @%L+HR"%/G?&8W>B::1%,TJRE)ZXAA#TRO'K6PO>!+9A"?' E &SJV&WIP:$,X5(]$ M;6&)EI2+.[BM$X#7,(GH<>(;P>>V3J^)!QO\C 5U*(]9I!1'\C[/!S^,NZ>C M"<3=*!Z0[6DWG(;DU*(P5'>U>AO*M_0YQ1 ''YBWE='Y7GID>33N3J=C..8F M>QO537(817 6_0.3;]]0NL.L9#B&*QD"G M2!V7A*2*N<-=/;9,#<.0?\'7@NY@2OY%]*K&H-"^YA.4&V]U%$__AW)/N^%H M#,/NE$2/XNYI-'A>[0$,GE5[TCV=-A*3LW'8T! 3):,?EONPX/%H /'IY%\$ M'PQ&_/NO!)^,N1F'3P2GI(?1+NGA=-@F/>1R/W3-Z>]=07,T:W_1YL.8]K?Z M-MKVMG?Y>7V%?9Q>?PA\%&8MB7R%*S(->Y-1!TQ]N:Y?G"[]A7:I'5V/?3.C M[Q$T/('&5YIX:5XX0/N%,_L;4$L#!!0 ( +> "5?6#ZGG& H -<< 9 M >&PO=V]R:W-H965T]^NPN>K*R[]4NE*G%?Y,:?#I955;[=W_?I4A72CVRI#)XLK"MDA4MWL^]+ MIV3&1$6^/QV/#_<+J/I@.1UKZR122& M!H4VX;^\CX[H$!R/GR"81H(IZQT$L9;O927/3IQ="4=O@QO]8%.9&LII0U&Y MKAR>:M!59[,TM;6IM+D15S;7J59^*.;K<+$6+YJ;+T_V*X@CHOTTLCX/K*=/ ML#X4GZRIEEYC[=R? OM1F)@_%03,?3@QW\#EK;#YC? MP8_;+OXQF_O*(5?^V6=PX/>JGQ\5T%M?RE2=#E A7KD[-3A[_FQR.'ZW0]M7 MK;:O=G$_.Y=>>V$7XHIXFTJ&K#89;FB3ZC)7_/C"&@]K,G[>9\3_0(SX;:E0 M8*DM2FG6Y-#:R#K3E>;&4=TK,E3(" M#BRE Y$V1$?PHZLUBJ-:BB^CZY&X448YF>=KDJM*DB0W\2PWNKYX_NQX.AV_ M8ZI?9K,KOIZ\>SDDJY(>_A6,<371DME.W=0Y6\EVT\/KRXN1^-7P;UMJ0Q[ MHT(: !E9,J1'7HE>(R&N EP**"]D]A4USO>'"?E'>]8?W*R!;8:0)X<.:>T< M/>@2"*-2Y3W 5$!_(<5":K>1U&B+. *B6N6UJ933A2CQUV9>E"'.*AMQ%-MP M)7.90WDE0G>0E7@/<<5<.7$PX1J<#L5*>F"@ [!F8N%L(9JH2V-J*-[K@'E= MB^AH8)G.SB/!)6TR^"H?+TS!GYIZSQ# MJ@EJ93')OM8FM(HV"SHY_)W,I4PAG3W1.559\$SS.@L93+PN0G%0]DV.WGDQ M"W9\5J5UB)41U&7$9+SW5XXFD:R5=$(1>C[V?8C60Z9E@&U4,#3H:$WN3:"H MKC2KB&CJX'N'!D* ;U>H)[_4)45!(I>_6D<5$6-2L'1^S@FD/'1V GT>3C#D M<7%G.771LM+;T0Y$2/H1H3]0T8LA&J&^VTR.QK/O-6ZOEI;P@"S),&;,O*1\7[/YSSC\'_H(=03*5I2,4]]J#9]V@)Q<6\A;.+=5D4(M/:;8 M,D2:BBF1BP5\+U+E&,P<%S7!8-%F+&A4!(IAS$#2FESI]H&^.AI@&"T2Z7OY#Q7K7WM6PF0 MT*ZXL3F5LV<0XSZ QFRO'*5.)>]C($;B(D9X&X):FHVI:=-@0FJ #4!6W:/$ M#4) ,=+L@V$2G!"<:CU%4G^#U[>U8D/BS",4R(%5:8<-YI%*< Y+;PU,7Z,7 M>*_)!PSWH1FV"BP 5-8U:E*])!)8%=+8]G>L[3@&RE36GDJVJGE,:?$HTV#E M1.S:9-:36; +B@Y;*#K<"23OD;Z>>P 5=IH#]LBAO#I?^"G=A^VM,U MHL=:PB02Q@$/N4!X4);.WK-+$*P_'8TFV._RG!)YJ7(&K,(:M0;^N%L,8(O: M9 T2 *?H!4(,H$>C#BWAE)PAU[K)PXKBE>2A*9(+'8N5:A>K7>$X:L-QM--_ M'Y&%_?W@1^BZ@+)I^MPB\3\/[\ ;T']V?9$' M1V_>B2^D_8JR'=E-FZZF*:B!\[KSE#.VS+$5I M.9JI+'4E\R3D/]!^ Y18[^ZH]T62ECV_!+' HK*>8Q2&O8 AD.!)\-H>.Z&Y MF9"T1^JB'U=.8TUA68$1FQ'%DGJC+1_T69FT3J5)KLV!C+JW!#IKGB8%4%%Q MI)S,U![UZB&5)7DDS37O<7.JZG@KC.RL]QSM8*&KS030T:XM1@)"((]PE3;;F6%*];82T7.:F&:/H2($6 MHY7VB@:4N!IQ)XC.<72#CAK$C4/GHK,V'1(P+E!-]V.B#*!+40JS,!4AP$$5 M27SW>V-C=UBD71NC3%SQH^N;TH4*Y JX!0]D"M8"1V!;/>#$I. MZ6)>._\(C=NB"^'URTG*XO840 M9D8II'K!2P2I'@IGF(3_>S& MPG>%=+"(N&R.>4JI.3\PAU5YR"JB39H)KPNV+NL.@3R0Q#X2=FO:R- #5;6B M'6&C2"ACN2;NR6-9NUKCF[:QO/E.?TC!CHZM,OOPU(I7:0GE^]K.3V!+9U9_ MP]Q'YPAH]9,P0'^879\CSWT-JMGU%WZR-SX>)N>UAQ24(EP[IQ66P_/B-UL" M#X_'KU^*S@DJ^;5I6V*V65O:>Q\[^\O.)K?#R9/QYEA[O-,?EW&2Q4J@5MLG M@YB=:Q/[!2_8:SK>"F[K/>7^:9*2CB2*!<]=X2#MB4!,]\8'0_%!:I?\C@U& MB4\8<##U->=[EZ$!;D9/<5W/OY(^2/G&P32:7TLL I\5];6(#7R"^4FZ=,EC MWY,J'.R-)\/DNX/5I//%8?)3'!9.-1IW 3BV#C!Z:^2G24YV27XPV]UIM:*" MHP-,QFW7U&)P9/*TH+!'-=VPV=,PKRN"=\W<*$.Q*V &X876ACOM80^\Q*<= M:*GQV:N^V7^UFX5O5YO7PR0_) M=T-S3:X6(!V/CEX/A M?T<)%94O^&ULC55=;]HP%'W/K["R:6HEUJ0)7V6 !+35-JT:*K1]F/9@ MD@NQZMBI[91NOW[73DB91M%>P!_WGGN.[7LRW$KUJ#, 0UYR+O3(SXPI!D&@ MDPQRJL]D 0)WUE+EU.!4;0)=**"I2\IY$(5A-\@I$_YXZ-;F:CR4I>%,P%P1 M7>8Y5;^FP.5VY)_[NX5;MLF,70C&PX)N8 'FKI@KG 4-2LIR$)I)012L1_[D M?#!MVW@7<,]@J_?&Q"I92?EH)U_2D1]:0L A,1:!XM\SS(!S"X0TGFI,OREI M$_?'._1KIQVUK*B&F>0/+#79R._[)(4U+;FYE=O/4.OI6+Q$J?OM3GL)?0#]](B.J$R/&N"CF6E]30\5#)+5$V&M'LP$EU MV4B."7LI"Z-PEV&>&5_/%V22/)5,,W=*)TNZXJ!/AX%!=!L3)#72M$**WD#J MDALI3*;)E4@A_3L_0%8-M6A';1H=!?Q:BC,2ART2A5%\!"]NI,8.+_Y/J3\F M*VT4/HN?A\166.W#6+95!KJ@"8Q\[ 4-ZAG\\8=WY]WPTQ&F[89I^QCZ>(&M MEY8\!&VG)@,RT1J,KK0H2,E$I.0;HRO&41CH0VJ.UCNL9HF5 MUI)CUS*Q(<8^B[IUV6_D8HFL+;=GQ\VKN=&*&]UQH\B-OW*S^V6.ZU89W@?0#>R9V@99+&X6BZ\&=69JY#8 6 N MD@&!]=^3B\B[A$(BF,:6,AF9<4#J*&6JY".HCY> L8K$K4XG]+XC"X4FDP!" MV 8@G=B;*R@HJS1(%Y"42B'^3F7_PEM*0_D_JN-6K]_V]N[$FR2)*G$'7M!. M-5B&42]NEA.9YTQ;I],DZG@/R TIYU2@,>:VXOX9=J.Z[*&#C;MAO2N@(5J? M]O[KCUOMJ$T./=9@STUR4!OGF1HIEL)4QM*L-K8\J=SH-;SR=+S"#4-)'-:8 M&I[U.CY1E4]6$R,+YTTK:=#IW###3PLH&X#[:RG-;F(+-!^K\1]02P,$% M @ MX )5_%2UO,^ P !P< !D !X;"]W;W)K&ULA551;]LX#'[/KR"\84B H'9L)TV[)$"[[G ;,*!HNKN'80^*S<1"92F3 MY*:[7W^DG'BY(LN]V)1$?OQ(BM1L9^R3JQ ]O-1*NWE4>;^]CF-75%@+=V&V MJ.ED;6PM/"WM)G9;BZ(,1K6*TR29Q+60.EK,PMZ]7&_!-74M[,]; M5&8WCT;18>-!;BK/&_%BMA4;7*+_NKVWM(H[E%+6J)TT&BRNY]'-Z/HV9_V@ M\)?$G3N2@2-9&?/$BT_E/$J8$"HL/",(^CWC!U2*@8C&CSUFU+EDPV/Y@/Y' MB)UB60F''XSZ6Y:^FD?3"$IDNGDNS\XI-^1N-G_QS^$.UQY$+J$CS\:Z7\>I^#;S1=!/DY],62^K1LJ&!F?;I\IPB?AWRLD!I.*/D/EK"A MS@9C01E'*6KTZX->>\!I*^6S+)$$J0M3,X82GC2]H2O;,7._LDI#!3PY\Y5% M#!!.OD#=7AGD*P-4<.P*'E1(2(>PJV11@;#LI3"65'O"@0!RO#6:ZLGY8(HN M&/69)5UAH$EPF@L=,)5&BZ:4S+HP1$"[5G)&R3($XSS]VH8A#S0=K>#YPBD@ M,L+UUD;1J*.N>]QQ#F<4? DN(]WNB%,#E$Z*3>PR'E' 2\ MA7Z>I3!@(E&TVG<)E2XJ&ULE57;;MLX$'WW5PS4 M"Q*@E639<=+4-I"D+3:+#9J-L]F'Q3[0TL@F0I$J.;*3O]\A92LNUC5:0!!O M)RY=8"1>;&C6OE,96@GAH%XFK+8HB M@"J59&DZ2BHA=30=A[E;.QV;AI34>&O!-54E[/,E*K.>1/UH.W$G%TOR$\ET M7(L%SI#^JF\MCY*.I9 5:B>-!HOE)+KHGU^>>/M@\"!Q[7;ZX#V9&_/H!]?% M)$J](%28DV<0W*SP"I7R1"SCVX8SZK;TP-W^EOU+\)U]F0N'5T;]+0M:3J*S M" HL1:/HSJQ_PXT_06!NE M_6&]LTPCRQI&I-F!64$G=MN)I$X>? 60;0!9T MMQL%E9\$B>G8FC58;\ULOA-<#6@6)[5/RHPLKTK&T72V-);>WZ.MX%JOT!$' MG!P?S/Q=R1Y4/R[SZ?6\KA?DI_<RKU LB? BK/C[$BU>FJH5^?OOJ+.N??G0]%]205R-W0BF,9&[3.#9PQ^>]#K9KW'MQUML_R%QJ2<]\U,A8EF7K M&/H#_GKWAH1J^W @]B==[$]^.O9_-D*3).'+"$>_+8B^LMSA0MC"Q^P/7*&" M 7P1TL*#4 W"#0K76&PCC,R^2-'0N8(KWGRPVC;[#L0R4[MK- NP@OA(#>-IK:,=K/=(W31 MUMX7\_8%NQ%V(;4#A25#T_B4DVK;5Z$=D*E#)9X;XKH>NDM^2-%Z UXOC:'M MP&_0/&ULE5;;CMLV$'W?KQ@H09 WM75UGIC&[ W:;-- MM]C&3EN@Z ,MC2UA*5(E*7O]]QE*MNRHCH$^D.+ES.&9&5XTVDKUK#-$ R\% M%WKL9,:4=ZZKDPP+IF]DB8)F5E(5S%!7K5U=*F1I;51P-_"\@5NP7#B343WV MI"8C61F>"WQ2H*NB8&HW0RZW8\=W#@-?\G5F[( [&95LC7,T7\LG13VW94GS M H7.I0"%J[$S]>]FD<77@#]RW.J3-EA/EE(^V\Y#.G8\*P@Y)L8R,/IL\!XY MMT0DX]\]I],N:0U/VP?VGVK?R9][.-P8G#K_< @V!L$M>YFH5KE!V;8 M9*3D%I1%$YMMU*[6UB0N%S8I!L^ BX2^5N('0 MZT'@!>$%OK!U.*SYPO_E\-_3I3:*ML@_YUQN&*/SC/;8W.F2)3AVZ%QH5!MT M)F]>^0/O_06]4:LWNL0^F=,Q3"N.(%=P5OLYP19 @KR>F0YF(-QN8? MZED;'D.3][(HF=B]>74;^/%[?<6M&&/%Y">!9-H*I:1AF[0>,)'"!TRP6**" MT*^' WC[FBR)6E:: /K=W=6]U 9F3.?ZR'!J=W5TVYI^1B48?$+&34812> U M!#T_\N@;]8;';]>,[1C\1EGP>WW/@VNX[@ 6N-DPVL=&*DV@81P0;SR,FKH# MGLZ?X$$3MD0+#L\R3E')A%&;:^!K67;=V%YCJ1*H4H'AQ*5UNF M: ])L+G8EVX^*KI7FQ1,Q6Z;H<(+?%.15BKGWR$6TC!N-YS7&])>ID;8\^/; M?<,+X=S1=T_NZ0+5NGZ--"2R$J:YLMO1]L&;-O?\$=Z\EH],K7.A@>.*3+V; MN.^ :EZ@ID,;LK[UE]*0KW4SHT<;E070_$I*<^C8!=K?@,DW4$L#!!0 ( M +> "5>6NHL#'0, "P' 9 >&PO=V]R:W-H965TW.3:6B1V9CLM_/<[ M.R5DJ!1>8I_/W^?OSKES?R75HUX@&GC*4J$'WL*8_-3W=;S C.DCF:,@STRJ MC!DRU=S7N4*6.%"6^E$0=/R,<>$-^V[M5@W[LC I%WBK0!=9QM3S.:9R-?!" M[V5APN<+8Q?\83]G<[Q#\S._563Y%4O",Q2:2P$*9P-O%)Z>M^U^M^&!XTK7 MYF CF4KY:(W+9. %5A"F&!O+P&A8XAC3U!*1C+]K3J\ZT@+K\Q?V"Q<[Q3)E M&L(XM7RQ3[;ZP*O=&/0_B0AN9K<&D(..B M'-G3.@\U0#=X!Q"M 9'371[D5'YEA@W[2JY V=W$9BUM[,,[*KZD((ER!F]E;]*Z ME6VSUOL%PDRF5)50;Z/Q'N#'T3N!0&Z2P#$[MXJ[B(>KY3W84OL MA,P@"._9ZSJ+Q RHAQ>&[=,>.[+"<-2:,6H6@R!(J M:L5)_]75F,PEA9E9?!CYK;".;S>/PRZ-'5HACF;8#ANC#!6/'8^02V8[&DSD M5!H>ZSI9T/8#1W92Q18Z.5%4&E'T419KF?JV#93;?MD]K2CG]#64SJU:KIV!4=L#7[>4[ M"5=Y]=>\. 0 #$- 9 >&PO=V]R:W-H965T)V7O(%-"#@DQB)0O&S@"CBW0)C&IPK3JT-:Q^9ZAW[M MN".7!=5P)?F?;&G2B7?AD26L:,'-K=S^"A4?EV BN7;_R;:T':!Q4F@CL\H9 M,\B8**_TDZ\RC7>;SZ"#@[X4X)W'0 M(U$0Q0?PXKH2L<.+?TXE_IHMM%%XJ/YNJT49JM\>RKYHESJG"4P\?),TJ UX MTYH_'T*9"4YON),K(FQ MAX2XIP)#&GQX);.B5[M#';'BCJB:EAE %) .J"P5+@ON5);%Q M)*BVK+#U4+>^YT!>0P+9 A2)0W<[(J?-IZ(LR FFU!N.!LW%F?VKLLS:_ ]XW:52 MF3,#*L-<-Z -"JS!)V&\,W&;SGMDKE%U$V EL[T^]%":E+*>.<)9=3TAPUX< M_]( C7K]4;\!XO9']RH,@KU>V?T!'1O4.C8X1L?L3SFYM=535FOF5+-6%3L( M_N,JYF0*AQ^38MAJ=+$9X1GJ)"D5:RR9TQEHZE1I\*WJD>HTD57]ZU+IX/=T MSY%6->F%)=VB<.TG!J&>RJ,[.<_:[PGB<:?LF:CE4<,A:C>78:ER))6P',N! M8Z,V2,:2/!W@.>JZN(VP/2PJIJK6-A8V3-$<"L,2W7X^*Y / B=6SO[!PG*I MM:VGV,4L252!9DQ@6; B39/1Z)@J?%O+XX7QN4;:-^X_U@G+=) Z M2NJ1&3\Y2D[;V_3!;XRQF;HS,W5"\D 9';+=,\9L&E#7 YRN);*N-#5!_)4V_ E!+ M P04 " "W@ E7SMI'?>0$ "-#0 &0 'AL+W=OON,.F.\D, 7^ 33Y@AB2;V>TD;1K2[G0Z?1#V M!3QK6UY)#J2_OE>R,1"(-_L"MGQU[KD^.E?RY9*+;W*!J&"5)ID?= MK@P7F#+9X3EF]&3&1!/P5XQ+N74-NI(IY]_TS9=HV+(U(4PP5!J!T=\S7F.2:""B M\;W";-4I]<3MZS7ZK:F=:IDRB=<\^1I':C%L#5H0X8P5B7KDR\]8U=/7>"%/ MI/F%915KMR LI.)I-9D8I'%6_K-5]1[>,\&M)KB&=YG(L+QABHTN!5^"T-&$ MIB],J68VD8LS+ M2B5H$?Q[J,82HG<80AOC7.8LQ&&+5KY$\8RMT<BC"1DM M*A($/@-#%L92HI+ L@CN8C:-DUC%* _Q;D0^S/MI@:",VC#5GB1KF8>9 D6/ MKGF:L^SEXX>!ZP07TDH,([9AE&P8T; F38IAK=BYM;ZURC+.K=]S%$S%V1Q* M,*&=M"".*U!>#U/>N.9_-3A2+='F^[_3-+ M@_B."PVB]&M1^N\696(:5OP?PA\%RU2LF.XD\"4K>Z)I+E-J>/"T__Y@P[%< MB(=4;*:B46<\(:DT2B6=K#E]W^84;SA9):<#F@+?%42VH2#S"A/+(IZ;DJCP M\>0:!CUW(ZE1V/IJ6AU&I^R9<.8D*.KVOQ%8BP,FFW.QEPR.XPQ>D EY D'' MWD>+8AGR@I8C3<.W81R[8\,O#5+[M=3^3_KOTXKV/%T'AVH)P@.*F$=K-7EV M4,?&/(?=>%,(HRJ]>1FO("U[*>I>NNNKMHZQ*B7IC8=Z76C"ZRC/ ]^S?J/3RL[P$;CD>TH0 M^$WN#^HE$?R$^_,\03J'*); -9,+N-5=<]O]CYC0^X_@B3>8O#'CX<6QDSK4 MJ6A^7;4,ZJ(;%:T#LM6P$D[W378$@6L];O7K]4[ MIXHL3XG)S+@*%RR;ZRXE7D/L;!>D4CLX:U1H4"LT>+="MX4JJ.9[:D%ID<(# M>]&O[* (C:"'11CO[W%MF)4ITRIE7J6$R-C9TG;.<*5@IINR:79F[Z1Q.CG/ M:'$#>Z52K8A5+B'KL6ZJ5>\I/7F#(:93 O"]6Y@_4U)W@CI0="WFP+Z MX \&30'^CP*"'P4,( ALZC%U_4[;\7WKB>NEW6_;04!U2PGKH\@S2XJMK>#8 M:??\/ISL=8_=Y?7V]M_=.B*G*.;F0T""02]/R_5H_:TQ+H_8F_#R0^6>B7F< M22(PHZEV)Z#M6Y2'__)&\=PPF%#J#G,\[5^D8GJ+_ 1O\# M4$L#!!0 ( +> "5?D^F[>W0( $H& 9 >&PO=V]R:W-H965TYN\YWQMZX"I'@KE;:+:**J#F/8U=4 M6 MW8AK4?+(QMA;$H=W&KK$HR@"J59PFR2RNA=31<>K,$[61MSXX,WY2)*O"!46)!G$/RXQ2M4RA.QC)\]9S1UD+AU=&?9,E58OH+((2-Z)5],GL7F/O9^KY"J-<^ ^[+G>:1%"T MCDS=@UE!+77W%'?]>W@ ./L7(.T!:=#=7114OA DEG-K=F!]-K/Y1; :T"Q. M:O]15F3Y5#*.EA_XN[\SSD&#%E:5L A//HNU0O=T'A-?X-/BHB>[[,C2?Y#- MX+W15#EXJ4LL_\3'+&Q0E^[57:9'"=^V^@2R9 QIDF9'^++!;1;XLO]W^_UB M[CRP_3^88Y=XTHO.&Q@A45K)4ET(ZH$06%:54)C M"#5)H=0]E.%Z4/LWZ<*;E!JH0MBTU'(4H#ODE3;$9X5JN2;V2<6??LK>SU^, M/'-\]LC).ZB[RD)?69Z/3Y_- M]L_1Q\;;.0)@"5DV@\FSL_'T-!]]-B04Y*?3\60V@UF>C?,DAT.%$S_H[QKM M-DPQYS^,IJ[5A]UA4%YT\^%W>C=EWPN[E2Q2X8:AR]FA] I]O#!="'_@+AI^/Y2]02P,$% @ MX )5VS?#FW! P M 0H !D !X;"]W;W)K&ULK5;=;YM($'_W7S&B M595*#F P8*>V)2=-[WI2FRCN)0^G>UC#V$8!ENXNL?/?W^R"2:RXU _W OLU MO_GXS>SL9,O%H]P@*MCE62&GUD:I\L)Q9+S!G$F;EUC0SHJ+G"F:BK4C2X$L M,4)YYGBN&SHY2PMK-C%KMV(VX97*T@)O!<@JSYEXOL2,;Z?6P-HOW*7KC=(+ MSFQ2LC4N4/U=W@J:.2U*DN98R)07(' UM>:#B\M0GS<'[E/#:;4JM>#K\1[]B_&=?%DRB5<\>T@3 MM9E:(PL27+$J4W=\^R M"8S<7PAXC8!G[*X5&2L_,\5F$\&W(/1I0M,#XZJ1)N/20I.R4()V4Y)3LX7B M\>.&9PD*^>'=R!M$G^#Z9Y6J9V!% E>\>$*ATF6&<$OQ0B$P 2,$9S\8+1(1K.B1NEE[52[Q=*0_C&"[61<%TDF!S*.^1 ZX6W]^+2ZP3\JRIL\-T^ M>*[G=^#Y;51\@^?__U'Y9[Z42E"R_7LL+K7:X7&UN@ O9,EBG%I481+%$UJS M#^\&H?NIPZEAZ]2P"WVVH().*C*9K^"!"<$*!7-=%.36,5L[T8[;.M\7M]:Q M;72P1@?0%0)J@R#3'>0F 7JH$P"(/FSIZT,JP4 6BO:6^MZXZ#4&2W@P=48; M/[AB63OMW51**B(G+=; I-;_&6/,ERC 'QAD#X;#83\:A_ >O+'M!7 .ONVY M1T0/##HBYMG1 #HH"5I*@I,IN4/*FS16;2;-*8")[*2H$_T$BL2+3FETLEKG MGK+>6\K@9,J^5R;ZAZZU],VI@NC6[WW7M23U"E-'*!OUW7!$D0_L<-C[0Z< MG0R\<3\:!)H0.QCU[FOYL\"/^M'(AX^T'/J'R(>,GI/H>1>!84M@>#*!-6LW MI>DV7:QU0I[ &B]?&IJNJXH8J6FZXGG)BN?FRI*]FM3F?)FQXD@-'B/T-WPN M-HPVWW#9E.37@LBFKAW#/$KLL>]Z[S,^#-B MXQ19ORM3??N>C8*(F'\/.C7&MAO]MJQIX/NZJOWP14/8NVF ][E#]SWN4,2I MU.T.O+ ?1#HCAP/;#QJIX&@N.:_:%:KNT.UJ^[Z9UVW]Y7C] M./K&Q)IB"AFN2-2U(ZI\43\XZHGBI6GR2Z[HR6"&&WJCH= ':'_%N=I/M(+V MU3?[#U!+ P04 " "W@ E71;F^N* " #G!0 &0 'AL+W=OC9,=+@32[R!3)]_1HB9PV2C^9 M'"2RFDF06%M=4D M#$U:8,G,J:I04F2M=,DL;74>FDHCRSRH%&$<1>=AR;@,DJGWW>MDJFHKN,1[ M#:8N2Z8W-+E3!^A:;-/8L# M2&MC5=F!24')9?ME+]U_V %<1F\ X@X0>]WM05[E#;,LF6K5@';9Q.8,7ZI' MDS@NW:4LK*8H)YQ-'O 998UPO&0K@>9D&EIB=;$P[1CF+4/\!L,YW"EI"P.? M98;9:WQ(:GI)\5;2/#Y(^*V6IS"*/D PKX> A^TM8%@AK):@UNZYP%TN=A?KD\A(X9C M+@FE:D,>P:-[:_!($=UH;ETY1S >T?*Q-P;7JBRY M<0/%P'!,$;<,OI-FW>Z/6D]["4=P,>SPG;'OKL.=YBM1YW[$&$A5+6W;A[VW MGV)7;?/^2V]'X!W3.2=I M<$C4XOS@+0[5AI-U95OI57RM)@\&9!DQBU2Z#X M6BF[W;@#^MF>_ 502P,$% @ MX )5TMY:._[ P C0D !D !X;"]W M;W)K&ULS5;;;N,V$'W75PS419$ VNAJV4EM [EL MMUEL-D$N[4/1!UH:6T0D4B6I..G7[Y"2O0G@I'DIT =))#5S>,[,\#)=2W6O M*T0#CTTM],ROC&F/PE 7%39,'\@6!?U92M4P0UVU"G6KD)7.J:G#)(KRL&%< M^/.I&[M2\ZGL3,T%7BG07=,P]72"M5S/_-C?#%SS567L0#B?MFR%-VCNVBM% MO7"+4O(&A>92@,+ES#^.CTXR:^\,?N>XUL_:8)4LI+RWG?-RYD>6$-98&(O MZ/. IUC7%HAH_#U@^MLIK>/S]@;]5Z>=M"R8QE-9_\%+4\W\B0\E+EE7FVNY M_@T'/2.+5\A:NS>L!]O(AZ+31C:#,S%HN.B_['&(PWLS=LD6->G\: M&L*W5F$Q8)WT6,DK6#E<2&$J#9]$B>5+_Y!X;>DQ-$KJ;1 )@&%UMAR'W- M3<6%\S:V1F%A]Q3GH;"0HN U61GI++1A!ATQXDA[F&)V%] 'WFVE$%]4*E"= MX;;.O#-)ZXPI3F$O.L4-)U9?<<6*)S@^O^>EA*N*T89 \15:UKRDB4IOB"Y\ M@'%,KX^NX5WV$U.EG5(P[UU2 M2B1MXO?8)T+_ MB%061?;Q[@2=$37_A\);#PY"&K290O[@O/:2."%R_<>[E88"(W?3(P7$X ,E MR;VSB?=MJ)%!<9;T,N-@DL1]4K -_SQ?YCN21"-&UL?511:]LP$/XK0BNCA1$Y]IILF6U(&L8V"(2&=@]C M#XI]MD5DR9/DN/WWDV3'I)#TQ=))]WWWG>[.<2?505< !KW47.@$5\8T"T)T M5D%-]40V(.Q-(55-C355272C@.8>5',2!L&,U)0)G,;^;*O26+:&,P%;A71; MUU2]KH#++L%3?#IX9&5EW %)XX:6L /SU&R5M4O6469])=7PPD"[1CI6 %RZ@P:)EELA6&B1)M)6<9 XUNUV HX_H.W2 F MT(9Q;M]5Q\18'8Z-9$/,51\SO!+S5RLF* H^H3 ((_2T6Z/;F[NW-,2F,>82 MCKF$GC>ZPGM)])_E7AME:__WDLZ>[_-E/C^SI1@IXM:54!SMZ12ORBR_9^(O32VO_RVL@,-RCG8^T)* "5?A)=&80P0 #07 9 >&PO=V]R:W-H965T'#YSWV QR_]N)"V6<> @CT-8E3OK1"(;(' MV^9^" GA YI!*N\<*$N(D*?L:/., 0GRH"2V7<>9V F)4LM;Y->VS%O0DXBC M%+8,\5.2$/;_(\3TLK2P]7+A.3J&0EVPO45&CK #\3';,GEF5RI!E$#*(YHB M!H>EM<(/&SQ7 7F+?R*X\*MCI(:RI_2S.GD?+"U']0AB\(62(/+G#&N(8Z4D M^_&E%+6JG"KP^OA%_5T^>#F8/>&PIO&_42#"I36S4 '"^#AC?"!B6 _==H=6 M_I=3Q*/\.;S9@"!1S-^B7]#'W0:]^?'MPA8RD6IN^Z7HNA!U;XA.T!--1EAVL>NF^]/+1-0K^Y8L!>Z[(W1#"OFPUQOV)GYIP^R*7HO(.'_:?KY6.B.]+JJ1#SPC/BPM&0- MX,#.8'D__8 GSJ\Z9GV*;7H2:_ <53Q')G5O37BHHV6,ZDJK$)OD8JJ8GKWA MR%%_"_M\#:*GI T0XPK$V CB;T923HJ"ZE,NN(Z*4:(KE4)L?$5EKH/24\X& ME$D%96*$\J>Q!H@L5,[ M+.=.TWTIW!/27M4V?:DUH5[95FQ\/XOWD(=1AJ)4@$PA.&)$:$M;J:6Z7'UR MSL!M?FYK?:O9JX]2UPI7;9JC<>O1N&8'0^5"*@#9_WPME-!3*K0#<5NEPW4T MI6-MSM?Y6?>DUJ13VV5L=(_>*@CR+T<6:O\:E)90KQ:Y5+OF+9MJ2G5?:9N$ M:@.,S0YX"\R7Y5DNU!$]R+6T+#8, I2T/Q(MLUZ-/:)F.S M3[ZU8#"'=08Q;B\9]"_//>PQKOTQ-AOD:IK/F/1 6BZ]^F3<-LJM]^,>'AG7 M)AF;7;):,A#.0>\%S<&=:;2MLGYAV5?:)I/:+F.S7WX&'Z(SV<=@FI]Z] "5?[H7U44P, (\) M 9 >&PO=V]R:W-H965T0474M"LCQS5[(C&KRSC8QFHM2PK@8C28D01.2P.(.+N NMMNO]]LN M/97=L-O.U,^-*F@,.>/O"\]J@:-JD$?>K2B*B48*!*;!6#, MCY1#KCL#5T&-+)2IRV,T#6;NL8-^V- />^G74 A,$87IJ5.RXD ERP]D*<43 MR*LUH!;9I:1"#5M*!F'H=6L)&RUAKY8_,/LDMH08, 8[#ITA",^(PT$W[:BA M'?72;B04E"7V$H25$)=2XA40:BNA2\7H3,5DVJUBW*@8]ZJX%YKRFA%[6E5[ M7=3C\\B/)\-N\DE#/NDMC59Y=U%._H?ZF#;2IKUQ6<2Q++$+P3,.+-6M;WH6 MDF!\(2E\[[6!>O^).!99QI295MV]S#LG#R]PMYJWW\O]"^L.RS&C.4[0S*0B M[[^A&J^M8G2A,_BO_=+O;7QU2K:837J667=:UEAO\G)TH2'XK\W1[^^.E80< M7FK1CJRWHZU3S'FC' R#?Q>)VQJOYE,%!\^!Y8IPV*.9=SU&9V0U_:N-%H6= MN#NA<7[;98I?3"#- 7R_%T*_;,P0;[[!HG\ 4$L#!!0 ( +> "5>21- / M,0, *4* 9 >&PO=V]R:W-H965T3'(!JXG-; >Z_?K924@AN*C:^D+\ M<F"RB(/.-+8'IFQD5!E.Z*N2N7 M DA6D8K<#3PO<@M"F1,/J[$[$0]YJ7+*X$X@618%$;^O(.?KD>,[FX%[.E\H M,^#&PR69PP34P_).Z)[;JF2T "8I9TC ;.1<^A?COL%7@&\4UG*KC8R3*>>/ MIG.3C1S/+ AR2)51(/JS@FO(04%9_25/31ZV M"%K'3@@:0M EA"\0<$/ KXT0-H3PM1%Z#:&R[M;>J\0E1)%X*/@:"8/6:J91 M9;]BZWQ19L[)1 D]2S5/Q3=L!5+IC5<2489NB7@$1:8YH FDI:"*@D3'B1ZC MN3Q!IVBB3VI6ZGD^>P%]BAXF"3H^.D%'1O+K@I>2L$P.7:47;,*Z:;.XJWIQ MP0N+P^B6,[60:,PRR"S\Y# _.L!W=:+:; 6;;%T%!P6_E.P,8>\#"KP 6]9S M_7IZ8+/S?]''_QQ])QFX/3JXTL,OZ&V?A.+Y),CGD_#CU^JA M7=WW%3T*<0$VE]%>7'\PZ+C1U;^QB=<;:/PKC7<693ZN.HX\W= M>G<+$/.JX)$HY253]3W:CK8UU6552G3&K_R+:]\RGN@:K"Z9GN7K DX_O7/* M),IAID-Y9WV]"Z(NBNJ.XLOJU9]RI6N(JKG0=20( ]#S,\[5IF,"M)5I_!=0 M2P,$% @ MX )5V$R82Z# @ [@8 !D !X;"]W;W)K&ULM55=3]LP%/TK5H8FD$:3)K2;6!L)VDUC&A*BP!X0#VYRVUCX M([-O6OCWLYTT*U,(+]M+XNO<Y8QB3#9W*I4&DR4[H(+$PY(O,(>_ S_KQP[B'(+2M;/L9[_IY M'O]\A)VO$FGB_YK^.]_V%IR06", ]= M0ZHUG'1K<#YT:DJ:P32P1F- ;R!(W[\;CJ//70WZ1V0OVG72MNNDCSU]^R_N M*K_F''M.YYJ;=&A'O]DOJC?EA=11*W74*_5&(>5=:D9OJ^E-J=6$>Y8B0*^] MTQJ2J4IB[2[M;FOF9][#PC_I]4UP2?6:24,XK"PT&GRTQ^O:7>L 5>D-:JG0 MVIU?%O9" NT2[/>54K@+W 'M%9?^!E!+ P04 " "W@ E7B4-"D3D# !Z M"0 &0 'AL+W=O,L>BCXPTK5%A")5DK*3?[]+TM'L0%7ZL(>]6")Y MS]$YE]>\G&V5?C 5HH7'6D@SCRIKF_,X-D6%-3/'JD%)*RNE:V9IJ->Q:32R MTH-J$6=),HEKQF64S_SIZXY>O*NHDX MGS5LC4NT?S4WFD9QQU+R&J7A2H+&U3QZGYXOIB[>!]QQW)J]=W!.[I5Z<(.K M@4E!S65XLL=='O8 V?@[ M@&P'R'X4,-H!1MYH4.9M73++\IE66] NFMCW1GZAKN)(;-)9VR!IX>XF6<6'>P1$LJ7+*5B"H%?S1,FFY92[W! A5Y+;C M%M=,EURNX1-N4, (/C*NX8Z)%N$:F6DU!NHKV;3T.(([7G#)[1-<*ZLT+)1N MX,LUUO>HO]+R&XC!5$RCF<66G#J]<;%S=1%<9=]Q-2%.:2L#'V2)90]^,8Q/ MLP&"F%+RN/893\ EF2C?H$#<,OL2!XZN'9@)Q1M^TCSS?Z MOVW[ET^D!*XLUN9KW[X&V>-^V>Y(.S<-*W >T9EE4&\PRG_^*9TDO_;E]#\B M.\CPN,OP>(@]_]SX!%F7XK=( MS@:)#JR>=%9/!IGOE*!J$/17[K,7L&DX@%Q3V>3)\>GD;!9O]L6_&G8@;=)) MFPQ*N^7FX6BE$8%+V@HJ=-#,8I_.29^ 9#P^?2'T];@#I:>=TM-!I1\>&^IL M6$+)-[Q$6?8>>X$C3?8__D+?8,B!M&DG;3HH;6E5\0"-Y@7Z4KY40E Q0X,Z MG-"]91TXIP=I.IN\$/M*4) ;[[6W&O7:=WT#A6JE#9VNF^TN%N]]/XW_#0^W MDFNFUUP:$+@B*!48E9T.G3X,K&I\L[Q7EEJO?ZWHD:': @ P0D !D !X;"]W;W)K&ULK59M;YLP$/XK%JNF5EK#6PA51Y#2L&F=UBGJR_9AV@<' M+@$5;&:;I/OWLPVA24-1,R4?@FWN>>[N.6-?L*;LD:< CT5.>%C(Q6BO#1- M'J=08#Z@)1#Y9D%9@86XHMISO4_6M>V MGF^@N.*"%@U81E!DI'[BIT:'+8 ]? 7@- #G) V />M'H8-8*B5J5/1 M.D18X#!@=(V8LI9L:J#%U&B9?D94V>\$DV\SB1/A-TJ6Y_? "G1-5L"%K*C@ MZ#0"@;.F$)Z5QQFW'B:UIZ<5SS9Z(82 MD7+TB220[.)-&74;NK,)_XAC&ACP1 M.+ 5&.'[=_;(^MBEUC')HB.1[2@Y;)4<]K&'LXK%J3P*$$^Q9.\2KB;P-($Z M&%>AXUGR%YBK;4EZ_1PJR;[/T=#U_=;E3JY>FZOWMEQQ02LBNG*M"49;?NW] M3/>-+EZ81+V!_&=)1VV:H]XT)TF2J6L"YZAL,DYZRMM+=NAW,=JKF]VQ5Z(C M^=R1QV_E\7OE>3XQNM3HQ1ZJAM^QF_:VRI$\UEJ86Y=; 6RIFP2.8K7?Z\NB M76W[D(F^?E^L3V5_4K<3SS1UJ&H9X(6NHK=$Z% MO)#U,)4]%C!E(-\O*!6;B7+0=FWA/U!+ P04 " "W@ E7U8 [13O-OQ\EJZ9IJ73E':%]22R; M?+QWOI.>GRD?/PKY4,PY5^ASEN;%R6"NU.+U<%A,YSQCQ2NQX+E^Y4[(C"E] M*.^'Q4)R-JLF9>D0!P$=9BS)!Y/CZKDK.3D62Y4F.;^2J%AF&9-/;W@J'D\& MX>#+$Q^2^[DJGQA.CA?LGE]S]7%Q)?71<(,R2S*>%XG(D>1W)X/3\/49/2HG M5"/^2/ACL?48E51NA7@H#RYF)X.@C(BG?*I*"*;_K?@93],220BN@ZLHK6.5-L MFKP7^?W+&RXS=)&O>*'T.Z0* M]/R<*Y:DQ0_H);K6E3-;IAR).]0^^B7Z>'V.GC_[ 3U#28YNYF)9L'Q6' ^5 MCK!<9SBMHWFSC@9_)9I?E_DK1((7" >8M$P_)9\7=;0M811.T1E$W\NEBP*3\9Z"XMN%SQP>3[[T(: M_-B6'B P*UEDDRSB0E\G2Y7T$T/_!3H3A4)O6)&TEL,:DE:0Y1EG-<'!N'SO M5MNTG L?2"O:T(H.H74C%$O;&*W1XFU&)!P=[3"*FKQ)&)#-*"O4>!-J[ S5 ME)VN0/2.RYRAMYRE:JZ/I^C3)<]NN6RM0B=PURH$ K-R0#R"KHPVK(]"./6H0BL8-0GL&68&.-X&.O[5? M]67S'7MBZ#>-X.I3)V#7T@,"L[B'@1$>0>^=6H< E"\H-#MA6THMA._6&G.[ M<,,XV*UN]\J',C,R*W0*D\X=ZX9K#Q>UOJ/_']&[5S0/H15:)15&/5_!G"JN\X) T*S$V;T7>@6>(>= >+F&6 \VI78 M[I4/96946^C4.=W/ +2I0D;C:)?4GE%VL$8UA6[99/?NZ?45NBATZR[XGMX% M$D4U-Q\2*S0:*SSJOW>=.J]SPH#0[(09K1>ZQ=YAO3MN]BYI7KU]"#ELA!QV MZI[.O>N&ZW#U!@"R*1LIAMU2;.<,P*68,@W_\5J_GW(A)*LL2M?)P+U 9]_' MAW[#6S;9_\ G@S7*?#AEV*@_[,$KJS&MDT$PBG=.!NZ5#V5F-!V&MA#=&$CNG#_7AD&-&'/?AEN&F86;5;,_,AY["1N%LDN_$Z5Z /942,,B+]NUT$U.V"0K,39M09 M\>!VD:;;%8]'N^7M0W<1H[L(K-E%FC96"R?W(#M4HWA(%ZOKIT4R1;^P;(_1 MY<;L7(4^E!$QRHCT;W014*,+"LU.F%%GQ(/119I&%VE^3>5>^="-($9T1;!& M5PVWA]2^47:P1O!$72RJ&_W!=L&>G&WK!NQ:A5!H-GTCBZ+^+:D(U)*"0K,3 M9L19Y,&2BEHL*=S8.^%>^5!F6QNX@'=PM6SA:FG;/:/L8(WHB;I84M=E6OYR M=RVH(P6%9K,WRBCJWY&*0!TI*#0[84:?11X-LH,UFB?JXDB5&[%O93)]<,MD-V;G0O2AC6*CC>+^#:D8U)"" M0K,39O19[,&0BEL,*=SH7/?*AS(STBN&=:3B%K.IA=2>47:P1O;$73RI\Z28 M"CES;Y4&-:6@T&SZ1AO%_9M2,:@I!85F)VQKB[T'4RINFE+1B.X6N _I%1OI M%<.:4G'3;VKAY!YDAVI$3]S%E+J92YUWX>Y94$<*"LVF;Y11W+\C%8,Z4E!H M=L*,.HL].%)QBR/5O"CY$%W4B"X*:TC1%JNIP6G/(#M4(W=HIQU32R6R]2:I MT_SI<@=:C#K;O\RY]8N&3R M/LD+E/([/2MX-=)YD^M?+5@?*+&H;OR_%4I?;JN'<\YF7)8#].MW0J@O!^5O M"6Q^.V+R+U!+ P04 " "W@ E7@_+.,)\$ >&@ &0 'AL+W=OWUPQY[GVC[P)Z.4/L,]Z(?T5IH[ MOT2)6 )<,<&1A*>Q=X'/IZ1O#;(6?S%8J;5K9*D\"O'9WLRBL1?8'D$,H;80 MU/PL80IQ;)%,/_XM0+W2IS5T,/1?!$%[&^ M$ZO?H2#4LWBAB%7V'ZWRMH.>A\*%TB(IC$T/$L;S7_JE",2: =YG0 H#LFW0 MWV/0*0PZ&=&\9QFM*ZKI9"3%"DG;VJ#9BRPVF;5AP[C]C/=:FK?,V.G)'T*# M0G<0 EO2QQC0NRO0E,7J/?H9/=Q?H7<_OA_YVGBR[?VP0+W,4U#ZZ$5S/ M%?J51Q#5V$_=]I@X 'Q#L>1)7GE>$B?BAP4_19W@!)& =.HZY#:_@M"8X\R< M.+K3*R? ZAX?]T[5IBV8:$O5/7>1SX&X]L!WUYRJE(8P],ZP5R"5XDY]^ MP/W@ESK6#8%MQ*!;QJ#K0I_<2L9#EM(8T40LN*XCFR/T,P0[(RTG>!C8OY&_ M7.?A]'0DCU[)H^?D<1&&<@$18ER#0:_ED2/TUGB07@T-IZ,C:?1+>GC5G1 M?<,C% G4L>COL,!U'\/IYT@6@Y+%P,TB22F3ILYH% NEZE@,=G)JFX#3Q9$$ MAB6!H9/ 5/ ER&=+X,\Y2)K"0K-0G: 9-U/0S+Q4.J/WZ0:21Y"U=9D#!H"VX@!#JH:';PA)S2S 4BE2)A20KX@;H*#4I"A M20EINO _4 M%'MR=H+V5GLWP+&$2468?'?I*R"^7?OA MF7 EFK!;-=U1LV3D)LTCLU:3S'S>Z^OI6\NT&_O@C]J&[L*5\,*#UI*[(<%5 MQ*$-^88K_8;= FY+1R-91J26^G GS?NU:=Z&"L.5#,-.A3-YX!)HS/XSRYQ] MLKI V%CCU#)I0TN12DL1MY:Z2$"R,!NR7"RIW41"=^)1Y#7K@,'K]G-HTC:% MMAF52H$1W-;@)0U)J2(.;0@S4@DSXA9F;U@$%PCK>=[M[J:YV]&Q1"I51MRJ M;&T=',ZID6>U8]8-_>I"H0-M9--67([>A0(O[:#GQB M5T/V8$*AT*K;?#.^?%H>?EQD6_Y^U3P_.;DQHY5QA6)X,J;!J3UJD/EA1'ZC M19KMYYN:I4627 "5=) M?>VTE 0 & 7 9 >&PO=V]R:W-H965T0XON(Y&PGY'>UIE2#'UG*U3Q8:[TY"T,5KVE&U*G84&[NK(3, MB#:G\CY4&TE)4@1E:8BB:!1FA/%@,2NNW2*#R+"/RYP5-Q6X> MP.#API+=K[6]$"YF&W)/;ZG^NKF1YBRL51*64:Z8X$#2U3PXAV<7>&0#BB>^ M,;I3C6-@FW(GQ'=[\B&9!Y&MB*8TUE:"F+\MO:1I:I5,'?]6HD&=TP8VCQ_4 MWQ6--XVY(XI>BO0OENCU/)@$(*$KDJ=Z*7;O:=6@H=6+1:J*7[ KGQWC ,2Y MTB*K@DT%&>/E/_E1=40C *&. %0%H*+N,E%1Y1719#&38@>D?=JHV8.BJ46T M*8YQ^U9NM31WF8G3B\]"4P66-*9L2^Y2"EY?44U8JMZ M^#6C($D-Q?%"CQY M\!5@''Q9BUP1GJA9J$TU5C.,J\P796;4D7D$K@77:P7^Y E-'L>'IA5U4]!# M4RZ05_!CSD\!CDX BA &7V^OP.M7;SRZN.XB7.@..G0O!=]2>4^Y!N6A9K;] MMD-,'UWF4MI;?U_3[([*?]HZPJMO?7>F-B2F\\ 82U&YI<'B]]_@*/K#4_V@ MKGY0J&/O"Y;U>SL!1(,581)L29K3MG('+U#NL"YWZ.WL:Z)SR?1/8$9S:W'^ M\(_$C $T/0'%(/#4,ZKK&7D%;[6I(P$?N*:FL1HL.\HJ56!4R%@4;A?1:329 MA=N6Y.,Z^=B;_$8R'K,-2<%Y)G*NVQ*7"J-&7AA%47O>29UWXLWK6EL/F[;4 MI*1ZY8N0J1L]S^I[XWE:'#O303_J^9J]D>KH=.E1#+UI[^;V2:)I@ MV.5WZ*@+_=SLZ7B_2ON0 ;Y7XS ,_1SV@Z$*[M&S3HP.(OK]BAW7DQ_I>T^^)/]_(4P"BRO5C7TT.^\B/_=ZN M'_^2ZQVZD7_VW+ M#=B9U!$6^PG[_UV-PC&NDL;Z_D;(8AO)N\Y_B1DU=LS&Z-CVQ]ZOP*$5-W96 MG@/Z*OC1QP7CCO4>=J#'?M#O?^?--5^O]_X2V,<.^_CHV,[M:M ;)%9[G_65^OMX_-RT]0]7NX]7Q-YS[@"*5V9 MT.AT;'I'EMNYY8D6FV(+U "5>V.VSHE@0 !P; 9 >&PO=V]R:W-H965TS#;3)@FYHAZQNNX=A#[1,QT0D MT24IN_O[D;(BF15-6Y'V$DORO8?G7$OWGE"3'>-/8DV(!-_3)!-3;RWEYL;W M1;PF*197;$,R]WTI0KUI3)QX>/Z/?%^*5F 46Y)8E?]&E7$^]L0>69(7S1'YBN_>D%#34 M>#%+1/$7[,K8P -Q+B1+RV3%(*79_A-_+PMQD '1Q)0F8#.30C+A+ 0NF=6 MR+K#$L\FG.T U]$*31\4M2FRE1J:Z9]Q+KGZEJH\.;O'E(.O.,D)8"MP3S.< MQ10GX*T01 J LR7X0/&")E12(L#K.R(Q3<0%N 1S=4LM\V2?6,,LF]&C6 85$$&JT'%:N!D]9E)=>.FMI_#1G0/-CQ!M!EUG.BP M(CIT$IVO&9>7DO!4/0E;(J1JB])&<=A8'(8_\'.&&.RBBEWD9/<'D^IQY20F M=%N4$4NPTH_W5C_>;U13XESQ!1LE0C5B&^^H02H*P^L?F#>#1H/1P,Y]5'$? M=>*>L>SR#/ZC9E$CW2L,_I8@&!RY,\85_[&3_Y^Y$K $&TYCI8,^3[GRIE;M M]P/9D@3 "_#W1Y(N"/_'1M^Y1ML^TQ.848[KJAS7/;76ZSXE]P1F2(9!/9"# M%S?7,O54T[*$'>]:\, JP#X;;(EVDFPSS$&VGLK0.0'/;[)N'/O/#:RVHSN0 MJ;4>Q] ]CWMHV>X5VE2A.Y!9A7K\0_?\[ZGYNU=I4XGN0&8E:G\!3Q@,^IC1 M%8VQ4LKDFG# %GJ!HBHTV^3U*$'N4>)>J&UC[0O-+$MM;TSB!3HO46G9/ M:*;LVA-!MRER#A1G:IN;O3N0*:^V3-#MF=I.I1<8&KOB[D"FXMH50:<#:3': M7N!D[%J[ YG_6]=N"+G=4 ^CS;U"BRKT &16H79>R.V\>AIM[E7:5*([D%F) M@\V6$[;N8+3EV=&Q%KK'FGN1UELQ_\=>#*K='PK[VH!Z@3=SR.X)S91=VSWD MMGNNL>9.;7.C]^SA4.WAD-O#M1QK;K0VBKL#F8IK>X;<&T]GCS74W#IJ[(NY M8TR&M9-"W;:7SFG!S6TCR]Z8)>KXYABJK1)R6Z6^QLBXL7MKV1^S134WR/R# M5Q?ZO9%J9H\T$R A*Y467(U4#?C^5Z!&ULK9=M;]LV$,>_RD$KA@1PH@<_)9EM($X6 M+$-2!''3OBCZ@I;.%E&)U$C*;O?I=Y1DV:UEN/>D)B.9FX0+?%*@\S1EZNL4$[D>.[ZS>?',E[&Q+]S)*&-+G*%YR9X4 MC=S:2\13%)I+ 0H78^?:OYKZ?6M0S'C/<:UWGL%N92[E9SNXC\:.9XDPP=!8 M%XQ^5GB#26(]$<<_E5.G7M,:[CYOO-\5FZ?-S)G&&YE\X)&)Q\Z% Q$N6)Z8 M9[G^"ZL-%8"A3'3Q%];57,^!,-=&II4Q$:1;,/Q58+:X+CPI[*S"CZRLG.3.X85_">)3F"7, =%TR$ MG"5PK34:#4Q$\,#9G"?<<-1PW5$KMAM:]IN:_@P+X&\"B%B37\*2*,OK5W2:-:J& CU#1H=?AW+LZAZW4@ M\()NB[]N+7RW\-<]*GP'WM+MNT7%5\R&:*D]G&QT_WH*C\ATKC"RXGXG;0=> MA)QK5"LVI[,HI+5S))UCPED1^A\?:'&X-YCJ3TU2EJ2]9E*;%ZYTQD(<.W3Q M[4KH3'[_S1]X?[3HT*MUZ+5YG\QBJ\9MZ+FO>BE9?2^*8R4/[*Z$*%/*/$1Y5+&\HY=,&:4"[V4,[ZAU N:Y3+ MH]+M*->!&TF1IY96JG);\L8T[>W#!'YP &:G;/FM,-=AJ'(BX8*N*MW28Q3^?L@/#S $6X;@ M5U_/HTFD6G(7=-#M7AY W18;OS6'__H0J];;Y3P<8MM:X+<7@Y\]U=X>1' H MLK;YWV\O *],9,=/MK]?JP9[N.Y.*Y?: [(-JX90YL*475W]MFZ*K\M6<#N] M[*@?F5IRH2'!!9EZYT,"4&636@Z,S(K&<"X-M9G%8TR-/2H[@;XO)$E1#>P" M];\*D_\ 4$L#!!0 ( +> "5?CB/K]+P, "\+ 9 >&PO=V]R:W-H M965TYCV8,(%K"9V9ALH_WZV$S(H:58F>$ALYY[C>XX_N-T5XT]B#B#1I:C$X(4$JD9L'HM80!IJHE4 M&K]+3JN:4@.WVQOVST:[TC+& @8L_4$F"7 /^M,P0E M(##.%%*,#T,L<;_+V0IQ':W8=,.8:=!*/J%ZV4>2JZ]$X63_*RC3!#H;@L0D M%2WT 3V.ANCL?:MK2\6OH^RDY!H47-XK7"&Z8U3.!?I$)S#9Q=LJKRHY;Y/< MM==(.(*\C3S_''F.Y]7ETPR_7= V\AT#]VO@PW_ L8*[;AU\1XU?6>T;/K_9 MZI]78R&YVN^_:E*Z+BB">@I]!UR('"?0L]0A%\"78/5/3]S0N:RSYYADPR.1 M[5@75-8%3>R%=2AAF;IP$E /B298PKDZX2+A)-=72)V;C:R'NMF2O;-4G6JI.HT^/.C4' 75E#LZPTIGV*CSAB;<+"77@G'& M%O5ZP[W).VZ\IW<_RO4[CK<;-6S,Z#_7-:KT1F\Z@J)692/VT(,6[6\11_]> MN'&D.7?XH<]YG1N-V$/=:$ZD4]P>==O^2%D4_MA;)48&?&9*-7UI MJ6U?5!O5:%4-7IDBR/X;7I22=YC/"!4HA:F".NU(G4]>E&=%1[+<%"QC)E7Y M8YIS5=$"UP'J^Y0QN>GH":H:N?\'4$L#!!0 ( +> "5?V1]T@> ( &$& M 9 >&PO=V]R:W-H965T2?.3*QG7E#[W'@AJX+;0?\-*G(&A>H M[ZIK:7I^YY+1$KFB@H/$?.:=#:?SB5WO%GRGN%4[;;"1+(6XMYTOV-N M-G*4%T23-)%B"]*N-FZVX4)U:@-'N3V4A99FEAJ=3B_1A*3@^ (UH4R=P 6 MYN"SFB&('-PTG"F%6@'A&5Q2LJ2,:FI$ _A6H22:\C4PM_#G%99+E+_@""B' MVT+4RHA4XFN#:C?T5RW6O,$*]V!]K?DI1,$["(,P@KO%!1P?G3RW\4VD7;AA M%V[H?*,]ODTDTSZ@1CCJ%]IO8ZHJLL*99RZ_0KE!+WW[9A@''P]@11U6=,@] M?9E':>_20.2#6N& ..8^Y,8T=J;VZ]NDT3@*$G_3@S+J4$8',[1SP+UI&OV' M-(T[MO'!-)W74B+7()[2]43;!]O8C9\GJ#\_<<<0'V2X%&;;@499_CM&_!HC M''_HYYAT').#'+="$]:WV>3UI8B'X8O-_)V*88OO%9%KRI6Y?KF1!:<3 RN; M@M9TM*A<$5D*;4J2:Q;F'X#2+C#SN1#ZL6/K4O=72?\"4$L#!!0 ( +> M"5<=Q6Y=90( ($% 9 >&PO=V]R:W-H965T%??H=.R'* M1EMI+XF/?2[_G^WC=*WTHRD1+3Q70III4%I;GX>AR4NLF!FI&B6M+)2NF"53 M+T-3:V2%#ZI$F$3125@Q+H,L]7-W.DM58P67>*?!-%7%],L5"K6>!G'P.G'/ MEZ5U$V&6UFR),[3?ZSM-5MAG*7B%TG E0>-B&ES&YU<3Y^\=?G!HQ N$*_' M"UM.@[, "ERP1MA[M?Z '<^QRY&*NJ+I@45%RV?_;<[<,@ M()YL"4BZ@,3K;@MYE3?,LBS5:@W:>5,V-_"H/IK$<>D.968UK7**L]DG)"0# M!S=H&1?F$(Y@1@=?- )!+6#FSXK_1OC:,&FY96X3X5:VU\'OZYS.&KZ5"->J MJIE\V=\[2^+3"P-?:M3D(Y?05DE#2XI=W3#OU%VUZI(MZCXV<@3CZ!TD43+^ M.SPDT)XVZ6D3GV^\)=\0S?1H3T,T_@;-$EK^#YKJT42[@3\OY\9JNF._-E&V MJB:;5;F^.STN?=I&[H"8]!"3_X,HN,E5(RV06MRJ M?I/DME <^4KNS5IET2A.P]507CCH*/&ULK95M;YLP$,>_ MBL6FJ9760J"!K2-(;=IJF]8M:M3MM0N7@&IL9IND^_8[&\+2A+ '[4WPP_W_ M^=T9SO%:R$>5 VCR5#*N)DZN=77NNBK-H:3J5%3 <6[QQO[&Y8RX/5,%4L&]%IO.)\\8A M&2QHS?2=6+^'-I^Q\4L%4_:7K-M8SR%IK;0H6S$2E 5OGO2IK<.6 'WZ!7XK M\/]4$+2"P";:D-FTKJBF22S%FD@3C6YF8&MCU9A-PQJ!#/V;MI"7#80_@&(@-P*KG-%KGD&68]^.JP/!_0N%J2KBK^I MRJ4_:/BQYJ>JHBE,'/S8%<@5.,FK%Z/0>]>7WG\R>Y;L69?LV9#[;K(D%4KW)=RXA-;% M]*I5,HK>QNYJ.X_]F& 4=#'/\,8=WOBO\*#Y-OH(&Z/Q(.%^S$'"L",,!PGG MN9#Z1(,L6T3[P0YPAOL,P0[F?DAX@#+J**-!RL]X0_T.+-H[/G_D[Y#MQP11 MN(/F;O7'$N327AL*WZR:ZZ95=JO=S71A&[+[*[RYUFZI7!;8[1@L4.J=1E@3 MV5P5S42+RG;;!Z&Q=]MACK M"5&PO=V]R:W-H965T):JW@$F\UF+:NF?XS0Z%6T^ X6"_<\;*R M;B%,DX:5.$?[T-QJFH4#2LYKE(8K"1J+:7!^?#8;N_/^P'>.*[,Q!J=DH=2C MFUSGTR!RA%!@9AT"H]\2+U (!T0T?O>8P9#2!6Z.U^A77CMI63"#%TK\X+FM MIL'[ '(L6"OLG5I]QEZ/)Y@I8?P75OW9*("L-5;5?3 QJ+GL_NRI]V$C((Y? M"8C[@-CS[A)YEI?,LC31:@7:G28T-_!2?321X])=RMQJVN449].O2)(,[%^B M95R8 SB$.5U\W@H$5<"\;1J!= F6";A@IH(KND:XEMUS<+[>H6 6<[A7T(/M M 9=P7ZG6,)F;)+3$TV4+LY[3K.,4O\)I C=*VLK )YEC_F]\2/H&D?%:Y"S> M"?BEE4)A?PO[>P0[R...7L'==,IL.I4YIPKG%-]P2O=. M606B<^KG^<)832_SUS:7NN0GVY.[:CTS#[T--O#6IB+AAJ6.P7;:'? $P_L>L(R/8V3<+F%S'@@,]Y)QK>* M0U4UJ;5@=.M5Y5Z#/Q[LV=\-TR:4A<@6%1D>G1$!WK:.; M6-7XVB2%M9$&'=HFT"H*FZ9I+]SDTE@X=K"=%K[][*0-W>I6J&\2 M/]W_?F?'=QDNN7B4!8!"SR5E2D1*8))PA ?G(^>1?7/J!,6A6_""PE!MM9$*9,9(J"0*B.!]6L!5T"I4=(<3RM1I_-I##?;:_7K)G@=S Q+N.+T)\E4 M,7(&#LH@QS55=WSY!58!A48OY50V3[1LU\:>@]):*EZNC#5!25C[QL^KC=@P M"((=!L'*H-D(MW744(ZQPLE0\"429K56,XTFU,9:PQ%F3F6JA)XEVDXE-Z!# MDNAX# H3*D_0*9KJD\]J"HCGZ+I6M0!T2Q@IZQ)-\(L^$271$2(,W1>\EIAE MQ]_:I)W=@;A%A M$ _=A06GW^'T]^+\ BQV(/1M"*U:N($0AYX=(>P0PD,10AM"N(40#09VA*A# MB Y%B&P(T=L1X@XA/A0AMB'$;T<8= B#0Q$&-H3!]K<0[_@6SCN$\[T(]P7H MJI,K$#:'YUL.?3^*[!Y][S4W>OM]Z8/MY!/YP7\4[D:-,O7^%HLY85*[R+69=Q;K,$1;0MN.XE53MF9=JW3&5L/N12?X"4$L#!!0 ( +> "5&PO=V]R:W-H965TZ%?)6I0":W/$L5S,KU;HXLVT5I\"I.A$%Y/AD)22G&H=R;:M" DTJ M$,]LSW%"FU.66]&TFKN1T524.F,YW$BB2LZI_/\",K&=6:YU/_&%K5-M)NQH M6M U+$#_6]Q('-DM2\(XY(J)G$A8S:QS]VSN^@9017QEL%4[]\2DLA3BU@RN MDIGE&$600:P-!<7+!N:0988)=?QH2*WVG0:X>W_/_KY*'I-94@5SD7UCB4YG MUJE%$EC1,M-?Q/8#- F-#%\L,E7]DFT3ZU@D+I46O &C L[R^DKO&B-V ,AS M'. U &\?$#P"\!M Y9Q=*ZO2NJ2:1E,IMD2::&0S-Y4W%1JS8;E9QH66^)0A M3D>?L%(^"J5( 9(L4BJ!O+X$35FFWI"W9(%EDY09$+$B<\&+4M/*?1Q>LJS4 MD-3HFQ;]EBAS55-;HSSS$CMNI%S44KQ'I(3D6N0Z5>1=GD#2Q=N85IN;=Y_; MA==+^'>9GQ#?^9-XCNO6'&SI_';-H(+*.84%K6-#''OTC-,V.95C#1A7,[%.;*!B/W#"< MVIM=[8=A8> '3M"&=52-6E6C7E5SD6] :K;$KP*37H&4N';XH<:WY/LU\"7( MH\O2R_K491F(K&- V!H0OH@Z#HLJ[N5^ZJ(,1-:Q8=+:,'D153P9 MTK"!R#J&N<[#4<%Y7ATWN,Z&' 3CR?Z&_.NXKK*=0XS;J^QS85;HF27=S_W4 M)1J*K>N$]^"$]R+*NI$QE&D#L75->SB8N;W'F)["]@^W7\?W#^KZ,,R=G([& M^SNUO7-.YR#75?NBL%++7-?'VG:V;9'.J\9@;_["M$[5^?^!INZ[KJE<,_P2 M,E@AI7,R1E&R;F7J@19%U0TLA<;>HKI-L?T#:0+P^4H(?3\P+V@;RN@G4$L# M!!0 ( +> "5=[Z\Q T08 ,@_ 9 >&PO=V]R:W-H965T$2%G.6+;KKBC,Z*H"CL&IHVZ$8TB#N3DV+9%9^<))D( M@YA=<9)F443YPSD+D[O3CMYY7/ I6"Q%OJ [.5G1!;MFXLOJBLNY[IHR"R(6 MIT$2$\[FIYTS_=@WS#R@6.-KP.[2K6F2[\I-DOS(9_S9:4?+MXB%;"IR!)7_ M;MD%"\.<)+?C9P7MK'/F@=O3CW2GV'FY,S5I9]0A,S:G62@^ M)7<>JW:HG_.F29@6?\E=N>YPT"'3+!5)5 7++8B"N/Q/[ZL#L16@]YX),*H MXVE _YD LPHP#\W0JP)ZAV;H5P']0S,,JH#!H1F&5<#PT RC*F!T:,"X"A@7 M.I3GKSCY%A5T6O@8P3DVN13'\LDW#& M>/KZU5L>;^^)==?Q M$=^5QW)]0(W' WIN*(&7E!\1;?".&)IA-AT/=?C?67Q$C.&SX=:><)J'ZT6X MT70T#\AN:L]F=PX/;\KN_EIV[]>R^P><.*,Q>TT$$N:#8#7W>VOW>RKZY'I))91,:3R5W1CI]9L@)N7"IGO$>4GK%[2\ M>W8[&?1ZO?'XI'N[+:@R:5M!D3 ;"7.0,!<)\Y P?_>D&WU-T];GO&9>?VU> M7VG>11)%L@^=%NTH9R+@3';-!4D+^9K<*WF#?>XIT[9U#PFSD3 '"7.1, \) M\T&PFJ*#M:(#I:(NI[&0;>+S2BKCV][5!SM^]S5S-!S4_;:0.6TDS$'"7"3, M0\)\$*RFY'"MY%"IY.=$T)#,:<#)+0TSUB2EDM!6RN%NVS_4M.W6O[02F=1& MPAPDS$7"/"3,!\%J5H[65HZ45GYBJ>#!5#P^%[TC7W,YWU4]2>*G:29_^Y<) MDLS)9WI/O@5BF3]R!?&BL6%5YFOK\&C'8=ULD!\WJHVAU5[?*%;K2U;.BY9T#\KI07/Z*%I=Q4WE25<.[LL'IWS< M\W&$*6\L!6K]Z,UJI!2T90F@.EN5":!Z7Y*%I=W4WA M2%=7CC[R8!'$-'S^]M[;?0X9-3R'7*@3M9836BZ"TAPHS872/"C-1]'JVV'T^W3ALJD:VOKE#RU!0FJWO5M)T<[A[ M93I-*VK]G?7<9N#NBMZ!0!^UOW5]-G4?75WXL5,11#0?SIQG(I-=Q/0E/D&+ M0U":!:794)H#I;D5;;N'-&SP$EH@0M'J]FY*1+JZ1O3QEO'W9V&8B**@_G%5 MF/K]DD4WC#>^G*0&ME852;.@-!M*70_Q]]14^' M%IV@- M*LZ$T!TISH30/2O-1M/I5L*E0Z7M*5"_IA4#K5%":!:794)H#I;D5 M;;L7,FKHA>RNM=,Q_AT%*&-3@#+4!:CJI;VR957U*-2E.:C:'63-^4I0__S/0H#6N&"TBPHS8;2'"C-A=(\*,U'T>I7P:849JA+ M8?O?<%4#6BML-(S_F&9_K#]Y%0N:UH;2'"C-A=(\*,U'T>IV;JICAKHZ]I+^ MKAK9VE=HW0Q*LU]"(XT^@T N"N2A0#[JB)<"=[>^WHT87Q2??J=2S2P6>9*M MI>O/R\^*CZJ?++_0CRV]8;FM'SM-RUW]V"L_*M^D+;]QOZ1\$<0I"=E<;H)V M-)0/#[S\;+R<$G_P/4$L# M!!0 ( +> "5=W<:=U>@, 'X- 9 >&PO=V]R:W-H965T"OD@UHA:G@L&%>38*7U^CP,5;;" M@J@SL49N[BR$+(@V0[D,U5HBR1VH8&$21?VP()0'Z=C-WP ;L57BENU=PU6RER(!SNXR2=!9"-"AIFV%,3\;7"*C%DF$\?/FC1H]K3 M_>L=^Y].O!$S)PJG@GVCN5Y-@F$ .2Y(R?2]V/Z%M:">Y_9/'VH@]0-)[!I#4@.100*<&=)S0*C(GZXIHDHZEV(*TJPV; MO7#>.+110[D]QIF6YBXU.)W.M,@>5H+E*-7;-\,D'GR"ZY\EU4] > Y3P3/?'^W&HC0H;2YC5$5]6$2?/1-R'6\'U2L$USS%OP4_]^#CQ M$(3&OL;#9.?A9>)E_+OD9]")/D 2)9VV@/SP*\P,/';PQ!-.ISG2CN/K/,,W M942I_8,0$EQZPO?/9BG<:"S4CS;C*]YN.Z\M*.=J33*>_E-JIIZC;K>;ZESI58I2>0 M@>?I'C1>#%[U_._1OL_M&E/.M31OSM*8]9DN6AWR[GVL0WXA'7A"(A4D4%05 MV=3FG#PICT?#QJ/AP1YA;=4AZ3]\*6,K7=[-3RQNHT;:Z'1IQ^?^Z(5TK01[ M0SI1>DSM=ADZ^] MEGRM3?)2'6M2N-?A%BB7KO%7D(F2ZZK9;6:;CXL+UU*'OY977R:W1)J2J8#A MPD"CLX%)=EDU^]5 B[7KE^="F^[;7:[,!Q)*N\#<7PBA=P.[0?/)E?X'4$L# M!!0 ( +> "5?R\S,S&@, $@* 9 >&PO=V]R:W-H965T5=$ MW!]BQM=CI^L\#%S01:K,@!N-EF2!EZB^+:="]]PZ2D)S9))R!@+G8V?2W3_L M6@=K<45Q+3?:8*C,.+\QG;-D['@&$688*Q."Z-\*CS#+3"2-X[8*ZM0YC>-F M^R'ZJ26OR7=-$I6,G="#!.2DR=<'7G[ B%)AX,<^D_<*ZLO4%XY:P0Y9>6?W%5";#CT_!<<_,K!M[C+1!;E,5$D&@F^!F&L=333L%2MMP9' MF5F52R7T+-5^*KI4/+Y)>9:@D-M;H=\=',#);4'5/1"6P!%G*Q2*SC*$J=8+ MA< $K!.\/T9%:"8_P"Y5B"]%\ V8=SSE0JX80EF#SU=S7AFK7_P/K0;PWXN6 =Z'D[X'M^#]Z! M"S(E F7U:\G0JW7MV0R]_T=7^/Y%@X SA;G\T21RB7BO&;$Y_OMR26(<._I\ M2Q0K=*+MK6[?.VC18Z_68Z\M>O2UR&@95L,:A*#MU#\ M&9%VN5MS_CN9L"83OG9%+#T]VK84X;.='?C#03=HWB[#&MSP+91^!-@N\?#9 MCO8[P0O'K^L]/D;>:Q6\TA-_$+!*LJG@;M ;#,+>"_@V'LON6XA88VS7L$KV M5,3^[R#=C<<]1[&P)8R$F!=,E>]\/5J729.R.'@T+VNL "5&PO=V]R:W-H965TU*!(@M=YLR4YM 7D;EJ%=@WAM/PS[0$MGFX@DNB1EQ\!^ M_$A)EKU8II.TP[[8I,2[>Y[C0YYNN&+\08LM7(W[I MAMJ@7/&5XDKLC$%3F3#VH">WR%([OM5.KB:D- M=\<;[[^4Y!69"1%XQ=)O-)'SD=6W(,$I*5)YSU:_8DVHI_W%+!7E+ZSJM8X% M<2$DRVICA2"C>?5/'NM$[!AT#QEXM8%7XJX"E2BOB231D+,5<+U:>=.#DFII MK<#17._*6'+UEBH[&8TEBQ_F+$V0BW=O^IX;?H";[P65:R!Y E>80&D$)]0>0!?")Y7(NX"9/,/FWO:U8-E2]#=5+S^CPMR+O@.^<@>=X/GP97\/) MVU-X"S:(.>$HZC]#)+])JE]&\O_GI,*?'U5DN)68B;_:,ES![+;#U ?^7"Q( MC"-+G6B!?(E6].Z-&S@?#$GH-DGHFKQ'GPLII*)+\QE,<$;SO!R1E.0QGL'O M139!7E*KLO]W:_XK'E6D7AE)WS/+R'?=@3^TERT >PW WH\ _%8>:+4Q%VJS MU 4%-X_(8RKTGM$8%=ZM=-HP5\'[NY@=KS,(VT$'#>C@V:"QQKY!?)M+3M5] M&<-7DA8EPC9@Q@#MH@"#'L(&>?A3TWV/NJCH->J\2*ZN[X*D\)%.L8V4.78( M:R1<@.M 5ETJ7A<2LC8=]G[#J__J'7F1R/O[(G=\/VC7RZ!!-W@UNA]5^&!? MX<%!@;O.MB(Y_[7$S1%>KG%WIYRZ/R_?+Y/XD<@;C8<;B0?'%.YZ6U:>T?=3 M'9_5E4C $H5FI,L:5NHANJR9=%['VA6Z%_3"_@'=;(NN:RQGT1$Y/P.S6>YU M^%V]=]V.WSN >ULG77.A_(-)M>M/E/TH?QM-77-Y?0%ZH83FE=J M/3W&LY6C&8K9W>I ,^:SLM 3$K,AEU8XT M3YMN[J+J8;;+JU;P$^'J\T! BE-EZG1"E2Y>=5?51+)%V=%,F%3]43F "5=(L'#L!0, *,+ 9 M>&PO=V]R:W-H965T?Z^&+?P9KQ!Y$" M2/289U0,K53*9=^VQ3R%'(M+M@2J9A:,YUBJ+D]LL>2 8P/*,]MUG,#.,:%6 M.#!C-SP<-6S M:Y:8Y$ %811Q6 RMJTX_ZNGU9L%W FNQU49Z)S/&'G3G2SRT'!T09#"7F@&K MSPK&D&6:2(7QN^*T:DD-W&YOV#^9O:N]S+" ,B,A#UXS*5*"(QA W MX"?M^* %;RMW:HO>\0Z[C>@WQC)\/=YNV=&]+D!M_D1KR3&[.GS0SZ>343DJLKX5=3-I1Z?K.>OB;[8HGG M,+34/2B K\ *W[[I!,['IJ-X3;+):Y)%KT2V$Z'?O\9+ MJP1WMP+O^'L>M?*_P*/C4M'I4CL>!;5'0:M'WV0*O,F=X+@[KX5'2Z MU(X[O=J=7JL[YJULJZ//P#4$L#!!0 ( +> M"5?>E.\(30( %P& 9 >&PO=V]R:W-H965T)A[<]-I8L^-@.TWW[;&=-"J0 M10*-E\9GW^_/Q9=K7'/Q(', A8Z,%C)Q?)+ >&IT>4<%"947J$+1 JT()3J]R9C3VD=D^UE+>>LX0R>X/Q4%2X*_5UH;SNIS0M/Y4ESB!Q M=$]+$ =PTI&2*$P19KPJ5)_#AN.-Y3#?T"'U MW5'L'7J$KSOAZT'A]\<,I!S0;."CX$PTF?#PLS= M!19[4DA$8:=1OAOI>Q'-+&L"Q4L[/S9_R!,@C[?<:Y.@1E)W1]* M^A-02P,$% @ MX )5VXG"Z!- @ I04 !D !X;"]W;W)K&ULK51M;],P$/XK5IC0)D&3)B5,)8W4%]"&-*EJ-_B ^. F MU\::8P?;:;9_CU_2K!M9!1)?&M_YGN>>N_HN:;BXEP6 0@\E97+B%4I58]^7 M60$EE@-> =,W6RY*K+0I=KZL!.#<@DKJAT$0^R4FS$L3ZUN*-.&UHH3!4B!9 MER46CS.@O)EX0^_@6)%=H8S#3Y,*[V -ZJY:"FWY'4M.2F"2<(8$;"?>=#B> MCTR\#?A&H)%'9V0JV7!^;XSK?.(%1A!0R)1AP/JSASE0:HBTC%\MI]>E-,#C M\X']BZU=U[+!$N:Y*B;>I8=RV.*:JA5OKJ"MYX/ARSB5]AA]'PX>6[C9,/OT,DC\_;'^/T/BX"G&R?*/7GP)8F<7@409KYERKZ?S=KMF M:D?LA7^F=Y!;&4\T;H'=8+$C3"(*6TT9##[J"19N*3A#\.9Q&FWZ>RVF633/NST03&RK0D@5Y*=3;^^$B;(@)#ME'U)#+[W^-PKH7,$ M3)X8?Q0K0B3XFJ6Y.!^LI%R_]SPQ7Y$,BW=L37+US8+Q#$MUR)>>6'."DR(I M2SWH^Y&789H/II/BW V?3MA&IC0G-QR(399A_GQ)4O9T/@@&+R=NZ7(E]0EO M.EGC);DC\GY]P]615Z$D-".YH"P'G"S.!Q?!^UGHZX0BXD]*GL3>9Z!+>6#L M41]<)^<#7S,B*9E+#8'5ORV9D3352(K'/R7HH/I-G;C_^07]EZ)X5LJ=?25G04./-62J*O^"IC/4'8+X1DF5ELF*0T7SW M'W\M&[&7H'#L";!,@,D>6:E DN"5KQB7-E^#M%9&8IN('< ;NU*Q)-BD!; %>(F\X M6U")'VA*Y3/XO,(27' "/C&A45)*$G"_5@-T^0SDBH 92[(BX -G0JB(+G5ZC M@ZKQ1@5>V(%WQ=0DPIRJX9QO.)54#<673R1[(/QO6[>=:'J->2_6>$[.!VH1 M$81OR6#Z_7=!Y/]D*[4GL%KA855X6*"CHR?Z=;Y;!?5J\N6C"@?7DF3"VH:P MSS;T!%9KP[!JP] Y_N7U9ZMQEQ@5B7KUWTY'P<3;[C-WAM3X1!6?R#DL?ZP) MQ\5PS-0"8KW@HSY[WQ-8K=915>O(V?L/)%?%IL72AQ-U'5(A=?%;ZW#LL(9[ MO8[&PU%C0-I!L3^,[$,25S1C)\UB15YPE@&V&QR66\?/X.+ZD28,W*RPDB>G.KOQ M3IW=?:'5JS<"'7Q+A0YZE>B^T.JM,"(=O%JEW9EV9L!:XBN #I=H=#_XW\(? M]*K\?:'5ZS7:'_0I_D%;V&&@-P#U=:@=%<9['J%.U>A_X#8 MZI\S.>K@FNB MIF+*UOK*M!)MZWMKM6R'H Z*1O\#I]0>[5%*F-I*K1HY;%*TA(5QY-MI0J/8 MT._+IT"G]I\ZV?M"J]=MW !TNX%=W8YBG>DG%_L*-."JTW@)Z/821S@RV/8* M0= TR98@..RX2*"Q$_" G= 7B9+.#/-'(O%#2H"H=OU6KJB]GOA^DVL["*$. M/P^-^$.GHD[OEY;T*AC1P>-VD*GNCE-;YE::T\0P^;>WQ86AG&''X=&&*%; M&&=JZ68I3;!48^\RNVZ-GM#J51N-A?$W-+O0*> GMZ(GM'HKC)9#MY8[ MS"YLZW+KGI0[IGZ3U @W.B#\F^Q'*>X0]16TM/1O[07.*V\(" M&(<=JHN,ZB+WEOL$?XIZW5_WA5:OVT@WK^ Z>S M.(J:]T%L80$,87/HO;WGY!GAR^+U 0'F;)/+W2/SZFSUBL)%\6#>,^&[]QL^ M8;ZDN0 I6:A4_]U(=87O7AG8'4BV+IZZ/S I659\7!&<$*X#U/<+IN90>:!_ MH'IQ8_H?4$L#!!0 ( +> "5>WVR720@, "@4 - >&PODEX3 M"MSM:SHD[?@C"9S+J_WXQ<6N"2A5[1[ MA.A5RURHLD4Q^?@X^4/BF'3O*.D#RIAP?U?8CCXW.HYWCM$2#\W8WS"A@Y![ M+2]YBVJ)85THHT%6R$V]1,0%C#+-6?!(Q9",J> 3Q8&5T9R+E0MW(# M1*$" M;0K5I&I#I'IR<-OUH(9KG9S+0MG<+H/[/:F'[P'K'ACD0C0&.\0%1H.2:LV4 MO#$=.]@>%!W;Y?E<;A3-%5N],E&X*]F2230J5,-6G:9!T:#03+P([BLSG< M=5&& &I=Y*:1UHRZ862G3(@[>,!_9CO:RVQKS^R.R:9I#-5-)^,Z MH+^MYK2W9:,7Z08E?RSTEX69CK1]*&QVJUC&E[:_S!H#F'H;5Z=E*5:?!9_) MG+G)'YUP-*!K7C O%'\RV:!4IB; % D>F=)\NAWYK6AYSY9Z74[+#/?<.4'/ M_W:=9TPR1<6V:5/[;WF57^PXZKV69?NMLF_8Z[%^:[]UD]U3,!F?@LF3J,G^ M*9A,3L!D[]6^-0^:#.M3QM919N<@TT0#.# .R0\X>HI-TF"RX$)S6??F/$V9 M?':>,?*:3LR?03OZ9GS*,KH0^KX!AV33_LY2OLB39M0M+$0]:M/^!M-KQ\UI MU>3B,F5+EH[KKII-;#,P#9.UOH"PC]S8RX]@'(?Y$<"P/)@#C.-86)[_:3Y] M=#X.P[SUO4@?Y?11CF/YD+']8'G\G,1<_IDF213%,;:BX['7P1A;MSB&'[\: MY@T86![(]'=KC>\V7B&'ZP#;TT,5@LT4KT1LIOA: ^)?-V DB7^WL3S P'8! MJQW([\\#->7G1!'L*N8->X)Q)$DP!&K17Z-QC*Q.#!___F!/210EB1\!S.\@ MBC $GD8W'L?A>OW5+CYW^#H#U!+ P04 " "W@ E7EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M +> "5&PO=V]R:V)O;VLN>&ULQ9K?3^,X$(#_ M%:M/=]+NM?G5W47;E?9@N4/B6-0@7I%)IJU%8O=L!P[^^ILD5#B0CO9EZ%,; M)W6_3&Q_8SM?'XR]NS7F3OQ75]HM)AOOMT?3J2LV4$OWA]F"QC,K8VOI\="N MIVYK099N ^#K:AK/9O-I+96>?/NZJ^O23L,#XZ'PRF@L; NN%3RXE_/MH;A7 M3MVJ2OG'Q:3[7L%$U$JK6CU!N9C,)L)MS,/?QJHGH[VL\L*:JEI,HO[$-5BO MBC?%>0MY)6]=5^+E[5(BR&(RGV&%*V6=[Z[HZI?(> ]X<7_4>'.J*@_V1'KX MRYIFJ_2ZK0;O8AK<1A>'W6ZKPFO;.\6_/BO[N_:(&\30'BD\8<_*#IP/\MCH M$K2#4N W9RI5(D1S C([)"020 Y)R#GAX1, \A/!.0G7LB?=BVU>NI."(G#T FXPJIM=VQ6 M >1G O(S+^2Y^K=193LZMH3'R3?&^H]78&L1$(=TE%\B9L&<&[TFX2BO1,QB MNVZ<$UNP(M](.WB*55F/*"#&S$7)8 M=Q/,)6Q17/A$0S#*!C&S#79ID5Z+2TR-VV;V0=P^]@>/@UDE)8>86P[#;$G\ M=M6JR_T>\E%6B)FM0*9-@]E:3.DB9M;%>-HT&DW*'3'W/&,L?QJEI-01,ZOC M=2(U!IA0,DFXIQA41C529D]LR?9&>E"*>6:]!!K6CO,833)79-W7MT:#R1EG939.OL)N\$H MQ*34DS*KATX>!V,1I9Z46STD9KBYDU("2KEG-,\Y[EACI(R3,AOG-5?O0RB; MJHMGN,M(&2=C-@Z).=P,I8R3O=-,9APS[#,999R,VS@D9MAG,LHX&;=Q2,PL MQ*2,DW$;9V2>&""'F.1./?=DAYPK#MHFI9V,>\9#8@[:)J6=C'LAC<0]%P]Y+DM_\!4$L#!!0 ( +> "5&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R M1_0"^D0*=(8/!4Q)'CY%\0'8OCTJQS: M<=^=ZF[?U\7'\7"JJV8WCOV/E.IZ5XYMO>OZ00I#.'V009/,'.03Y_$$!03%_ M4(:@/'_0/03=SQ_T $$/\P<]0M#C_$&R1!F7!$D3K FT%N1:"+P6!%L(Q!8D M6PC,%D1;"-069%L(W!:$6PCD%J1;".P6Q%L(]%;46PGT5M1;"?36R<BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WH9Z&X'>AGH;@=Z& M>AN!WC;9+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#; M46\GT-M1;R?0VU%O)]#;)YO=!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z M!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9R6!WH%Z!X'>@7H'@=Z!>@>! MWH%Z!X'>&?7.!'IGU#L3Z)U1[TR@=T:]\W?J7[L!)AHE&DQ\;UB@[7G/>I+GBNNGK:,PVK1-%Z;9(D9WQ5@H M%]2:D%M'75J96]^:F+[Z%^9,N30OQ,1D4K#2=I&Z.(Y]C6QV?4MSLVKBZ&Z3 M?@ZU[::9IR9DHYO=QCYKFAGGFKHT,:VS=5=]2AGO$_)T^#]B?>UB3]W5%HT?CX[UITRZV:5B(VX9"?KS$%SW:^;PNJ;+EJDU'\N \ MF2HLB&+;Y+NB9\>38[IAVGWRD_.',L<"T\Y';UU($_/T^[C#2/K38Y<*D8_U M\5=\3TRE3WX_ZJ==4?7#['2]K]8OAWD$-CQ.O^./,WZO_\L^!$@?$J0/!=*' M!NFC .GC'*2/"Y ^+D'ZX!.41E!$Y2BD "5<8 M]G3)[P "L" 1 " :\ !D;V-0 "5>97)PC$ 8 )PG 3 " &UL4$L! A0#% @ MX )5UX>+];L!0 MTQ\ !@ ("!#@@ 'AL+W=O "5<+OYO890< #4D 8 " @3 . M !X;"]W;W)K#P & @('+%0 >&PO=V]R:W-H965T&UL4$L! A0#% @ MX )5_@4:&9&!@ >QX !@ M ("!JAD 'AL+W=O M"5>1.](+QP( , ( 8 " @28@ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ MX )5S04*JAX"0 -R\ !@ ("!A3 'AL+W=O&PO=V]R:W-H965T "5<- M*N??.0, "X' 9 " @7=6 !X;"]W;W)K&UL4$L! A0#% @ MX )5V9O%H,[ P /0< !D M ("!YUD 'AL+W=O&PO=V]R:W-H M965T "5<.3J:4BP4 ,0. 9 M " @4IB !X;"]W;W)K&UL4$L! M A0#% @ MX )5WE:J[_V!@ B!0 !D ("!#&@ 'AL M+W=O&PO=V]R:W-H965T "5=\OI>:@P, 8( 9 " M@7)U !X;"]W;W)K&UL4$L! A0#% @ MX ) M5V/=UIBU!@ $!$ !D ("!+'D 'AL+W=O&PO=V]R:W-H965T "5?;R [DTP( %8& 9 " @=V" !X;"]W;W)K M&UL4$L! A0#% @ MX )5T:PT\QU P M < M !D ("!YX4 'AL+W=O&PO=V]R:W-H965T "5>G6^,] M7 4 .T, 9 " @>R, !X;"]W;W)K&UL4$L! A0#% @ MX )5]8/J><8"@ UQP !D M ("!?Y( 'AL+W=OB[Q<# "X!@ &0 @('.G >&PO=V]R:W-H965T M "5?Q4M;S/@, <' 9 M " @1R@ !X;"]W;W)K&UL4$L! A0# M% @ MX )5_W(EVP^ P I@< !D ("!D:, 'AL+W=O M'9&D# 2 M" &0 @($&IP >&PO=V]R:W-H965T "5>6NHL#'0, "P' 9 " @::J M !X;"]W;W)K&UL4$L! A0#% @ MX )5WGU MU[PX! ,0T !D ("!^JT 'AL+W=O0$ "-#0 &0 M @(%IL@ >&PO=V]R:W-H965T "5?D^F[>W0( $H& 9 " @82W !X;"]W;W)K&UL4$L! A0#% @ MX )5VS?#FW! P 0H !D M ("!F+H 'AL+W=O&PO M=V]R:W-H965T "5=+>6CO^P, M (T) 9 " @6?! !X;"]W;W)K&UL4$L! A0#% @ MX )5XO&6T$- @ +@0 !D ("! MF<4 'AL+W=O&PO=V]R:W-H965T "5?[H7U44P, (\) 9 M " @5?, !X;"]W;W)K&UL4$L! A0#% M @ MX )5Y)$T \Q P I0H !D ("!X<\ 'AL+W=O&UL4$L! A0#% @ MX )5U0>D:': M @ P0D !D ("!<]D 'AL+W=O&PO=V]R:W-H965T M"5>#\LXPGP0 !X: 9 " @=?C !X;"]W;W)K&UL4$L! A0#% @ MX )5TE][;24! 8!< !D M ("!K>@ 'AL+W=O&PO=V]R M:W-H965T "5?YA>H?SP, #8, M 9 " @47R !X;"]W;W)K&UL M4$L! A0#% @ MX )5^.(^OTO P +PL !D ("!2_8 M 'AL+W=O&PO=V]R:W-H965T "5<=Q6Y=90( ($% 9 M " @6#\ !X;"]W;W)K&UL4$L! A0#% @ MMX )5T6XR^:@ @ NP< !D ("!_/X 'AL+W=O&PO=V]R:W-H965T "5<^;#<.[ ( -0( 9 " @9X$ 0!X;"]W M;W)K&UL4$L! A0#% @ MX )5R6:P0)B P M7 X !D ("!P0^O,0-$& #(/P &0 @(%: M"P$ >&PO=V]R:W-H965T "5=W M<:=U>@, 'X- 9 " @6(2 0!X;"]W;W)K&UL4$L! A0#% @ MX )5_+S,S,: P 2 H !D M ("!$Q8! 'AL+W=O8>^P# #O#@ &0 @(%D&0$ >&PO=V]R:W-H M965T "5=(L'#L!0, *,+ 9 M " @8<= 0!X;"]W;W)K&UL4$L! M A0#% @ MX )5]Z4[PA- @ 7 8 !D ("!PR ! 'AL M+W=O&PO=V]R:W-H965T "5>.HAV$$P8 ,0A 9 " M@&UL4$L! A0#% @ MX ) M5[?;)=)" P *!0 T ( !%2P! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ MX )5R=E MU:4, @ A"4 !H ( !=34! 'AL+U]R96QS+W=O XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 175 336 1 false 53 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.aikidopharma.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity Sheet http://www.aikidopharma.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments Organization and Description of Business and Recent Developments Notes 8 false false R9.htm 008 - Disclosure - Liquidity and Capital Resources Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResources Liquidity and Capital Resources Notes 9 false false R10.htm 009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - FPS Acquisition Sheet http://www.aikidopharma.com/role/FPSAcquisition FPS Acquisition Notes 11 false false R12.htm 011 - Disclosure - Investments in Marketable Securities Sheet http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities Investments in Marketable Securities Notes 12 false false R13.htm 012 - Disclosure - Short-Term Investments Sheet http://www.aikidopharma.com/role/ShortTermInvestments Short-Term Investments Notes 13 false false R14.htm 013 - Disclosure - Long-Term Investments Sheet http://www.aikidopharma.com/role/LongTermInvestments Long-Term Investments Notes 14 false false R15.htm 014 - Disclosure - Notes Receivable Notes http://www.aikidopharma.com/role/NotesReceivable Notes Receivable Notes 15 false false R16.htm 015 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 16 false false R17.htm 016 - Disclosure - Leases Sheet http://www.aikidopharma.com/role/Leases Leases Notes 17 false false R18.htm 017 - Disclosure - Net Loss per Share Sheet http://www.aikidopharma.com/role/NetLossperShare Net Loss per Share Notes 18 false false R19.htm 018 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock Stockholders??? Equity and Convertible Preferred Stock Notes 19 false false R20.htm 019 - Disclosure - Revenue Sheet http://www.aikidopharma.com/role/Revenue Revenue Notes 20 false false R21.htm 020 - Disclosure - Commitments and Contingencies Sheet http://www.aikidopharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 021 - Disclosure - Regulatory Sheet http://www.aikidopharma.com/role/Regulatory Regulatory Notes 22 false false R23.htm 022 - Disclosure - Related Party Transaction Sheet http://www.aikidopharma.com/role/RelatedPartyTransaction Related Party Transaction Notes 23 false false R24.htm 023 - Disclosure - Segment Reporting Sheet http://www.aikidopharma.com/role/SegmentReporting Segment Reporting Notes 24 false false R25.htm 024 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.aikidopharma.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 025 - Disclosure - FPS Acquisition (Tables) Sheet http://www.aikidopharma.com/role/FPSAcquisitionTables FPS Acquisition (Tables) Tables http://www.aikidopharma.com/role/FPSAcquisition 26 false false R27.htm 026 - Disclosure - Investments in Marketable Securities (Tables) Sheet http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables Investments in Marketable Securities (Tables) Tables http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities 27 false false R28.htm 027 - Disclosure - Short-Term Investments (Tables) Sheet http://www.aikidopharma.com/role/ShortTermInvestmentsTables Short-Term Investments (Tables) Tables http://www.aikidopharma.com/role/ShortTermInvestments 28 false false R29.htm 028 - Disclosure - Long-Term Investments (Tables) Sheet http://www.aikidopharma.com/role/LongTermInvestmentsTables Long-Term Investments (Tables) Tables http://www.aikidopharma.com/role/LongTermInvestments 29 false false R30.htm 029 - Disclosure - Notes Receivable (Tables) Notes http://www.aikidopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables http://www.aikidopharma.com/role/NotesReceivable 30 false false R31.htm 030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities 31 false false R32.htm 031 - Disclosure - Leases (Tables) Sheet http://www.aikidopharma.com/role/LeasesTables Leases (Tables) Tables http://www.aikidopharma.com/role/Leases 32 false false R33.htm 032 - Disclosure - Net Loss per Share (Tables) Sheet http://www.aikidopharma.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://www.aikidopharma.com/role/NetLossperShare 33 false false R34.htm 033 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Tables) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables Stockholders??? Equity and Convertible Preferred Stock (Tables) Tables http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock 34 false false R35.htm 034 - Disclosure - Revenue (Tables) Sheet http://www.aikidopharma.com/role/RevenueTables Revenue (Tables) Tables http://www.aikidopharma.com/role/Revenue 35 false false R36.htm 035 - Disclosure - Segment Reporting (Tables) Sheet http://www.aikidopharma.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.aikidopharma.com/role/SegmentReporting 36 false false R37.htm 036 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 37 false false R38.htm 037 - Disclosure - FPS Acquisition (Details) Sheet http://www.aikidopharma.com/role/FPSAcquisitionDetails FPS Acquisition (Details) Details http://www.aikidopharma.com/role/FPSAcquisitionTables 38 false false R39.htm 038 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities Details http://www.aikidopharma.com/role/FPSAcquisitionTables 39 false false R40.htm 039 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities Sheet http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable Investments in Marketable Securities (Details) - Schedule of Marketable Securities Details http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables 40 false false R41.htm 040 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments Sheet http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable Short-Term Investments (Details) - Schedule of Short-Term Investments Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 41 false false R42.htm 041 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs Sheet http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 42 false false R43.htm 042 - Disclosure - Long-Term Investments (Details) Sheet http://www.aikidopharma.com/role/LongTermInvestmentsDetails Long-Term Investments (Details) Details http://www.aikidopharma.com/role/LongTermInvestmentsTables 43 false false R44.htm 043 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments Sheet http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable Long-Term Investments (Details) - Schedule of Long-Term Investments Details http://www.aikidopharma.com/role/LongTermInvestmentsTables 44 false false R45.htm 044 - Disclosure - Notes Receivable (Details) Notes http://www.aikidopharma.com/role/NotesReceivableDetails Notes Receivable (Details) Details http://www.aikidopharma.com/role/NotesReceivableTables 45 false false R46.htm 045 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable Notes http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable Notes Receivable (Details) - Schedule of Notes Receivable Details http://www.aikidopharma.com/role/NotesReceivableTables 46 false false R47.htm 046 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities Details http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables 47 false false R48.htm 047 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis Sheet http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis Details http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables 48 false false R49.htm 048 - Disclosure - Leases (Details) Sheet http://www.aikidopharma.com/role/LeasesDetails Leases (Details) Details http://www.aikidopharma.com/role/LeasesTables 49 false false R50.htm 049 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable Leases (Details) - Schedule of Lease Assets and Liabilities Details http://www.aikidopharma.com/role/LeasesTables 50 false false R51.htm 050 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about The Company???s Operating Leases Sheet http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable Leases (Details) - Schedule of Summarize Quantitative Information about The Company???s Operating Leases Details http://www.aikidopharma.com/role/LeasesTables 51 false false R52.htm 051 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations Sheet http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable Leases (Details) - Schedule of Lease Expense to Current Period Operations Details http://www.aikidopharma.com/role/LeasesTables 52 false false R53.htm 052 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases Sheet http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases Details http://www.aikidopharma.com/role/LeasesTables 53 false false R54.htm 053 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Sheet http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable Leases (Details) - Schedule of Future Minimum Payments Details http://www.aikidopharma.com/role/LeasesTables 54 false false R55.htm 054 - Disclosure - Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share Sheet http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share Details http://www.aikidopharma.com/role/NetLossperShareTables 55 false false R56.htm 055 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails Stockholders??? Equity and Convertible Preferred Stock (Details) Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 56 false false R57.htm 056 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Sheet http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 57 false false R58.htm 057 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Sheet http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 58 false false R59.htm 058 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity Sheet http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 59 false false R60.htm 059 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue Sheet http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue Details http://www.aikidopharma.com/role/RevenueTables 60 false false R61.htm 060 - Disclosure - Regulatory (Details) Sheet http://www.aikidopharma.com/role/RegulatoryDetails Regulatory (Details) Details http://www.aikidopharma.com/role/Regulatory 61 false false R62.htm 061 - Disclosure - Related Party Transaction (Details) Sheet http://www.aikidopharma.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://www.aikidopharma.com/role/RelatedPartyTransaction 62 false false R63.htm 062 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss Sheet http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss Details http://www.aikidopharma.com/role/SegmentReportingTables 63 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0623_dominarihold.htm 4775, 4776, 4777, 4778, 4779, 4780, 4781, 4782 f10q0623_dominarihold.htm domh-20230630.xsd domh-20230630_cal.xml domh-20230630_def.xml domh-20230630_lab.xml domh-20230630_pre.xml f10q0623ex31-1_dominari.htm f10q0623ex31-2_dominari.htm f10q0623ex32-1_dominari.htm f10q0623ex32-2_dominari.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0623_dominarihold.htm": { "axisCustom": 1, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 799, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 175, "dts": { "calculationLink": { "local": [ "domh-20230630_cal.xml" ] }, "definitionLink": { "local": [ "domh-20230630_def.xml" ] }, "inline": { "local": [ "f10q0623_dominarihold.htm" ] }, "labelLink": { "local": [ "domh-20230630_lab.xml" ] }, "presentationLink": { "local": [ "domh-20230630_pre.xml" ] }, "schema": { "local": [ "domh-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 525, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 215, "http://www.aikidopharma.com/20230630": 52, "http://xbrl.sec.gov/dei/2023": 4, "total": 271 }, "keyCustom": 54, "keyStandard": 282, "memberCustom": 35, "memberStandard": 16, "nsprefix": "domh", "nsuri": "http://www.aikidopharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.aikidopharma.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - FPS Acquisition", "menuCat": "Notes", "order": "11", "role": "http://www.aikidopharma.com/role/FPSAcquisition", "shortName": "FPS Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Investments in Marketable Securities", "menuCat": "Notes", "order": "12", "role": "http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities", "shortName": "Investments in Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Short-Term Investments", "menuCat": "Notes", "order": "13", "role": "http://www.aikidopharma.com/role/ShortTermInvestments", "shortName": "Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Long-Term Investments", "menuCat": "Notes", "order": "14", "role": "http://www.aikidopharma.com/role/LongTermInvestments", "shortName": "Long-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Notes Receivable", "menuCat": "Notes", "order": "15", "role": "http://www.aikidopharma.com/role/NotesReceivable", "shortName": "Notes Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Fair Value of Financial Assets and Liabilities", "menuCat": "Notes", "order": "16", "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Leases", "menuCat": "Notes", "order": "17", "role": "http://www.aikidopharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Net Loss per Share", "menuCat": "Notes", "order": "18", "role": "http://www.aikidopharma.com/role/NetLossperShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock", "menuCat": "Notes", "order": "19", "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Revenue", "menuCat": "Notes", "order": "20", "role": "http://www.aikidopharma.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "21", "role": "http://www.aikidopharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Regulatory", "menuCat": "Notes", "order": "22", "role": "http://www.aikidopharma.com/role/Regulatory", "shortName": "Regulatory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Related Party Transaction", "menuCat": "Notes", "order": "23", "role": "http://www.aikidopharma.com/role/RelatedPartyTransaction", "shortName": "Related Party Transaction", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "24", "role": "http://www.aikidopharma.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "25", "role": "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - FPS Acquisition (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.aikidopharma.com/role/FPSAcquisitionTables", "shortName": "FPS Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Investments in Marketable Securities (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables", "shortName": "Investments in Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "domh:ScheduleOfShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Short-Term Investments (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.aikidopharma.com/role/ShortTermInvestmentsTables", "shortName": "Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "domh:ScheduleOfShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Long-Term Investments (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.aikidopharma.com/role/LongTermInvestmentsTables", "shortName": "Long-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Notes Receivable (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.aikidopharma.com/role/NotesReceivableTables", "shortName": "Notes Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.aikidopharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Net Loss per Share (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.aikidopharma.com/role/NetLossperShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.aikidopharma.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.aikidopharma.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "37", "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - FPS Acquisition (Details)", "menuCat": "Details", "order": "38", "role": "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "shortName": "FPS Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities", "menuCat": "Details", "order": "39", "role": "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable", "shortName": "FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "domh:RealizedlossGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities", "menuCat": "Details", "order": "40", "role": "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable", "shortName": "Investments in Marketable Securities (Details) - Schedule of Marketable Securities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "domh:RealizedlossGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c81", "decimals": "-3", "first": true, "lang": null, "name": "domh:InvestmentInVicinityMotorCorp", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments", "menuCat": "Details", "order": "41", "role": "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable", "shortName": "Short-Term Investments (Details) - Schedule of Short-Term Investments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c81", "decimals": "-3", "first": true, "lang": null, "name": "domh:InvestmentInVicinityMotorCorp", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c85", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs", "menuCat": "Details", "order": "42", "role": "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable", "shortName": "Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c85", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c87", "decimals": "0", "first": true, "lang": null, "name": "domh:PurchaseShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Long-Term Investments (Details)", "menuCat": "Details", "order": "43", "role": "http://www.aikidopharma.com/role/LongTermInvestmentsDetails", "shortName": "Long-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c87", "decimals": "0", "first": true, "lang": null, "name": "domh:PurchaseShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherLongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments", "menuCat": "Details", "order": "44", "role": "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "shortName": "Long-Term Investments (Details) - Schedule of Long-Term Investments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherLongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Notes Receivable (Details)", "menuCat": "Details", "order": "45", "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "shortName": "Notes Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "domh:DebtInstrumentMaturityDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable", "menuCat": "Details", "order": "46", "role": "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "shortName": "Notes Receivable (Details) - Schedule of Notes Receivable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "domh:DebtInstrumentMaturityDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities", "menuCat": "Details", "order": "47", "role": "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c143", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis", "menuCat": "Details", "order": "48", "role": "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c143", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "49", "role": "http://www.aikidopharma.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c148", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities", "menuCat": "Details", "order": "50", "role": "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable", "shortName": "Leases (Details) - Schedule of Lease Assets and Liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c148", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about The Company\u2019s Operating Leases", "menuCat": "Details", "order": "51", "role": "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable", "shortName": "Leases (Details) - Schedule of Summarize Quantitative Information about The Company\u2019s Operating Leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations", "menuCat": "Details", "order": "52", "role": "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "shortName": "Leases (Details) - Schedule of Lease Expense to Current Period Operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherOperatingActivitiesCashFlowStatement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases", "menuCat": "Details", "order": "53", "role": "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "shortName": "Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherOperatingActivitiesCashFlowStatement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments", "menuCat": "Details", "order": "54", "role": "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "shortName": "Leases (Details) - Schedule of Future Minimum Payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share", "menuCat": "Details", "order": "55", "role": "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "shortName": "Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c155", "decimals": "0", "first": true, "lang": null, "name": "domh:SharesCancelled", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "56", "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c155", "decimals": "0", "first": true, "lang": null, "name": "domh:SharesCancelled", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c163", "decimals": "INF", "first": true, "lang": null, "name": "domh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOfWarrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity", "menuCat": "Details", "order": "57", "role": "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c163", "decimals": "INF", "first": true, "lang": null, "name": "domh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOfWarrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "menuCat": "Details", "order": "58", "role": "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity", "menuCat": "Details", "order": "59", "role": "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c64", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity", "menuCat": "Statements", "order": "6", "role": "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c64", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnderwritingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue", "menuCat": "Details", "order": "60", "role": "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable", "shortName": "Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnderwritingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsNetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Regulatory (Details)", "menuCat": "Details", "order": "61", "role": "http://www.aikidopharma.com/role/RegulatoryDetails", "shortName": "Regulatory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsNetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Related Party Transaction (Details)", "menuCat": "Details", "order": "62", "role": "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "shortName": "Related Party Transaction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c169", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueRevenueRecognized1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss", "menuCat": "Details", "order": "63", "role": "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable", "shortName": "Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c169", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueRevenueRecognized1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Description of Business and Recent Developments", "menuCat": "Notes", "order": "8", "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments", "shortName": "Organization and Description of Business and Recent Developments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Liquidity and Capital Resources", "menuCat": "Notes", "order": "9", "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResources", "shortName": "Liquidity and Capital Resources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_dominarihold.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.aikidopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "domh_AccruedSalariesAndBenefit": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.", "label": "Accrued Salaries And Benefit", "terseLabel": "Accrued salaries and benefits" } } }, "localname": "AccruedSalariesAndBenefit", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "domh_AdditionalPurchasedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Purchased Shares.", "label": "Additional Purchased Shares", "terseLabel": "Additional purchased shares" } } }, "localname": "AdditionalPurchasedShares", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsDetails" ], "xbrltype": "sharesItemType" }, "domh_AmericanInnovativeRoboticsInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "American Innovative Robotics Investment Member", "terseLabel": "American Innovative Robotics Investment [Member]" } } }, "localname": "AmericanInnovativeRoboticsInvestmentMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_AmericanInnovativeRoboticsLLCInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "American Innovative Robotics LLCInvestment Member", "terseLabel": "American Innovative Robotics, LLC Investment [Member]" } } }, "localname": "AmericanInnovativeRoboticsLLCInvestmentMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "domh_AmountOfCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost.", "label": "Amount Of Cost", "terseLabel": "Amount of cost" } } }, "localname": "AmountOfCost", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "domh_AssetsAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Abstract0", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract0", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_AssetsAbstract1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Abstract1", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract1", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_BusinessCombinationDepositswithClearingBroker-Dealer": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits with Clearing Broker-Dealer.", "label": "Business Combination Depositswith Clearing Broker- Dealer", "terseLabel": "Deposits with Clearing Broker-Dealer" } } }, "localname": "BusinessCombinationDepositswithClearingBroker-Dealer", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "domh_BusinessCombinationWealthManagementLiabilities": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Wealth management liabilities.", "label": "Business Combination Wealth Management Liabilities", "terseLabel": "Wealth management liabilities" } } }, "localname": "BusinessCombinationWealthManagementLiabilities", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "domh_CancellationOfCommonStockRelatedToInvestmentInCBMinShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cancellation of common stock related to investment in CBM.", "label": "Cancellation Of Common Stock Related To Investment In CBMin Shares", "terseLabel": "Cancellation of common stock related to investment in CBM" } } }, "localname": "CancellationOfCommonStockRelatedToInvestmentInCBMinShares", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "domh_ChangeInFairValueOfLongtermInvestment": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of long-term investment.", "label": "Change In Fair Value Of Longterm Investment", "terseLabel": "Change in fair value of long-term investment" } } }, "localname": "ChangeInFairValueOfLongtermInvestment", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_ChangeInFairValueOfShorttermInvestment": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of short-term investment.", "label": "Change In Fair Value Of Shortterm Investment", "terseLabel": "Change in fair value of short-term investment" } } }, "localname": "ChangeInFairValueOfShorttermInvestment", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_ClearingBrokerDeposits": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of clearing broker deposits.", "label": "Clearing Broker Deposits", "terseLabel": "Deposits with clearing broker" } } }, "localname": "ClearingBrokerDeposits", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "domh_CollectionOfPrincipalOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of collection of principal outstanding.", "label": "Collection Of Principal Outstanding", "terseLabel": "Collection of principal outstanding" } } }, "localname": "CollectionOfPrincipalOutstanding", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "domh_ConsolidatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Member", "terseLabel": "Consolidated [Member]" } } }, "localname": "ConsolidatedMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "domainItemType" }, "domh_ConvergentConvertibleNoteCurrentPortionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convergent Convertible Note Current Portion Member", "terseLabel": "Convergent Convertible Note - Current [Member]" } } }, "localname": "ConvergentConvertibleNoteCurrentPortionMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_ConvergentConvertibleNoteNoncurrentPortionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convergent Convertible Note Noncurrent Portion Member", "terseLabel": "Convergent Convertible Note - Non-Current [Member]" } } }, "localname": "ConvergentConvertibleNoteNoncurrentPortionMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_ConvergentTherapeuticsIncInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convergent Therapeutics Inc Investment Member", "terseLabel": "Convergent Therapeutics, Inc. Investment [Member]" } } }, "localname": "ConvergentTherapeuticsIncInvestmentMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "domh_ConvertiblePromissoryNotePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note Percentage.", "label": "Convertible Promissory Note Percentage", "terseLabel": "Convertible promissory note percentage" } } }, "localname": "ConvertiblePromissoryNotePercentage", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "percentItemType" }, "domh_DebtInstrumentMaturityDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of maturity date.", "label": "Debt Instrument Maturity Date1", "terseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate1", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "dateItemType" }, "domh_DeemedDividendsRelatedToSeriesOAndSeriesPRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deemed dividends related to series O and series P redeemable convertible preferred stock.", "label": "Deemed Dividends Related To Series OAnd Series PRedeemable Convertible Preferred Stock", "terseLabel": "Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock" } } }, "localname": "DeemedDividendsRelatedToSeriesOAndSeriesPRedeemableConvertiblePreferredStock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "domh_DepositsWithClearingBrokerPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deposits with clearing broker.", "label": "Deposits With Clearing Broker Policy Text Block", "terseLabel": "Deposits with clearing broker" } } }, "localname": "DepositsWithClearingBrokerPolicyTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "domh_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_DominariSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dominari Securities Member", "terseLabel": "Dominari Securities [Member]" } } }, "localname": "DominariSecuritiesMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "domainItemType" }, "domh_EffectOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of new accounting pronouncements not yet adopted.", "label": "Effect Of New Accounting Pronouncements Not Yet Adopted Policy Text Block", "terseLabel": "Effect of new accounting pronouncements not yet adopted" } } }, "localname": "EffectOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "domh_EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of new accounting pronouncements to be adopted in future periods.", "label": "Effect Of New Accounting Pronouncements To Be Adopted In Future Periods Policy Text Block", "terseLabel": "Effect of new accounting pronouncements to be adopted in future periods" } } }, "localname": "EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "domh_FPSAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPS Acquisition [Abstract]" } } }, "localname": "FPSAcquisitionAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_FPSAcquisitionDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) [Line Items]" } } }, "localname": "FPSAcquisitionDetailsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "stringItemType" }, "domh_FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities [Line Items]" } } }, "localname": "FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities [Table]" } } }, "localname": "FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_FPSAcquisitionDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) [Table]" } } }, "localname": "FPSAcquisitionDetailsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "stringItemType" }, "domh_FPSPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPSPurchase Agreement Member", "terseLabel": "FPS Purchase Agreement [Member]" } } }, "localname": "FPSPurchaseAgreementMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "domainItemType" }, "domh_FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities [Line Items]" } } }, "localname": "FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities [Table]" } } }, "localname": "FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_FractionalSharesAdjustedForReverseSplits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of fractional shares adjusted for reverse split.", "label": "Fractional Shares Adjusted For Reverse Splits", "terseLabel": "Fractional shares adjusted for reverse split (in Shares)" } } }, "localname": "FractionalSharesAdjustedForReverseSplits", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "domh_IncreaseDecreaseInAccruedCommissions": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued commissions.", "label": "Increase Decrease In Accrued Commissions", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedCommissions", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_IncreaseDecreaseInPrepaidAcquisitionCost": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Prepaid Acquisition Cost.", "label": "Increase Decrease In Prepaid Acquisition Cost", "negatedLabel": "Prepaid acquisition cost" } } }, "localname": "IncreaseDecreaseInPrepaidAcquisitionCost", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_InvestmentInASPIsotopesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In ASPIsotopes Member", "terseLabel": "Investment in ASP Isotopes [Member]" } } }, "localname": "InvestmentInASPIsotopesMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInAerocarveUSCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Aerocarve USCorporation Member", "terseLabel": "Investment in AerocarveUS Corporation [Member]" } } }, "localname": "InvestmentInAerocarveUSCorporationMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInAndurilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Anduril Member", "terseLabel": "Investment in Anduril [Member]" } } }, "localname": "InvestmentInAndurilMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInAutomationAnywhereMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Automation Anywhere Member", "terseLabel": "Investment in Automation Anywhere [Member]" } } }, "localname": "InvestmentInAutomationAnywhereMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInDatabricksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Databricks Member", "terseLabel": "Investment in Databricks [Member]" } } }, "localname": "InvestmentInDatabricksMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInDiscordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Discord Member", "terseLabel": "Investment in Discord [Member]" } } }, "localname": "InvestmentInDiscordMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInEpicGamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Epic Games Member", "terseLabel": "Investment in Epic Games [Member]" } } }, "localname": "InvestmentInEpicGamesMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInFieldPointSecuritie": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in Field Point Securities.", "label": "Investment In Field Point Securitie", "terseLabel": "Investment in Fieldpoint Securities" } } }, "localname": "InvestmentInFieldPointSecuritie", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "domh_InvestmentInKayaNowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Kaya Now Member", "terseLabel": "Investment in Kaya Now [Member]" } } }, "localname": "InvestmentInKayaNowMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInKernaHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Kerna Health Inc Member", "terseLabel": "Investment In Kerna Health Inc [Member]" } } }, "localname": "InvestmentInKernaHealthIncMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInKrakenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Kraken Member", "terseLabel": "Investment in Kraken [Member]" } } }, "localname": "InvestmentInKrakenMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInMasterclassMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Masterclass Member", "terseLabel": "Investment in Masterclass [Member]" } } }, "localname": "InvestmentInMasterclassMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInQxpressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Qxpress Member", "terseLabel": "Investment in Qxpress [Member]" } } }, "localname": "InvestmentInQxpressMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInSpaceXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Space XMember", "terseLabel": "Investment in SpaceX [Member]" } } }, "localname": "InvestmentInSpaceXMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInTesspayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Tesspay Member", "terseLabel": "Investment in Tesspay [Member]" } } }, "localname": "InvestmentInTesspayMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInTevvaMotorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Tevva Motors Member", "terseLabel": "Investment in Tevva Motors [Member]" } } }, "localname": "InvestmentInTevvaMotorsMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInThrasioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Thrasio Member", "terseLabel": "Investment in Thrasio [Member]" } } }, "localname": "InvestmentInThrasioMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_InvestmentInVicinityMotorCorp": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in Vicinity Motor Corp.", "label": "Investment In Vicinity Motor Corp", "terseLabel": "Investment in Vicinity Motor Corp." } } }, "localname": "InvestmentInVicinityMotorCorp", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "monetaryItemType" }, "domh_InvestmentInVicinityMotorCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Vicinity Motor Corp Member", "terseLabel": "Investment in Vicinity Motor Corp. [Member]" } } }, "localname": "InvestmentInVicinityMotorCorpMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "domh_IssuanceOfSeriesPRedeemablesConvertiblePreferredStockForCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series P redeemable convertible preferred stock for cash.", "label": "Issuance Of Series PRedeemables Convertible Preferred Stock For Cash", "terseLabel": "Issuance of Series P redeemable convertible preferred stock for cash (in Shares)" } } }, "localname": "IssuanceOfSeriesPRedeemablesConvertiblePreferredStockForCash", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "domh_KayaNowPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kaya Now Promissory Note Member", "terseLabel": "Kaya Now Promissory Note [Member]" } } }, "localname": "KayaNowPromissoryNoteMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "domh_LeaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Axis", "terseLabel": "Lease [Axis]" } } }, "localname": "LeaseAxis", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofFutureMinimumPaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future minimum payments [Member]" } } }, "localname": "LeasesDetailsScheduleofFutureMinimumPaymentsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofFutureMinimumPaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Future Minimum Payments [Table]" } } }, "localname": "LeasesDetailsScheduleofFutureMinimumPaymentsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofLeaseAssetsandLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Lease Assets and Liabilities [Line Items]" } } }, "localname": "LeasesDetailsScheduleofLeaseAssetsandLiabilitiesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofLeaseAssetsandLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Lease Assets and Liabilities [Table]" } } }, "localname": "LeasesDetailsScheduleofLeaseAssetsandLiabilitiesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of lease expense to current period operations [Abstract]" } } }, "localname": "LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Lease Expense to Current Period Operations [Table]" } } }, "localname": "LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of summarize quantitative information about the company\u2019s operating leases [Abstract]" } } }, "localname": "LeasesDetailsScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Summarize Quantitative Information about The Company\u2019s Operating Leases [Table]" } } }, "localname": "LeasesDetailsScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of supplemental cash flow information related to leases [Abstract]" } } }, "localname": "LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "xbrltype": "stringItemType" }, "domh_LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases [Table]" } } }, "localname": "LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "xbrltype": "stringItemType" }, "domh_LegacyAIkidoPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legacy AIkido Pharma Member", "terseLabel": "Legacy AIkido Pharma [Member]" } } }, "localname": "LegacyAIkidoPharmaMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "domainItemType" }, "domh_LessDepositPreviouslyTransferredInOctober2022ToFPS": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxesPaid", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Less Deposit Previously Transferred In October2022 To FPS", "negatedLabel": "Less - Deposit previously transferred in October 2022 to FPS" } } }, "localname": "LessDepositPreviouslyTransferredInOctober2022ToFPS", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_LessPresentValueDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Less present value discount.", "label": "Less Present Value Discount", "terseLabel": "Less present value discount" } } }, "localname": "LessPresentValueDiscount", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "domh_LiabilitiesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Abstract0", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract0", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "domh_LiquidityAndCapitalResourcesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources [Abstract]" } } }, "localname": "LiquidityAndCapitalResourcesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_LongTermInvestmentsDetailsScheduleofLongTermInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]" } } }, "localname": "LongTermInvestmentsDetailsScheduleofLongTermInvestmentsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "domh_LongTermInvestmentsDetailsScheduleofLongTermInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) - Schedule of Long-Term Investments [Table]" } } }, "localname": "LongTermInvestmentsDetailsScheduleofLongTermInvestmentsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "domh_MarketableSecuritiesGainLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities Gain Losses", "terseLabel": "Total" } } }, "localname": "MarketableSecuritiesGainLosses", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "monetaryItemType" }, "domh_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net loss.", "label": "Net Loss", "terseLabel": "Net loss" } } }, "localname": "NetLoss", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "domh_NetLossperShareTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Lossper Share Tables Line Items", "terseLabel": "Net Loss per Share [Abstract]" } } }, "localname": "NetLossperShareTablesLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NetLossperShareTables" ], "xbrltype": "stringItemType" }, "domh_NetLossperShareTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share (Tables) [Table]" } } }, "localname": "NetLossperShareTablesTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NetLossperShareTables" ], "xbrltype": "stringItemType" }, "domh_NoteReceivableConvergentTherapeuticNoncurrentPortion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Note receivable, convergent therapeutics, non-current portion.", "label": "Note Receivable Convergent Therapeutic Noncurrent Portion", "terseLabel": "Note receivable, Convergent Therapeutics, non-current portion" } } }, "localname": "NoteReceivableConvergentTherapeuticNoncurrentPortion", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "domh_NotesReceivableAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable At Fair Value Abstract", "terseLabel": "Notes receivable, at fair value" } } }, "localname": "NotesReceivableAtFairValueAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "stringItemType" }, "domh_NotesReceivableAtFairValueCurrentPortion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.", "label": "Notes Receivable At Fair Value Current Portion", "periodEndLabel": "Notes receivable at fair value, current portion at June 30, 2023", "periodStartLabel": "Notes receivable at fair value, current portion at December 31, 2022", "terseLabel": "Notes receivable at fair value, current portion" } } }, "localname": "NotesReceivableAtFairValueCurrentPortion", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable", "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "domh_NotesReceivableAtFairValueNoncurrentPortion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.", "label": "Notes Receivable At Fair Value Noncurrent Portion", "periodEndLabel": "Notes receivable at fair value, non-current portion at June 30, 2023", "periodStartLabel": "Notes receivable at fair value, non-current portion at December 31, 2022", "terseLabel": "Notes receivable at fair value, non-current portion" } } }, "localname": "NotesReceivableAtFairValueNoncurrentPortion", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable", "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "domh_NotesReceivableAtFairvalueCurrentPortionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable At Fairvalue Current Portion Member", "terseLabel": "Notes Receivable, at Fair Value - Current Portion [Member]" } } }, "localname": "NotesReceivableAtFairvalueCurrentPortionMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_NotesReceivableAtFairvalueNoncurrentPortionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable At Fairvalue Noncurrent Portion Member", "terseLabel": "Notes Receivable, at Fair Value - Non-Current Portion [Member]" } } }, "localname": "NotesReceivableAtFairvalueNoncurrentPortionMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_NotesReceivableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Line Items]" } } }, "localname": "NotesReceivableDetailsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "domh_NotesReceivableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Table]" } } }, "localname": "NotesReceivableDetailsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "domh_OnMarch272023TheCompanyAcquiredAllAssetsAndLiabilitiesOfFpsAsDisclosedInNote4Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "On March272023 The Company Acquired All Assets And Liabilities Of Fps As Disclosed In Note4 Abstract", "terseLabel": "On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:" } } }, "localname": "OnMarch272023TheCompanyAcquiredAllAssetsAndLiabilitiesOfFpsAsDisclosedInNote4Abstract", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "domh_OperatingLeaseCostWeightedAverageTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": ".", "label": "Operating Lease Cost Weighted Average Table Text Block", "terseLabel": "Schedule of Summarize Quantitative Information about The Company\u2019s Operating Leases" } } }, "localname": "OperatingLeaseCostWeightedAverageTableTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "domh_OperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities.", "label": "Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilities", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "domh_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Member", "terseLabel": "Operating lease [Member]" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "domainItemType" }, "domh_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases Abstract", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "stringItemType" }, "domh_OriginalCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amoun t of original cost.", "label": "Original Cost", "terseLabel": "Original cost" } } }, "localname": "OriginalCost", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "domh_PaymentOfPurchasePrices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Purchase Price.", "label": "Payment Of Purchase Prices", "terseLabel": "Purchase amount" } } }, "localname": "PaymentOfPurchasePrices", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "domh_PromissoryConvertibleNoteReceivableConversionIntoCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Promissory convertible note receivable conversion into common shares.", "label": "Promissory Convertible Note Receivable Conversion Into Common Shares", "terseLabel": "Promissory convertible note receivable conversion into common shares" } } }, "localname": "PromissoryConvertibleNoteReceivableConversionIntoCommonShares", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_PurchaseOfShorttermAndLongtermPromissoryNotes": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of short-term and long-term promissory notes.", "label": "Purchase Of Shortterm And Longterm Promissory Notes", "negatedLabel": "Purchase of short-term and long-term promissory notes" } } }, "localname": "PurchaseOfShorttermAndLongtermPromissoryNotes", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_PurchaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares purchase shares.", "label": "Purchase Shares", "terseLabel": "Purchase shares" } } }, "localname": "PurchaseShares", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsDetails" ], "xbrltype": "sharesItemType" }, "domh_Purchaseofshort-termandlong-terminvestments": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of short-term and long-term investments.", "label": "Purchaseofshort-termandlong-terminvestments", "negatedLabel": "Purchase of short-term and long-term investments" } } }, "localname": "Purchaseofshort-termandlong-terminvestments", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_RaefanIndustriesLLCInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Raefan Industries LLCInvestment Member", "terseLabel": "Raefan Industries LLC Investment [Member]" } } }, "localname": "RaefanIndustriesLLCInvestmentMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "domainItemType" }, "domh_RealizedlossGain": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of realized loss gain.", "label": "Realizedloss Gain", "negatedLabel": "Realized loss" } } }, "localname": "RealizedlossGain", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "monetaryItemType" }, "domh_ReclassifyFromConvertibleNoteReceivableToNotesReceivableAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassify from convertible note receivable to notes receivable at fair value.", "label": "Reclassify From Convertible Note Receivable To Notes Receivable At Fair Value", "terseLabel": "Reclassify from convertible note receivable to notes receivable at fair value" } } }, "localname": "ReclassifyFromConvertibleNoteReceivableToNotesReceivableAtFairValue", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_RedemptionOfSeriesPRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of redeemable preferred stock, excluding currently redeemable preferred stock. Includes amounts representing dividends not declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Redemption Of Series PRedeemable Convertible Preferred Stock", "terseLabel": "Redemption of Series P Redeemable Convertible Preferred Stock" } } }, "localname": "RedemptionOfSeriesPRedeemableConvertiblePreferredStock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "domh_RedemptionOfSeriesPRedeemablesConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of redeemable preferred stock, excluding currently redeemable preferred stock. Includes amounts representing dividends not declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Redemption Of Series PRedeemables Convertible Preferred Stock", "terseLabel": "Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)" } } }, "localname": "RedemptionOfSeriesPRedeemablesConvertiblePreferredStock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "domh_RegulatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Regulatory [Abstract]" } } }, "localname": "RegulatoryAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_RegulatoryDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Regulatory (Details) [Line Items]" } } }, "localname": "RegulatoryDetailsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "stringItemType" }, "domh_RegulatoryDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Regulatory (Details) [Table]" } } }, "localname": "RegulatoryDetailsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "stringItemType" }, "domh_ReturnOfDepositfundingOfDepositIntoAManagedAccountNet": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Return of deposit (funding of deposit) into a managed account, net.\r \n.", "label": "Return Of Depositfunding Of Deposit Into AManaged Account Net", "negatedLabel": "Acquisition of FPS, net of cash acquired and receivable owed from FPS" } } }, "localname": "ReturnOfDepositfundingOfDepositIntoAManagedAccountNet", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_ScheduleOfComputationOfDilutedLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Computation Of Diluted Loss Per Share Abstract" } } }, "localname": "ScheduleOfComputationOfDilutedLossPerShareAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfFairValueAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value assets and liabilities [Abstract]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfFairValueOnARecurringBasisAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfFairValuesOfTheAssetsAcquiredAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Values Of The Assets Acquired And Liabilities Abstract" } } }, "localname": "ScheduleOfFairValuesOfTheAssetsAcquiredAndLiabilitiesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfFutureMinimumPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Payments Abstract" } } }, "localname": "ScheduleOfFutureMinimumPaymentsAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfLeaseAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Lease Assets And Liabilities Abstract" } } }, "localname": "ScheduleOfLeaseAssetsAndLiabilitiesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfLeaseExpenseToCurrentPeriodOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Lease Expense To Current Period Operations Abstract" } } }, "localname": "ScheduleOfLeaseExpenseToCurrentPeriodOperationsAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfLongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investments Abstract" } } }, "localname": "ScheduleOfLongTermInvestmentsAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfMarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Marketable Securities Abstract" } } }, "localname": "ScheduleOfMarketableSecuritiesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfNotesReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Notes Receivable Abstract" } } }, "localname": "ScheduleOfNotesReceivableAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfQuantitativeInformationFairValueMeasurementsInputsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative information fair value measurements inputs.", "label": "Schedule Of Quantitative Information Fair Value Measurements Inputs Text Block", "terseLabel": "Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs" } } }, "localname": "ScheduleOfQuantitativeInformationFairValueMeasurementsInputsTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "domh_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Quantitative Information Regarding Level3 Fair Value Measurements Inputs Abstract" } } }, "localname": "ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfRestrictedStockAwardsActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Awards Activity Abstract" } } }, "localname": "ScheduleOfRestrictedStockAwardsActivityAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenuesAndNetLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of segment profitability that are most relied upon by the CODM are gross revenues and net loss [Astract]" } } }, "localname": "ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenuesAndNetLossAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Short Term Investments Abstract" } } }, "localname": "ScheduleOfShortTermInvestmentsAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of short term investments.", "label": "Schedule Of Short Term Investments Table Text Block", "terseLabel": "Schedule of Short-Term Investments" } } }, "localname": "ScheduleOfShortTermInvestmentsTableTextBlock", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "domh_ScheduleOfStockOptionActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option Activity Abstract" } } }, "localname": "ScheduleOfStockOptionActivityAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfSummarizeQuantitativeInformationAboutTheCompanySOperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Summarize Quantitative Information About The Company SOperating Leases Abstract" } } }, "localname": "ScheduleOfSummarizeQuantitativeInformationAboutTheCompanySOperatingLeasesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Abstract" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfTotalRevenuesDisaggregatedByRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Total Revenues Disaggregated By Revenue Abstract" } } }, "localname": "ScheduleOfTotalRevenuesDisaggregatedByRevenueAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_ScheduleOfWarrantActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "localname": "ScheduleOfWarrantActivityAbstract", "nsuri": "http://www.aikidopharma.com/20230630", "xbrltype": "stringItemType" }, "domh_SeriesD1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series D1 Preferred Stock Member", "terseLabel": "Series D-1 Preferred Stock" } } }, "localname": "SeriesD1PreferredStockMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "domainItemType" }, "domh_SeriesORedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series ORedeemable Convertible Preferred Stock Member", "terseLabel": "Series O" } } }, "localname": "SeriesORedeemableConvertiblePreferredStockMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "domh_SeriesPRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series PRedeemable Convertible Preferred Stock Member", "terseLabel": "Series P" } } }, "localname": "SeriesPRedeemableConvertiblePreferredStockMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of equity instruments other than options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1", "terseLabel": "Outstanding beginning balance, Weighted Average Remaining Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "durationItemType" }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodTotalIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options issued in period total intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Issued In Period Total Intrinsic Value", "terseLabel": "Outstanding ending balance, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodTotalIntrinsicValue", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "monetaryItemType" }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value1", "terseLabel": "Outstanding beginning balance, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "monetaryItemType" }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of outstanding warrant.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Of Warrant", "periodEndLabel": "Outstanding ending balance, Warrants", "periodStartLabel": "Outstanding beginning balance, Warrants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOfWarrant", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "sharesItemType" }, "domh_ShareBuybackProgramAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share Buyback Program amount", "label": "Share Buyback Program Amount", "terseLabel": "Share Buyback Program amount" } } }, "localname": "ShareBuybackProgramAmount", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "domh_ShareRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company Share repurchased.", "label": "Share Repurchased", "terseLabel": "Share repurchased (in Shares)" } } }, "localname": "ShareRepurchased", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "domh_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractual": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual", "periodEndLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "periodStartLabel": "Outstanding beginning balance, Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractual", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "durationItemType" }, "domh_SharesCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares cancelled.", "label": "Shares Cancelled", "terseLabel": "Shares cancelled (in Shares)" } } }, "localname": "SharesCancelled", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "domh_ShortTermInvestmentsDetailsScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Line Items]" } } }, "localname": "ShortTermInvestmentsDetailsScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "stringItemType" }, "domh_ShortTermInvestmentsDetailsScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Table]" } } }, "localname": "ShortTermInvestmentsDetailsScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "stringItemType" }, "domh_ShortTermInvestmentsDetailsScheduleofShortTermInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) - Schedule of Short-Term Investments [Line Items]" } } }, "localname": "ShortTermInvestmentsDetailsScheduleofShortTermInvestmentsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "domh_ShortTermInvestmentsDetailsScheduleofShortTermInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) - Schedule of Short-Term Investments [Table]" } } }, "localname": "ShortTermInvestmentsDetailsScheduleofShortTermInvestmentsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "domh_StatedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Stated Interest Rate", "terseLabel": "Stated Interest Rate" } } }, "localname": "StatedInterestRate", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "percentItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) [Line Items]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "stringItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards Activity [Abstract]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "stringItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityLineItems", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "stringItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Stock Option Activity [Abstract]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "stringItemType" }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) [Table]" } } }, "localname": "StockholdersEquityandConvertiblePreferredStockDetailsTable", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "domh_TransferFromLongtermInvestmentToMarketableSecurites": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfer from long-term investment to marketable securities.", "label": "Transfer From Longterm Investment To Marketable Securites", "terseLabel": "Transfer from short-term investment to marketable securities" } } }, "localname": "TransferFromLongtermInvestmentToMarketableSecurites", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "domh_VicinityMotorCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vicinity Motor Corp Member", "terseLabel": "Vicinity Motor Corp [Member]" } } }, "localname": "VicinityMotorCorpMember", "nsuri": "http://www.aikidopharma.com/20230630", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r172", "r327", "r643", "r671" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable", "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r172", "r327", "r643", "r644", "r671" ], "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable", "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Employee forgivable loan receivable" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivablePurchase": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase from purchase of accounts receivable.", "label": "Accounts Receivable, Purchase", "terseLabel": "Receivable amount" } } }, "localname": "AccountsReceivablePurchase", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "auth_ref": [ "r79", "r80", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.", "label": "Accrued Rent", "terseLabel": "Rent payment" } } }, "localname": "AccruedRentCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r83", "r622", "r707" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r341", "r342", "r343", "r485", "r668", "r669", "r670", "r693", "r708" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "auth_ref": [ "r11", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.", "label": "Adjustments to Additional Paid in Capital, Stock Split", "terseLabel": "Fractional shares adjusted for reverse split" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r11", "r49", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of Series O redeemable convertible preferred stock for cash" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Estimated future stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r139", "r157", "r199", "r206", "r211", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r349", "r351", "r370", "r457", "r527", "r622", "r634", "r687", "r688", "r702" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r135", "r144", "r157", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r349", "r351", "r370", "r622", "r687", "r688", "r702" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Net Assets", "terseLabel": "Net assets" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BrokerageCommissionsRevenue": { "auth_ref": [ "r70", "r120" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commission revenue from buying and selling securities on behalf of customers.", "label": "Brokerage Commissions Revenue", "terseLabel": "Commissions" } } }, "localname": "BrokerageCommissionsRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r347", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r62", "r63", "r347", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable", "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r1", "r2", "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration amount" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other", "terseLabel": "Additional consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r108", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "FPS Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Other receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Accrued commissions" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r64", "r65" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total net assets of FPS Acquisition" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Percentage of acquired membership interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_CapitalUnitsNetAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net amount applicable to investors of capital units or shares.", "label": "Capital Units, Net Amount", "terseLabel": "Net capital amount" } } }, "localname": "CapitalUnitsNetAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.", "label": "Cash Acquired in Excess of Payments to Acquire Business", "terseLabel": "Interest income" } } }, "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r137", "r604" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r659" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Short-term investment" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "terseLabel": "Short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r34", "r97", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r3", "r97" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r131", "r141", "r142", "r143", "r157", "r176", "r177", "r184", "r186", "r193", "r194", "r253", "r267", "r269", "r270", "r271", "r274", "r275", "r295", "r296", "r298", "r301", "r308", "r370", "r476", "r477", "r478", "r479", "r485", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r515", "r536", "r558", "r596", "r597", "r598", "r599", "r600", "r642", "r665", "r672" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r102", "r265", "r266", "r602", "r686" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDiscountOnShares": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.", "label": "Common Stock, Discount on Shares", "terseLabel": "Common stock retirement shares" } } }, "localname": "CommonStockDiscountOnShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r668", "r669", "r693", "r705", "r708" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r82", "r515" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r82", "r515", "r533", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r82", "r459", "r622" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible preferred stock [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r90", "r157", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r370", "r687" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r78", "r79", "r113", "r115", "r158", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r377", "r611", "r612", "r613", "r614", "r615", "r666" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r67", "r293", "r377" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Membership interests rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r23", "r158", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r377", "r611", "r612", "r613", "r614", "r615", "r666" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r66", "r68", "r689" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Principal Amount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r466", "r660", "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized loss" } } }, "localname": "DebtSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r684" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Prepaid acquisition cost" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Revenue" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Deposit Liabilities, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r6", "r48" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendIncomeOperating": { "auth_ref": [ "r122", "r484", "r537", "r588", "r590", "r631", "r632", "r710" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating dividend income on securities.", "label": "Dividend Income, Operating", "terseLabel": "Dividend income" } } }, "localname": "DividendIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r168", "r174", "r176", "r184", "r185", "r186", "r190", "r362", "r363", "r443", "r465", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r168", "r176", "r184", "r185", "r186", "r190", "r362", "r363", "r443", "r465", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r173", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NetLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued Commissions" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Options to purchase common stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r133", "r147", "r148", "r149", "r159", "r160", "r161", "r163", "r169", "r171", "r192", "r254", "r255", "r310", "r341", "r342", "r343", "r345", "r346", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r371", "r372", "r373", "r374", "r375", "r376", "r391", "r468", "r469", "r470", "r485", "r558" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r140", "r369", "r605" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessCapital": { "auth_ref": [ "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework.", "label": "Banking Regulation, Total Risk-Based Capital, Excess, Actual", "terseLabel": "Excess amount" } } }, "localname": "ExcessCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r6" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of investments" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r320", "r321", "r322", "r323", "r324", "r325", "r366", "r401", "r402", "r403", "r612", "r613", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable", "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r320", "r325", "r366", "r401", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted prices in active markets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r284", "r320", "r325", "r366", "r402", "r612", "r613", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant other observable inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r284", "r320", "r321", "r322", "r323", "r324", "r325", "r366", "r403", "r612", "r613", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "verboseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable", "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r284", "r320", "r321", "r322", "r323", "r324", "r325", "r401", "r402", "r403", "r612", "r613", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r12", "r15" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r12", "r15" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Fair Value on a Recurring Basis" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r380" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Lease liability - current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r380" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Lease liability" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r292", "r306", "r359", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r464", "r610", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r679", "r680", "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Interest Receivable" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfNotesReceivable": { "auth_ref": [ "r411" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 4.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale of financing receivable.", "label": "Gain (Loss) on Sale of Financing Receivable", "negatedLabel": "Unrealized loss on note receivable", "terseLabel": "Unrealized loss on note receivable" } } }, "localname": "GainLossOnSaleOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r33", "r35" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "totalLabel": "Net cash paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in accrued salaries.", "label": "Increase (Decrease) in Accrued Salaries", "terseLabel": "Accrued salaries and benefits" } } }, "localname": "IncreaseDecreaseInAccruedSalaries", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposit" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesReceivables": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.", "label": "Increase (Decrease) in Notes Receivables", "negatedLabel": "Notes receivable, at fair value \u2013 net interest accrued" } } }, "localname": "IncreaseDecreaseInNotesReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r645", "r663" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r663" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Rent", "terseLabel": "Increase rent amount" } } }, "localname": "IncreaseDecreaseInPrepaidRent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in security deposits.", "label": "Increase (Decrease) in Security Deposits", "terseLabel": "Deposits with clearing broker" } } }, "localname": "IncreaseDecreaseInSecurityDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOtherDomesticDeposits": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest earned on US domestic deposits classified as other. Excludes money market accounts.", "label": "Interest Income, Other Domestic Deposits", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOtherDomesticDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableNoncurrent": { "auth_ref": [ "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of noncurrent interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable, Noncurrent", "terseLabel": "Interest income receivable" } } }, "localname": "InterestReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsLineItems": { "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of total revenues disaggregated by revenue [Abstract]" } } }, "localname": "InvestmentCompanyFinancialHighlightsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTable": { "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver.", "label": "Investment Company, Financial Highlights [Table]" } } }, "localname": "InvestmentCompanyFinancialHighlightsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTableTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver.", "label": "Investment Company, Financial Highlights [Table Text Block]", "terseLabel": "Schedule of Total Revenues Disaggregated By Revenue" } } }, "localname": "InvestmentCompanyFinancialHighlightsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r92", "r202" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 2.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r567", "r568", "r574", "r575", "r576", "r577", "r586", "r587", "r625", "r677", "r678" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Promissory note maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r475", "r504", "r505", "r571", "r573", "r580", "r593", "r625", "r634", "r706" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment Owned, Cost", "terseLabel": "Investment" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r475", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r518", "r519", "r566", "r569", "r570", "r572", "r578", "r579", "r581", "r582", "r583", "r584", "r585", "r592", "r594", "r595", "r625", "r634", "r706" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in security owned.", "label": "Investment Owned, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r111", "r124", "r125", "r132", "r221", "r222", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments in Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r383", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Expense to Current Period Operations" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee, Finance Lease, Description", "terseLabel": "Lease commencement date, description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r699" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months", "terseLabel": "Remaining Period Ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year Ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year Ended December 31, 2028" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year Ended December 31, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year Ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r389" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year Ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r157", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r350", "r351", "r352", "r370", "r514", "r608", "r634", "r687", "r702", "r703" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r87", "r116", "r461", "r622", "r667", "r683", "r694" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r136", "r157", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r350", "r351", "r352", "r370", "r622", "r687", "r702", "r703" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the liquidation basis of accounting.", "label": "Liquidation Basis of Accounting [Text Block]", "terseLabel": "Liquidity and Capital Resources" } } }, "localname": "LiquidationBasisOfAccountingTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResources" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Notes Receivable" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Note receivable, Convergent Therapeutics, non-current portion" } } }, "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-Term Investments" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r138" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "terseLabel": "Investments", "verboseLabel": "Long-term investments, Total" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments [Abstract]" } } }, "localname": "LongTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r73", "r655" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Total marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "MarketableSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r655" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 3.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)", "terseLabel": "Gain (loss) on marketable securities", "verboseLabel": "Loss on marketable securities" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "negatedLabel": "Realized loss on marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r89" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Security, Unrealized Gain (Loss)", "negatedLabel": "Unrealized (gain) loss on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r153" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r153" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r98", "r99" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r88", "r99", "r119", "r134", "r145", "r146", "r149", "r157", "r162", "r164", "r165", "r166", "r167", "r170", "r171", "r182", "r199", "r205", "r210", "r213", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r363", "r370", "r463", "r535", "r556", "r557", "r609", "r632", "r687" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAllocatedToLimitedPartners": { "auth_ref": [ "r53" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of net income allocated to limited partners.", "label": "Net Income (Loss) Allocated to Limited Partners", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLossAllocatedToLimitedPartners", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r152", "r175", "r178", "r179", "r180", "r181", "r183", "r186" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Loss Attributable to Common Shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoninterestIncomeOther": { "auth_ref": [ "r121" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total of noninterest income derived from certain activities and assets including (for example): (1) venture capital investments; (2) bank owned life insurance; (3) foreign currency transactions; and (4) mortgage servicing rights.", "label": "Noninterest Income, Other", "terseLabel": "Other" } } }, "localname": "NoninterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expenses)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r219", "r220", "r442" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Notes receivable, at fair value - current portion" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Notes receivable, at fair value - non-current portion" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Notes Payable [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating costs and expenses", "verboseLabel": "Operating Costs" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r199", "r205", "r210", "r213", "r609" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAllocatedToLimitedPartners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r191", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Lease Assets and Liabilities" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r380" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r380" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r380" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long -term operating liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r379" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets", "verboseLabel": "Operating lease right-of-use-assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r664" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r388", "r621" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate \u2013 operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r387", "r621" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term \u2013 operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationaboutTheCompanysOperatingLeasesTable" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r76", "r110", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business and Recent Developments" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r664", "r685" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r467", "r538", "r589", "r590", "r591" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expenses)", "verboseLabel": "Other (expenses) income" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r19", "r622" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other Current liability" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r455", "r653" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-Term Investments", "terseLabel": "Long-term investments, Cost Basis" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 1.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Operating cash flows - operating leases" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAllocatedToLimitedPartners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Net rent expense", "totalLabel": "Total other (expenses) income" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r74", "r456", "r658" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-Term Investments", "terseLabel": "Short-term investments, at fair value" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfOtherEquity": { "auth_ref": [ "r32" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to reacquire equity classified as other.", "label": "Payments for Repurchase of Other Equity", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfOtherEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r31" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment for fractional shares" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r676" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "terseLabel": "Accrued interest receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherReceivables": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from the purchase of receivables classified as other.", "label": "Payments to Acquire Other Receivables", "terseLabel": "Accrued interest receivable" } } }, "localname": "PaymentsToAcquireOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r662", "r700" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments to Fund Long-Term Loans to Related Parties", "negatedLabel": "Funds to employee forgivable loan" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r39", "r641", "r673" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r50", "r51", "r81", "r665", "r690" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in Dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r623", "r624", "r627", "r628", "r629", "r630", "r705", "r708" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r81", "r295" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r81", "r515" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r81", "r295" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r81", "r515", "r533", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r81", "r458", "r622" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r659" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r27" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Collection of Notes Receivable", "terseLabel": "Collection of principal on note receivable" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r4" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r4" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Redemption of Series O and Series P Redeemable Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of digital currencies" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalAndContractServicesExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.", "label": "Professional and Contract Services Expense", "terseLabel": "Professional service costs" } } }, "localname": "ProfessionalAndContractServicesExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r445", "r462", "r622" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock": { "auth_ref": [ "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for regulatory capital requirement for depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company, foreign financial institution and credit union.", "label": "Regulatory Capital Requirements under Banking Regulations [Text Block]", "terseLabel": "Regulatory" } } }, "localname": "RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/Regulatory" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r326", "r395", "r396", "r509", "r510", "r511", "r512", "r513", "r532", "r534", "r565" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r69", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Incurred fees" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r326", "r395", "r396", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r509", "r510", "r511", "r512", "r513", "r532", "r534", "r565", "r701" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r392", "r393", "r394", "r396", "r397", "r481", "r482", "r483", "r541", "r542", "r543", "r562", "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransaction" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r75", "r344", "r704" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r84", "r105", "r460", "r471", "r472", "r480", "r516", "r622" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r133", "r159", "r160", "r161", "r163", "r169", "r171", "r254", "r255", "r341", "r342", "r343", "r345", "r346", "r353", "r355", "r356", "r358", "r361", "r468", "r470", "r485", "r708" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r130", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r539", "r603", "r606" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r150", "r157", "r200", "r201", "r204", "r208", "r209", "r215", "r217", "r218", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r370", "r444", "r687" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r386", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Notes Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Computation of Diluted Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related To Leases" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-Term Investments" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Fair Values of the Assets Acquired And Liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price.", "label": "Securities Owned Not Readily Marketable [Table Text Block]", "terseLabel": "Schedule of Marketable Securities" } } }, "localname": "ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r44", "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r44", "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r13", "r14", "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Awards Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r654" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecurityOwnedNotReadilyMarketableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of marketable securities [Abstract]" } } }, "localname": "SecurityOwnedNotReadilyMarketableLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityOwnedNotReadilyMarketableTable": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price.", "label": "Security Owned Not Readily Marketable [Table]" } } }, "localname": "SecurityOwnedNotReadilyMarketableTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r195", "r196", "r197", "r198", "r199", "r203", "r207", "r211", "r212", "r213", "r214", "r215", "r216", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r656", "r657", "r691" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Business Combination [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredAndLiabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Restricted Stock Awards, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Stock Awards, ending balance", "periodStartLabel": "Number of Restricted Stock Awards, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "periodStartLabel": "Outstanding beginning balance, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Restricted Stock Awards, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Shares, Employee options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Day Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding ending balance, Intrinsic Value", "periodStartLabel": "Outstanding ending balance, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding ending balance, Number of Shares", "periodStartLabel": "Outstanding beginning balance, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "periodStartLabel": "Outstanding beginning balance, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Total Intrinsic Value, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Shares, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Employee options expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Grant Day Fair Value, ending balance", "periodStartLabel": "Weighted Average Grant Day Fair Value, beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life (in years), Options vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Day Fair Value, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Option term (in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r117", "r118", "r658" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "periodEndLabel": "Short-term investment at June 30, 2023", "periodStartLabel": "Short-term investment at December 31, 2022", "terseLabel": "Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueonaRecurringBasisTable", "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Abstract]" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r384", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease rent expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r131", "r141", "r142", "r143", "r157", "r176", "r177", "r184", "r186", "r193", "r194", "r253", "r267", "r269", "r270", "r271", "r274", "r275", "r295", "r296", "r298", "r301", "r308", "r370", "r476", "r477", "r478", "r479", "r485", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r515", "r536", "r558", "r596", "r597", "r598", "r599", "r600", "r642", "r665", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r25", "r133", "r147", "r148", "r149", "r159", "r160", "r161", "r163", "r169", "r171", "r192", "r254", "r255", "r310", "r341", "r342", "r343", "r345", "r346", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r371", "r372", "r373", "r374", "r375", "r376", "r391", "r468", "r469", "r470", "r485", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r159", "r160", "r161", "r192", "r429", "r475", "r498", "r507", "r509", "r510", "r511", "r512", "r513", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r528", "r529", "r530", "r531", "r532", "r534", "r539", "r540", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r626" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r159", "r160", "r161", "r192", "r429", "r475", "r498", "r507", "r509", "r510", "r511", "r512", "r513", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r528", "r529", "r530", "r531", "r532", "r534", "r539", "r540", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r626" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r56", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Granted shares" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r36", "r37", "r38" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxesPaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Net assets acquired, net of cash acquired and receivable owed from FPS" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r11", "r50", "r81", "r82", "r105" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r11", "r81", "r82", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of treasury stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Cancellation of common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Issuance of Series O redeemable convertible preferred stock for cash (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture", "terseLabel": "Stock-based compensation (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r11", "r25", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Redemption of Series O Redeemable Convertible Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of Series P redeemable convertible preferred stock for cash" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r81", "r82", "r105", "r485", "r558", "r597", "r633" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Cancellation of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r60", "r81", "r82", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceIncrease": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option, Exercise Price, Increase", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "StockOptionExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Cancellation of common stock related to investment in CBM (in Shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r11", "r81", "r82", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Retirement of treasury stock (in Shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r11", "r81", "r82", "r105", "r479", "r558", "r599" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchase of treasury stock (in Shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r82", "r85", "r86", "r101", "r517", "r533", "r559", "r560", "r622", "r634", "r667", "r683", "r694", "r708" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r104", "r156", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r310", "r360", "r561", "r563", "r601" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Stockholders\u2019 Equity and Convertible Preferred Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r36", "r37", "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Purchase price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income taxes withheld" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r292", "r306", "r359", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r464", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r679", "r680", "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, at cost" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockRetiredParValueMethodAmount": { "auth_ref": [ "r11", "r52", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.", "label": "Treasury Stock, Retired, Par Value Method, Amount", "terseLabel": "Retirement of treasury stock" } } }, "localname": "TreasuryStockRetiredParValueMethodAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r11", "r82", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Purchase of treasury stock (in Shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r11", "r82", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "Treasury Stock, Shares, Retired", "terseLabel": "Retired shares of treasury stock (in Shares)" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r24", "r54", "r55" ], "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r11", "r54", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of treasury stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnderwritingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the price paid by the public and the contract price less the related expenses. A broker-dealer may underwrite a security offering by contracting to buy the issue either at a fixed price or a price based on selling the offering on a best-effort basis.", "label": "Underwriting Income (Loss)", "terseLabel": "Underwriting" } } }, "localname": "UnderwritingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedByRevenueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized gain (loss)" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r41", "r42", "r43", "r126", "r127", "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r385", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r623", "r624", "r627", "r628", "r629", "r630" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r186" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r174", "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-07)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(a),(b))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.2)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)(1)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)(2)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(2)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(e)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "39", "Publisher": "FASB", "Section": "45", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r636": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r637": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r638": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r639": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//310-10/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "05", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481996/940-20-05-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "820", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481753/940-820-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org//205-30/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147479910/205-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 82 0001213900-23-065013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-065013-xbrl.zip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�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c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